Etiology and clinical management of adult meningitis in Indonesia by Rizal Ganiem, A.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/106968
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.

Etiology and clinical management 
of adult meningitis in Indonesia
Ahmad Rizal Ganiem
Publication of this thesis was financially supported by:
Departement of Medicine, Radboud University Medical Centre, Nijmegen.
KNCV Tuberculosis Foundation.
Design cover by Herlan Hazil A.
Layout by satia nugra-ha.
Printed and bound by Gita Print, Bandung, Indonesia.
ISBN 978-60295204-5-3
© 2013 Ahmad Rizal Ganiem
All rights reserved. No parts of this publication may be reproduced, store in a retrieval system of any 
nature, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or 
otherwise, withaout prior written permission of the publisher.
Etiology and clinical management 
of adult meningitis in Indonesia
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen,
op gezag van de Rector Magnificus prof. mr. S.C.J.J. Kortmann,
volgens besluit van het college van decanen
in het openbaar te verdedigen op Maandag 8 April 2013
om 13.30 uur precies
door
Ahmad Rizal Ganiem
geboren op 26 mei 1966 
te Bandung, Indonesië
Promotor
Prof. dr. A.J.A.M. van der Ven
     
Copromotoren   
Dr. R. van Crevel
Dr. R. Ruslami (Universitas Padjadjaran, Indonesia) 
  
 
Manuscriptcommissie
Prof. dr. D. Burger (voorzitter)
Prof. dr. D. van Soolingen
Prof. dr. D. van de Beek (neurologie, AMC, Amsterdam)


Etiology and clinical management 
of adult meningitis in Indonesia
Doctoral thesis
To obtain the degree of doctor
from Radboud University, Nijmegen
on the authority of the Rector Magnificus prof. mr. S.C.J.J. Kortmann,
according to the decision of the Council of Deans
to be defended in public on Monday April 8, 2013
at 13:30 hours.
by
Ahmad Rizal Ganiem
born on 26 May 1966 
in Bandung – Indonesia 
Supervisor: 
Prof. dr. A.J.A.M. van der Ven
Co-supervisors:
Dr. R. van Crevel
Dr. R. Ruslami (Universitas Padjadjaran, Indonesia)
Doctoral thesis committee:
Prof. dr. D. Burger (Chairman)
Prof. dr. D. van Soolingen
Prof. dr. D. van de Beek (neurology, AMC Amsterdam)
 Contents
Chapter 1 Introduction and thesis outline    11
Chapter 2 The effect of HIV infection on adult meningitis 
 in Indonesia: a prospective cohort study   21
 AIDS, 2009
Chapter 3 Comparison of real time IS6110-PCR, microscopy, 
 and culture for diagnosis of tuberculous meningitis 
 in a cohort of adult patients in Indonesia   43
 PLoS One, 2012
Chapter 4 Cerebral toxoplasmosis mimicking subacute meningitis in 
 HIV-infected patients: a cohort study from Indonesia  61
 PLoS Neglected Tropical Diseases, 2013
Chapter 5 Intensified regimen containing rifampicin and moxifloxacin for 
tuberculous meningitis: 
 an open-label, randomized controlled phase 2 trial  79
 Lancet Infectious Diseases, 2013
Chapter 6 Asymptomatic cryptococcal antigenemia 
 is strongly associated with mortality among 
 HIV-infected patients in Indonesia     109
 Submitted for publication
Chapter 7 Perception of illness and health-seeking behavior 
 in tuberculous meningitis patients in Indonesia: 
 a qualitative study       127
Chapter 8 Summary and general discussion    141
 Ringkasan       167
 Samenvatting      175
 List of publications      181
 Acknowledgements      185
 About the author      193

Introduction 
and 
thesis outline
Chapter 1
Chapter 1
12
Introduction and thesis outline
13
1
MENINGITIS, A GLOBAL CHALLENGE
Meningitis can be defined as inflammation of the protective membranes covering 
the brain and spinal cord, known collectively as the meninges. The majority of 
meningitis patients present with at least two of four signs/symptoms of fever, 
headache, neck stiffness, and altered mental status [1]. Other signs reflecting 
complications like cerebral nerve palsies or motor deficits may also be present, 
and this may result in death or sequalae in those who survive [2,3]. Meningitis is 
mostly caused by infection with bacteria or fungi. Patient characteristics, signs 
and symptoms and routine cerebrospinal fluid (CSF) examination can help make a 
diagnosis and guide treatment. However, these parameters are not 100% specific, 
and often no diagnosis can be made, as shown by a report from South Africa 
which revealed that almost half of meningitis cases had no definite diagnosis 
despite extensive microbacteriological testing [4].
Meningitis poses a big clinical challenge to physicians. Diagnosis is often difficult, 
and outcome is often poor. Despite the fact that many thousands of patients die 
each year from meningitis, this severe disease is not yet a public health priority. 
Etiology and diagnosis 
A common type of meningitis is acute bacterial (septic) meningitis that is 
mainly caused by Streptococcus pneumonia, Hemophilus influenza, and Neisseria 
meningitidis. It has a worldwide distribution with its causative pathogens 
varying by geographic distribution, age, and underlying medical and/or 
surgical condition [5]. Its estimated incidence is 2.6 – 6 per 100,000 adults 
per year in developed countries and up to 10 times higher in less developed 
countries [6]. Tuberculous (TB) meningitis usually has a somewhat more gradual 
onset (‘subacute meningitis’), developing over a period of days to weeks. It is 
estimated that 1-5% of TB cases may develop central nervous system TB [3,7,8]. 
Without treatment, death occurs in virtually all patients with TB meningitis, 
while delay in treatment results in a considerable risk of death or irreversible 
neurological damage. Bacteriological confirmation is the key to diagnosis, but 
using conventional methods its positivity rate is not satisfactory and molecular 
diagnosis is also not very sensitive [3,9–11]. 
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HIV infection complicates diagnosis and management of meningitis. HIV infection 
increases the risk of developing active TB by more than 20 times, and the risk 
of getting meningitis increases even more [12–15]. Further, meningitis in HIV-
positive cases has a broader differential diagnosis [4,16]. Cryptococcal meningitis 
has been closely related to HIV infection, and along with TB meningitis comprises 
more than 80% of meningitis in HIV positive patients [4]. Other HIV-related CNS 
infection like toxoplasmosis and neurosyphilis also need to be considered. 
 
Treatment and outcome
Prompt treatment of meningitis is crucial, but diagnostic uncertainty may delay 
proper treatment. The current treatment regimen for TB meningitis is suboptimal 
as shown by the fact that up to 50% of patients with TB meningitis die or remain 
neurologically disabled. So far no randomized clinical trials have compared 
different antibiotic regimens for TB meningitis. Corticosteroids, used as adjuvant 
treatment for TB meningitis, have shown a survival benefit, although its long-
term effects are somewhat disappointing [17,18]. Cryptococcal meningitis also 
has a high mortality, accounting for a large proportion of  ‘early deaths’  in patients 
with advanced HIV infection, especially in sub-Saharan Africa. Obviously, for all 
types of meningitis late presentation is a major contributor to the high mortality 
[19].
MENINGITIS IN INDONESIA
Indonesia, like other low-resource countries, still faces many cases of meningitis 
with significant mortality and morbidity. Indonesia has the fourth largest TB 
caseload worldwide, with an estimated prevalence of 680,000 cases of TB in 
year 2011 [20]. In Hasan Sadikin hospital, when we started this study in 2006, 
60-80 adult patients were admitted with clinical meningitis annually. The 
microorganisms causing meningitis were mostly unknown, as bacteriological 
confirmation of disease was rarely achieved and no survey had been conducted 
on this topic. Many patients were suspected of suffering from TB meningitis, 
mostly in the advanced stage, and more than 50% died during hospitalization.
In year 2006 when we started the study, Indonesia was experiencing a rapid 
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growth of HIV. The HIV prevalence in the general population was low (0.2%), 
but estimated prevalence rates in certain risk groups, especially injecting drug 
users (IDUs) were 50% or more [21]. Uptake of HIV testing was low, and many 
patients were not aware of their HIV status until hospitalization for advanced HIV 
infection or AIDS. This condition probably fuelled the development of TB and 
cryptococcal meningitis. However, when we started our study, there were no 
data regarding the HIV prevalence among meningitis patients, or regarding the 
etiology of meningitis in this group, neither in our hospital nor anywhere else in 
Indonesia. Meningitis patients were rarely tested for HIV infection, and no survey 
had been conducted. Still, clinicians had the impression that HIV was increasing 
the numbers of patients presenting with meningitis in Indonesian hospitals. Of 
note, HIV incidence rate among adults 15-49 years old in Indonesia is increasing 
more than 25% in 2011 as compared to year 2001 [22].
In summary, adult meningitis is common in Indonesia, but bacteriological 
confirmation is extremely rare, and epidemiological data regarding the cause, 
presentation and outcome were lacking prior to my PhD. Also, the impact of HIV 
on cause and outcome of meningitis in Indonesia was unknown. During my PhD 
I have therefore tried to answer some of these questions related to meningitis 
in Indonesia. 
THESIS OUTLINE
This thesis consists of studies related to the clinical presentation, diagnosis, 
optimal treatment and prevention of adult meningitis in Indonesia, both in HIV-
infected and non-infected individuals. The studies were conducted in years 2006 
– 2012, and involved both HIV-infected and non-infected individuals presenting 
at Hasan Sadikin hospital in Bandung, the referral hospital for West Java province 
(population: 43 million people), Indonesia.
During the last ten years there has been a gradual increase in the number of 
meningitis patients presenting to our hospital. However, before 2006 very 
few cases were bacteriologically confirmed, and systematic data regarding 
their severity and outcome were lacking. Therefore, as a first step towards 
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improvement of patient management, in Chapter 2 we examined the cause, 
clinical presentation and outcome of a cohort of adult patients presenting with 
meningitis.
This initial study showed that the majority of our patients had a diagnosis of 
probable TB meningitis. Bacteriological confirmation of TB meningitis is difficult. 
Microscopic examination of cerebrospinal fluid (CSF) is generally insensitive (2–
20 %), while culture is also not very sensitive and too slow to guide treatment. 
Nuclear acid amplification (NAA) tests may provide rapid confirmation of TB 
meningitis, but a systematic review and metaanalysis of the accuracy of NAA 
tests for diagnosis of TB meningitis showed that commercial NAA tests have a 
high specificity but a low sensitivity when compared with culture. There is some 
reason to believe that in-house PCR may be more sensitive, and in Chapter 
3 we asked ourselves the question if an in-house PCR could help improve the 
diagnosis of TB meningitis. 
Despite a thorough bacteriological workup, we were unable to make a definite 
diagnosis in many meningitis patients, especially among those who were HIV-
infected. In Chapter 4 we investigated the possibility that cerebral toxoplasmosis 
accounted for some cases of meningitis of unknown origin. Toxoplasmosis, a 
common opportunistic infection in advanced HIV infection, usually presents as 
space occupying lesions in the brain, but since imaging of the brain is rarely 
performed in meningitis patients in our setting, cerebral toxoplasmosis may be 
missed. We hypothesized that cerebral toxoplasmosis may falsely be diagnosed 
as TB meningitis.
TB meningitis has a very high mortality and morbidity. Its treatment follows that 
of pulmonary TB. Some TB drugs, especially rifampicin, show poor penetration 
into the brain and cerebrospinal fluid. Rifampicin is pivotal in the treatment of 
TB meningitis, but the current dose of rifampicin is at the lower end of the dose-
response curve. Higher dose of rifampicin has been studied in pulmonary TB by 
our group and others [23,24]. Intravenous rifampicin treatment, that probably 
leads to higher drug exposure, might be preferable in meningitis patients, many 
of whom are severely ill or unconscious. However, so far, no study has examined 
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a higher dose rifampicin, or the use of intravenous rifampicin in TB meningitis. 
Another option to intensify treatment and improve outcome of TB meningitis 
might be to add a fluoroquinolone. Among the fluoroquinolones, moxifloxacin 
has the highest activity against M. tuberculosis in vitro and in murine models, and 
has been proven to penetrate well into CSF of patients with TB meningitis. In 
Chapter 5 we asked ourselves the question whether a higher dose of rifampicin 
and adding moxifloxacin may lead to a better drug exposure with accepted 
tolerability, and whether this intensified treatment results in better clinical 
outcome. 
Early recognition can prevent the development or severe outcome of meningitis. 
Several studies in countries with a high burden of cryptococcal meningitis have 
found that the presence of cryptococcal antigen in the blood of HIV-infected 
patients is a risk factor for the development of cryptococcal meningitis and 
subsequent death. In Chapter 6 we asked ourselves the question whether 
this also holds true for Indonesia, and whether this may contribute to the high 
mortality among HIV patients in our setting.
Delay in accessing medical help has been related to high mortality in TB 
meningitis, as clearly shown in a Vietnamese study, where mortality increased 
in accordance to TB meningitis grade; i.e. 16.7%, 31.1% and 58.8% in grade 1, 2, 
and 3, respectively [17]. Most patients in our setting present with grade 2 and 3 
TB meningitis, reflecting delay in presentation. In Chapter 7 we asked ourselves 
the question why patients present at such late stage to the hospital, using in-
depth interviewing with a group of meningitis patients. 
The main findings of these studies are summarized and discussed in Chapter 8, 
and an outline of further research is proposed. It is hoped than this body of work 
will contribute to better management of meningitis, particularly TB meningitis, 
in Indonesia and elsewhere. 
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ABSTRACT
Objective
Indonesia has a concentrated but rapidly growing HIV epidemic. We examined 
the effect of HIV on causative organisms, clinical features and prognosis of adult 
meningitis.
Design
A prospective cohort study.
Methods
All adult patients at a referral hospital who underwent cerebrospinal fluid 
examination for suspected meningitis were examined for HIV and included in a 
prospective cohort study. Microbiological testing was done for common bacterial 
pathogens, mycobacteria and fungi. Patients were followed for at least 6 months, 
and logistic regression models were used to identify risk factors for mortality.
Results
Among 185 patients who mostly presented with subacute meningitis, 60% were 
male and the median age was 30 years. HIV infection was present in 25% of the 
patients; almost two-thirds were newly confirmed, and all presented with severe 
immunosuppression (median CD4 cell count 13/ μL, range 2–98). One-third of 
HIV-infected patients had cryptococcal meningitis whereas two-thirds suffered 
from tuberculosis.
After 1 month, 41% of patients had died. HIV infection was strongly associated 
with 1-month mortality (adjusted odds ratio 12.15; 95% confidence interval 3.04 
– 15.72) and death during extended follow-up (hazard ratio 2.48; 95% confidence 
interval 1.97–5.74).
Conclusion
Although HIV is still uncommon in the general population in Indonesia, its 
prevalence among adult meningitis cases already seems high. Mycobacterium 
tuberculosis and Cryptococcus neoformans are the main causes of meningitis in 
this setting, and mortality is very high, especially in HIV-infected patients. Our data 
suggest that adult meningitis cases in Indonesia should be screened routinely 
for HIV infection. Further studies are needed to address the high mortality.
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INTRODUCTION
Indonesia is witnessing one of the most rapidly growing HIV epidemics in Asia. 
Except for the region Papua, Indonesia has a concentrated epidemic largely 
driven by injecting drug use. The estimated prevalence of HIV among the 
general population is only 0.2%, but among risk groups, especially injecting drug 
users (IDUs), rates have been reported up to 50% [1]. Uptake of HIV testing is 
low, and many patients are only tested when they have advanced HIV infection 
or AIDS. Among patients diagnosed with HIV in 2006 in the top referral hospital 
for West Java, the median CD4 cell count was 32/μL (R. Wisaksana, personal 
communication). HIV patients with severe immunosuppression have a high risk 
of certain regular and opportunistic infections. Although definite diagnosis of 
such infections may be difficult in this setting, anecdotal data from Indonesian 
hospitals suggest that HIV infection is a major determinant of presentation and 
outcome of certain diseases, such as pulmonary infections, chronic diarrhea and 
dermatological problems.
Patients with advanced HIV infection often have severe neurological 
manifestations, especially meningitis. HIV infection is associated with a higher 
risk of cryptococcal, tuberculous and pneumococcal meningitis [2–4], and 
with a higher mortality of meningitis [5]. There are neither any data regarding 
the epidemiology of common adult meningitis in Indonesia, nor about a 
possible effect of HIV on its cause, presentation and outcome. We conducted 
a prospective study in a hospital setting in Indonesia to determine the HIV 
prevalence, causative agents, clinical and laboratory features and prognosis of 
adult patients with meningitis.
METHODS
Patient population and study design
Patients described in this study were admitted to Hasan Sadikin Hospital Bandung, 
Indonesia. This hospital serves the local community and acts as the top referral 
hospital for West Java Province (population about 40 million). Each year, about 
2000 neurology patients are admitted to the hospital, around 10% with central 
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nervous system (CNS) infections. Clinical data were recorded prospectively from 
all adult patients (> 18 years old) admitted with suspected meningitis to the 
ward between November 2006 and November 2008. The study protocol was 
approved by the Hospital Ethical Committee.
Study procedures
After providing informed consent, each patient underwent standard history 
taking, physical and neurological examination and lumbar puncture. The 
Glasgow Coma Scale (GCS) was used; an altered consciousness was defined as 
GCS < 14 and coma as GCS < 9 [6]. In the absence of computed tomography (CT) 
scan, considerations to perform lumbar puncture were based on clinical signs 
and symptoms.
Serological testing for HIV was done with informed consent during hospital 
admission for patients unaware of their HIV status and done anonymously for 
those who had died before consent was obtained. Follow-up was done until 
hospital discharge or death. At time of discharge, the outcome was graded 
according to the Glasgow Outcome Scale (GOS) [6]. All patients were reevaluated 
monthly until treatment was completed. Home visits and phone calls were made 
for those who were lost to follow up. The cause of death was determined by 
clinical signs only; autopsy was not performed.
Laboratory examinations
Cerebrospinal fluid (CSF) measurements consisted of standard macroscopic 
and biochemical analysis. Microscopy was done for cryptococci, acid-fast bacilli 
and bacterial pathogens using India Ink, Ziehl Nielsen and Gram staining, 
respectively. Culture was done for Mycobacterium tuberculosis (solid Ogawa and 
liquid MB-BacT; Biomerieux, Durham, North Carolina, USA), bacterial pathogens 
(blood agar, chocolate agar and brain–heart infusion) and fungi (Sabouraud). 
Cryptococcal antigen (CALAS; Meridian Diagnostics, Cincinnati, Ohio, USA) 
testing was done on CSF samples. All investigations were done at Department 
of Clinical Pathology, Hasan Sadikin Hospital. In a subset of patients, PCR was 
done on CSF for Streptococcus pneumoniae, Haemophilus influenzae, Neisseria 
meningitidis and Streptococcus suis [7] (courtesy Menno de Jong, Oxford Medical 
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Research Unit, Ho Chi Minh City, Vietnam). Species identification of Cryptococci 
was done at the Faculty of Medicine, University of Indonesia. Routine blood 
examination consisted of white blood cell count and differentiation, random 
blood glucose and sodium level. Mild and severe hyponatremia was defined 
as a serum sodium concentration less than 136 mEq/L and 125 mEq/L or less, 
respectively. Serum alanine transferase was measured as a baseline value and 
repeated in the case of suspected drug-induced hepatitis.
All blood samples were screened for syphilis using Venereal Disease Research 
Laboratory (VDRL) and for anti-hepatitis C virus (HCV) antibodies. Measurement 
of CD4 cell count for HIV patients only became available during the study. Chest 
radiograph abnormalities were recorded and classified as miliary, infiltrative, 
cavitary or other.
Diagnostic criteria
Diagnosis of meningitis was made using clinical or CSF criteria or both. Clinical 
criteria of meningitis included headache, fever and neck stiffness, with or without 
altered consciousness. CSF criteria were cell count more than 10 cell/mL, protein 
concentration more than 45 mg/dl or the CSF : blood glucose ratio less than 0.5; 
either alone or in combination [8].
Definite tuberculous meningitis (TBM) was diagnosed if CSF microscopy or 
culture or both were positive for M. tuberculosis [4]. Probable TBM was defined 
as meningitis with typical CSF findings in conjunction with suspected active 
pulmonary tuberculosis (TB) (using chest radiography), clinical sign of other 
extra pulmonary TB or bacteriologically confirmed TB outside the CNS.
Definite bacterial meningitis was defined as meningitis with detection of bacteria 
in CSF by microscopy or culture or characteristic CSF findings (a predominance 
of polymorphonuclear cells and a CSF : blood glucose ratio <0.4) in combination 
with a positive blood culture [9,10]. Probable bacterial meningitis was diagnosed 
in patients with clinical meningitis and characteristic CSF findings, without 
confirmatory bacteriological result, but with clinical improvement with antibiotic 
treatment.
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Cryptococcal meningitis was diagnosed if India Ink examination or cryptococcal 
antigen testing or both of CSF were positive [11].
The neurological status of patients with TBM was classified according to the 
British Medical Research Council (BMRC) definition as follows: grade I, normal 
consciousness, no neurological signs; grade II, confusion or neurological signs 
(meningeal or focal) and grade III, stupor or coma [4].
Drugs and dosage
TBM was treated with fixed dose combination of rifampicin (450 mg), isoniazid 
(300mg), ethambutol (750mg) and pyrazinamide (1500mg). For unconscious 
patients, drugs were given via nasogastric tube. Dexamethasone was given 
following recent recommendations [12]. Bacterial meningitis was treated with 
ceftriaxone intravenous (i.v.) 2–4 g/day for 10–14 days with administration of i.v. 
dexamethasone 20mg/day for 4 days [8,10].
Cryptococcal meningitis was treated with oral fluconazole (800mg/day) or 
intravenous amphotericine-B (0.7–1mg/kg bodyweight) if available [13]. HIV 
treatment was done in accordance with national guidelines, with nevirapine, 
lamivudine and zidovudine; patients on TB treatment received efavirenz instead 
of nevirapine.
Data analysis and statistics
Data were expressed as indicated using proportion (%), median and interquartile 
range (IQR). Parametric and nonparametric tests were used to identify 
differences between groups in continuous outcomes, and χ2 tests were used to 
compare categorical outcomes. Factors associated with 1-month mortality were 
identified using logistic regression. Factors significantly associated in univariate 
analysis and factors significantly different between HIV positive and negative 
patients were included in multivariate regression analysis. Progression to death 
was investigated by Kaplan–Meier estimates, and logistic regression was used to 
identify prognostic factors of death. Statistical analysis was done by SPSS version 
13. Survival curve was drawn using GraphPad Prism version 4.0.
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RESULTS
Patient characteristics
During the study period, 215 patients presented with suspected meningitis. 
CSF could not be obtained in 22 of the patients, and eight patients had other 
diagnoses, resulting in 185 patients in this study (Figure 1). Sixty patients were 
referred from other hospitals: 28 from hospitals in Bandung and the remaining 
from other cities.
Symbol * denotes declined lumbar puncture (16), contraindication to do lumbar puncture (5), and dry tap (1). 
ξ denotes toxoplasmosis (3), vascular lesion (1), miliary TB (2), space-occupying lesions (2)
Figure 1.  The case of 215 patients presenting with suspected meningitis. 
A total of 51 patients (27.6%) had a previous diagnosis of TB (pulmonary or 
extra pulmonary or both). Previous antibiotic treatment for bacterial infections 
(other than TB) was reported for 19 patients. Patients were mostly young males 
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presenting after a median duration of 2 weeks of complaints, with headache, 
neck stiffness, altered consciousness and focal neurological signs (Table 1). Forty-
seven patients (25%) were HIV-positive, 30 of which were newly diagnosed. CD4 
cell counts, available for 13 HIV patients, were very low (median 13/μL; range 
2–98). General and clinical characteristics were not associated with HIV infection, 
except for male sex, history of TB infection, duration of illness, headache and 
paraparesis (Table 1). The classic triad of headache, fever and neck stiffness was 
found in 61%. Cranial nerve palsies were present in 29%, hemiparesis in 23% of 
patients and paraparesis in 8% of the patients. The most common cranial nerves 
Table 1.  Demography, history, and physical examination (n=185) 
Data are presented as no. of patients / no. evaluated (%) unless stated otherwise. CI, confidence interval; CSF, 
cerebrospinal fluid; IQR, interquartile range; GCS, Glasgow Coma Scale; OR, odds ratio.
*p < .05 
**p < .01
Characteristics
HIV-positive
(n=47)
HIV-negative
(n=138)
P-value OR (95%CI)
General 
 Age in year - median (IQR) 30 (27-33) 29 (23-37) .57
 Male sex * 36 (76.6) 75 (54.3) .01 2.59 (1.21-5.55)
 History of TB * 19 / 46 (41.3) 32 / 129 (24.8) .04 2.13 (1.05-4.34)
Duration of illness  in days – median 
(IQR) *
30 (14-60) 14 (7-30) .01
Signs and symptoms on presentation
 Headache ** 37 / 46 (80.4) 122 / 130 (94.2) <.01 0.27 (0.10-0.75)
 Neck stiffness 43 / 47 (91.5) 126 / 130 (96.9) .14 0.35 (0.08-1.46)
 Body temperature > 38oC 17 / 41 (41.5)  48 / 122 (39.8) .81 1.09 (0.53-2.24)
 Altered consciousness (GCS < 14) 20 / 43 (46.5)  57 / 126 (45.2) .89 1.05 (0.53-2.11)
          Coma (GCS <9) 1 / 43 (2.3)  10 / 125 (8.0) .19 0.27 (0.03-2.20)
 Hemiparesis 12 / 47 (25.5)  28 / 121 (23.1) .74 1.14 (0.52-2.48)
 Paraparesis * 0 / 47 (0) 13 / 123 (10.6) .02 1.43 (1.29-1.58)
 Cranial nerve palsy 12 / 47 (25.5)  39 / 127 (30.2) .51 0.77 (0.36-1.65)
The effect of HIV infection on adult meningitis in Indonesia
29
2
affected were abduscens and oculomotor nerves. Eighteen patients (9.7%) had 
had seizures at some points, mostly generalized.
Laboratory findings
CSF findings confirmed meningeal inflammation in most of the patients. However, 
only 62% showed all the three diagnostic criteria of meningeal inflammation, 
and 14% had only one criterion or no abnormalities. Hyponatremia was 
common (68%) and was severe in 52% and mild in 16% of patients. Laboratory 
examinations showed lower CSF and peripheral leukocyte counts and higher 
plasma sodium among HIV-infected patients (Table 2). Reflecting the nature 
Table 2.  CSF, blood and radiological examination findings (n=185) 
Characteristics
HIV-positive 
(n=47)
HIV-negative 
(n=138)
p-value
Indexes of CSF inflammation
 Leukocytes / mL – median (IQR) ** 18 (2-143) 95 (17-232) 0.003
 % lymphocytes – median (IQR) 60 (22-90) 65 (38-87) 0.75
 % neutrophils – median (IQR) 22 (0-49) 27 (10-59) 0.16
 Protein in mg/dL – median (IQR) 120 (64-200) 140 (58-363) 0.27
 Glucose in mg/dL – median (IQR) 36 (14-45) 26 (11-45) 0.24
 CSF:blood glucose ratio – median (IQR) 0.37 (0.13-0.43) 0.23 (0.11-0.43) 0.12
Blood examination
 Leukocytes - x103/ mL – median (IQR) ** 5.50 (4.30-9.15) 11.50 (8.50-14.43) <0.01
 Plasma Na+ (mEq/L) – median (IQR) * 132 (125-138) 128 (121-134) 0.05
Radiological Examination
 Abnormal Chest X-ray – no. (%)** 23/45 (51.1%) 91/125 (72.8%) <0.01
 Infiltration – no. (%) 15 48
 Miliary TB – no. (%) 7 33
 Other – no. (%) 1 10
No blood examination was done in three HIV-negative patients, no chest X-ray in one HIV-positive and five 
HIV-negative patients. CSF, cerebrospinal fluid; IQR, interquartile range.
*p < .05 
**p < .01
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of the HIV epidemic in Indonesia, which is mostly driven by IDU, 71.8% of HIV-
infected and 4.7% of HIV-uninfected patients had antibodies against HCV.
Radiology
Chest radiograph abnormalities, mostly showing infiltrative and miliary lesions 
suggesting TB, were found in 67% of patients (Table 2). Chest radiograph 
abnormalities were more common among HIV-negative patients (p<0.01). 
Head CT scans were only available for 17 patients and were abnormal in 11. 
CT-scan abnormalities included cerebral edema, hydrocephalus and meningeal 
enhancement; no mass lesions were found.
Etiology
A definite cause of meningitis could be established in 102 patients (55%) (Table 
3). Mycobacterium tuberculosis was detected in 86 patients, mostly confirmed 
by culture. Cryptococcus species were identified in 15 patients (8%); 14 by 
means of India ink and confirmed by cryptococcal antigen test and one by 
cryptococcal antigen test only. Pneumococcal meningitis was diagnosed in 
one patient, confirmed by bacterial culture. Among 83 patients (45%) without 
microbiological confirmation, 67 had a probable diagnosis of TBM based on 
duration of symptoms (median 21 days), moderate CSF leukocytosis mostly 
consisting of mononuclear cells (median 69%) and a high prevalence (85%) of 
Table 3.  Final diagnosis according to HIV-status
Diagnosis
HIV-positive
(n=47)
HIV-negative
(n=138)
Total population
(n=185)
Tuberculous meningitis (TBM) 31 (66.0%) 122 (88.4%) 153 (82.7%)
Definite TBM 10 76 86
Probable TBM 21 46 67
Cryptococcal meningitis 14 (29.8%) 1 (0.7%) 15 (8.1%)
Definite bacterial meningitis - 1 (0.7%) 1 (0.5%)
Probable bacterial meningitis - 10 (7.2%) 10 (5.4%)
Unknown cause 2 (4.3%) 4 (3.6%) 6 (3.2%)
Data are presented as number of patients (percentage) 
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chest radiograph abnormalities typical for TB; 10 had a probable diagnosis of 
bacterial meningitis based on typical CSF presentation (median CSF cell count 
1168/μL with 90% neutrophils) and good response to antimicrobial therapy.
No cause of meningitis could be ascertained in six patients. Syphilis serology 
was negative in all patients. Thirty-nine patients (25%) with TBM were admitted 
to the hospital with BMRC grade I, 89 (58%) with grade II and 25 (16%) with 
grade III. The severity (grading) of TBM was not significantly associated with 
bacteriological confirmation or HIV status (t-test; p=0.33 and 0.50, respectively).
Treatment
TB treatment was given to 155 patients with an initial diagnosis of TBM: as 
continuation of ongoing TB treatment for 18 patients and newly started for 137.
Ceftriaxone was added in 12 patients; nine with pneumonia and three with 
suspected bacterial meningitis. The patient with definite bacterial meningitis and 
10 patients with suspected bacterial meningitis were treated with ceftriaxone 
for 7–14 days. Ten patients with cryptococcal meningitis were treated with 
amphotericine-B (n=4) or oral fluconazole (n=6), whereas two patients died 
before initiation of treatment, and treatment was unavailable for three patients. 
Dexamethasone was administered to 88 of 155 patients (57%) with suspected 
TBM, but none exactly followed the prolonged course as recently suggested 
[12] for logistical reasons and toxicity (gastrointestinal bleeding). The median 
initial dose of dexamethasone was 20 mg (range 10–40 mg), and duration 
of treatment varied (range 1–14 days). Eight out of 155 patients (5%) on TB 
treatment developed drug-induced hepatitis, four with grade 3. In these patients, 
rifampicin, isoniazid and pyrazinamide were substituted by ciprofloxacin and 
streptomycin. Four HIV-patients were on antiretroviral therapy (ART) prior to 
admission, and three newly diagnosed patients started ART after at least 2 weeks 
of meningitis treatment. Ventriculo-peritoneal shunting was performed in three 
patients with hydrocephalus.
Outcome
Mortality was high and strongly associated with HIV infection. Seventy-six 
patients (41%) died within the first month of follow-up, mostly in the first week. 
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The suspected cause of death was available in 68 patients and was neurologic in 
42 (62%) and systemic in 26 patients (38%). Of the patients who had undergone 
ventriculoperitoneal shunting, one survived and two died after 3 and 6 weeks, 
respectively. Among HIV-positive patients, seven out of 10 with TBM, and eight 
out of 14 with cryptococcal meningitis died. In univariate analysis, HIV infection 
was strongly associated with 1-month mortality [odds ratio (OR) 4.00; 95% 
confidence interval (CI) 1.99–8.07]. The effect of HIV was similarly strong when 
the comparison was limited to patients with TBM (OR 4.31; 95% CI 1.85–10.00). 
Other factors associated with 1-month mortality were altered consciousness 
and fever on admission. In multivariate analysis, only HIV status remained 
significantly associated (Table 4). No significant correlation was found between 
CSF biochemical parameters and death.
Sixty-three out of 111 patients (57%) left the hospital with a maximal GOS score 
and 48 (43%) with neurologic sequelae. All surviving patients were followed 
(median follow-up 56 days; IQR 4–214). During this follow-up time, 17 additional 
patients died after a median of 60 days (range 5–438). Using t-test, the score on 
the GOS upon hospital discharge was associated with this late mortality (p=0.002). 
Using Kaplan–Meier estimates, the death rates at 6 months were 25.6% (95% CI 
17.3–30.9%) for HIV-negative and 62.8% (95% CI 57.9–73.1%) for HIV-positive 
patients (Figure 2).
Figure 2.  Longterm survival of HIV-positive and HIV-negative patients
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DISCUSSION
In this cohort of Indonesian adults presenting with subacute meningitis, HIV 
infection was unexpectedly common and strongly associated with mortality. 
More than one-quarter of patients presented with HIV infection, which was mostly 
newly diagnosed. TB was the most common cause, and among HIV-positive 
patients, almost one-third suffered from cryptococcal meningitis. Mortality, 
both early and late, was more than twice as high among HIV-positive patients as 
compared with HIV-negative patients.
The most important finding in our study is the high HIV seroprevalence. HIV 
among the general population in Indonesia is still low at 0.2%, but 25% of this 
cohort of patients with meningitis were HIV-positive. Although HIV prevalence 
rates in some other Southeast Asian countries are declining, Indonesia is 
witnessing an accelerating growth [1]. It seems to be a matter of time before 
Indonesia, which has the fourth biggest population in the world, will have a more 
generalized HIV epidemic. Our data support the need for effective prevention 
and early detection of HIV in Indonesia. The low CD4 cell counts, confirming late 
presentation, further stresses the importance for earlier detection and timely HIV 
treatment. 
TB was the main causative agent of meningitis. The prevalence of TBM (83%) in 
this series is much higher compared with studies from low-income countries. In a 
large cohort of adult meningitis in Vietnam, TBM was diagnosed in 40% of patients 
[14]. Smaller case-series in Asia and Africa found prevalence of TBM ranging from 
13 to 46% [15–18]. The high prevalence of TBM in our setting was not due to the 
definitions we used. Bacterial confirmation of TBM in our cohort (56%) was higher 
than in previous studies from low-income countries whose diagnostic yields 
were 5–20% [4,19], though one small study from South Africa revealed a positive 
result in 60% of patients [20]. We believe that good flow of samples and use of 
large CSF samples and liquid culture contributed to our result. In our cohort, 
confirmation of TBM was lower in HIV-positive than in HIV-negative patients. 
This is different from other reports from Argentine and Vietnam, which reported 
a higher posi tivity rate among HIV positive patients [4,21]. The use of molecular 
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testing might further increase the number of confirmed cases [22]. The second 
most common pathogen was Cryptococcus neoformans, which accounted for 
almost one-third of cases among HIV patients. This finding reemphasizes the 
notion of cryptococcal meningitis as an important opportunistic infection 
among HIV patients [2]. The global burden of cryptococcal meningitis has been 
estimated at one million infections in 2006, with half a million deaths [23]. To 
our knowledge, this is the first publication of proven cryptococcal meningitis 
from Indonesia. Interestingly, we only confirmed one case of acute bacterial 
meningitis. This finding is in contrast with various reports from other Asian 
countries [7,14,24]. In the Viet nam cohort, 30% of its participants had bacterial 
meningitis, mainly caused by Streptococcus suis [14]. Bacterial meningitis due 
to S. suis is linked to contact with pigs or uncooked pig products [7,25], which 
is rare in Indonesia. Despite the difference with other studies, we believe that 
our findings do reflect the causative pattern of meningitis in patients who visit 
this referral hospital. We performed an extensive microbiological workup to 
all specimens, and CSF patterns and other supporting evidence (history, chest 
radiograph abnormalities) were consistent with TBM in the majority of patients. 
It could be that patients with acute bacterial meningitis may never have 
reached our hospital, either because they had died earlier or because they had 
received antibiotic treatment elsewhere. Although no viral diagnostic assays 
were performed, it seems unlikely that patients in this cohort suffered from viral 
meningoencephalitis. First, cryptococcal TB and bacterial meningitis altogether 
accounted for almost all cases. Second, the subacute presentation, frequent 
history of previous TB treatment and chest X-rays suggesting TB, the common 
presence of meningismus and cranial nerve palsies and the CSF patterns all 
point against herpes or enteroviruses as a cause of disease in this cohort.
Within 1 month, 41% of patients had died and another 9% died during further 
follow-up. The high mortality was strongly associated with HIV. Literature reports 
suggest that for cryptococcal meningitis, a low GCS score, a high fungal burden, 
a high CSF opening pressure and a poor inflammatory response (white blood 
cells <20) seem predictive of a poor prognosis [2]. For TBM, a low GCS score, 
advanced stage of disease on admission, and raised intracranial pressure seem 
predictive of a poor outcome [15,19,20]. In addition, given the high proportion 
of patients with a previous history of TB treatment, it is likely that at least some 
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patients in our cohort had multidrug resistant (MDR) TB, which strongly increased 
mortality in a study in Vietnam [26]. Unfortunately, drug resistance testing is not 
routinely available in our setting, and government regulations largely exclude 
the possibility of sending samples abroad. Possibly, neurosurgical intervention 
for hydrocephalus might have improved survival, but in our cohort, this was 
severely hampered by the low availability of CT scan. There are also opportunities 
to improve pharmacological treatment. The most effective drugs to treat 
cryptococcal meningitis [13] are not consistently available (amphotericine B) 
or not available at all (flucytosine) in Indonesia. Fluconazole prophylaxis and 
preemptive fluconazole therapy for those who screen positive for cryptococcal 
antigen may prevent meningitis and death [27,28]. With regard to TB, intravenous 
antituberculous drugs are unavailable, and one may question the bioavailability 
of oral drugs, especially when administered through a nasogastric tube in 
comatose patients. In addition, corticosteroid treatment for TBM was often not 
given in accordance with evidence from a large clinical trial [12]. Of note, so far 
there is not enough evidence to support the use of corticosteroids for TBM in HIV-
positive patients [29]. In addition, it is yet unknown whether immediate initiation 
of ART can improve outcome. Obviously, earlier detection and treatment of HIV 
will prevent cryptococcal and TBM and possibly improve its outcome.
Our study suffers from certain limitations. CT scanning was rarely available, 
and decisions to perform lumbar puncture were based on clinical signs only. 
In addition, there may have been selection of patients as we included patients 
in a single (large) hospital only. However, despite these limitations, we believe 
we are able to make some important conclusions. HIV is unexpectedly high and 
associated with increased mortality, cryptococcus is common, and TB is the 
main cause of adult meningitis in this setting. Our study shows that all adult 
meningitis patients in this setting should be tested for HIV and that there is a 
great need for effective prevention and early HIV testing in light of the growing 
HIV epidemic in Indonesia. The high mortality among our patients warrants 
further study to explore the benefit of earlier diagnosis, possible neurosurgical 
interventions and better drug treatment.
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ABSTRACT
Background
Bacteriological confirmation of tuberculous (TB) meningitis is difficult. Culture 
is slow and microscopy has insufficient sensitivity. We evaluated real time PCR 
targeting insertion sequence IS6110 among 230 consecutive adult patients with 
subacute meningitis in a referral hospital in Indonesia. 
Methods
Cerebrospinal fluid (CSF) samples were examined using microscopy, solid and 
liquid culture, and real time IS6110-PCR with a fluorescence-labeled probe using 
DNA extracted from CSF Forty. CSF samples of non-infectious neurology patients 
were used as negative controls. IS6110-PCR results were linked with clinical and 
CSF characteristics. 
Results
Most patients presented with subacute meningitis, after a median of 14 days of 
symptoms (range 7-30). After exclusion of cryptococcal and bacterial meningitis, 
207 patients were classified as definite or probable TB meningitis; 17.9% with HIV 
infection. In this group IS6110-PCR gave the highest positivity rate (68%, 95% CI 
62-74%) compared with microscopy of ZN-stained slides (11%, 95% CI 7-15%), 
and mycobacterial culture using solid (36%, 95% CI 29-42%) and liquid (44%, 
95% CI 37-51%) media. IS6110-PCR was positive in 92% of patients with culture-
positive and 42% of patients with culture-negative probable TB meningitis. 
Among culture-negative patients, a positive PCR was associated with a history 
of TB treatment, a longer duration of illness, a higher CSF cell count and protein, 
and a lower CSF glucose. IS6110-PCR was negative in all CSF samples from non-
meningitis control patients. 
Conclusions
Real time IS6110-PCR is a quick, sensitive, and specific test for diagnosing of TB 
meningitis in this setting. Its performance in other (less-developed) settings 
needs further study.
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INTRODUCTION
Tuberculous (TB) meningitis is the most severe form of tuberculosis and causes 
substantial morbidity and mortality in adults and children [1]. Early recognition 
and treatment of the disease is believed to be able to reduce the burden of 
this disease, but this is hampered by the fact that it is often difficult to find 
bacteriological proof for TB meningitis. [2,3]. Microscopy of cerebrospinal fluid 
(CSF), although inexpensive and rapid, has a poor sensitivity, ranging from 1.9% 
to 20% in different series, with the exception of one study (58%) that used 
large volumes of CSF [3,4,5]. CSF culture, also lacks sensitivity for diagnosing 
TB meningitis [2,3,4,6]. Furthermore, the slow growth of Mycobacterium 
tuberculosis, that usually takes up to 4 to 6 weeks limits the role of culture in 
decisions regarding initiation of TB treatment [7]. Therefore, a rapid and accurate 
diagnostic test would greatly benefit timely and adequate management of 
patients with possible TB meningitis. 
Nucleic acid amplification (NAA) tests seem an attractive diagnostic tool for TB 
meningitis because of their speed and expected high sensitivity. However, a 
systematic review and metaanalysis of the accuracy of NAA tests for diagnosis 
of TB meningitis showed that commercial NAA test had a high specificity (98%; 
95% CI 97-99%) but a low sensitivity when compared with culture (56%; 95% CI 
46-66%) among 14 studies combined [8]. The recently developed GeneXpert 
system, combining DNA extraction with a real time PCR that simultaneously 
detects both M. tuberculosis and rifampin resistance, has a lower sensitivity 
compared to culture, but to our knowledge only one study has reported use 
in suspected meningitis [9]. In that study none of 19 CSF samples were positive 
with GeneXpert. This method was not available in Indonesia when the study was 
performed.
In-house PCR for diagnosis of TB meningitis may be more sensitive, possibly due 
to the use of nested PCR, DNA extraction methods, or use of different molecular 
targets. However, the precise role of in-house PCR for TB meningitis remains 
uncertain. Many in-house assays have been evaluated without adequate 
standardization and using small groups of patients [10,11,12,13]. The present 
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study therefore evaluated in-house real time PCR targeting IS6110 in CSF samples 
from a well-characterized cohort of 230 adult patients with suspected meningitis, 
making comparisons with CSF M. tuberculosis culture and microscopy. 
METHODS
Ethics statement 
Anonymized CSF samples were used from an already-existing hospital 
collection, collected as part of a project ‘Optimization of diagnosis of meningitis’, 
approved by the Ethical Committee of Hasan Sadikin Hospital / Faculty of 
Medicine of Universitas Padjadjaran, Bandung, Indonesia (No. 85/FKUP-RSHS/
KEPK/Kep/EC/2006). The current study made use of an already existing sample 
collection, no separate patient consent was asked for this study. HIV testing is 
done routinely after verbal informed consent for all patients with suspected 
meningitis in Hasan Sadikin hospital. Consent is obtained from closest relatives 
(husband/wife or parents) for those patients who are unstable or unconscious 
at time of presentation. HIV testing was done anonymously afterwards for those 
who had died before consent could be obtained. This study was approved by 
the ethical review board of Padjadjaran University / Hasan Sadikin Hospital, 
Bandung, Indonesia.
Setting and patients 
Patients were recruited at Hasan Sadikin Hospital, top referral hospital for West 
Java, Indonesia, where approximately 100 adult patients present with subacute 
meningitis each year. A clinical diagnosis of meningitis in this setting is based 
on clinical findings, CSF criteria or both. Clinical criteria of meningitis included 
headache, fever and neck stiffness, with or without altered consciousness. CSF 
criteria were cell count >10 cell/mm3, protein concentration > 45 mg/dL, or the 
CSF: blood glucose ratio < 0.5; either alone or in combination. For this study, 
definite TB meningitis was defined as CSF microscopy or culture positive for 
M. tuberculosis. Probable TB meningitis was defined as meningitis with typical 
CSF findings in conjunction with either: suggestive chest X-ray abnormalities; 
suggestive TB lymphadenitis; bacteriologically confirmed TB outside the CNS. 
Definite bacterial meningitis was diagnosed if bacteria were detected in the CSF, 
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while probable bacterial meningitis was diagnosed in patients with characteristic 
CSF findings without a confirmatory bacteriological result. Cryptococcal 
meningitis was diagnosed if either India Ink examination or cryptococcal 
anti gen testing of CSF were positive [14]. Final diagnoses was reviewed by a 
panel of experts. Patients with suspected or proven bacterial meningitis are 
prescribed ceftriaxone with corticosteroids, those with cryptococcal meningitis 
amphotericin B, and those with presumed TB standard TB treatment with 
adjunctive corticosteroids according to national and international guidelines 
[15].
Clinical evaluation
All consecutive patients presenting with clinical meningitis between 2006 
and 2008 were included for this study. Signs and symptoms were recorded 
using standardized forms, and CSF was obtained for routine examination and 
microbiological testing as described below. Further routine examinations 
included chest X-ray examination and sputum examination if indicated. 
Neuroradiology is not routinely done in this setting since it is not covered by 
the government health insurance for the poor. For this study the HIV-status was 
determined anonymously for those patients who had died before consent was 
obtained. 
Routine CSF examination
Following a lumbar puncture, 5-10 mL CSF was obtained, transported to the 
laboratory within one hour, and divided into two tubes: one (0.5 – 1 mL) for CSF 
cells, protein and glucose, and one (8 – 10 mL) for microbiological testing. The 
second tube was then concentrated by centrifugation at 3000 x g for 10 minutes. 
The CSF sediment was used to prepare smears for direct examination of acid-fast 
bacilli after Ziehl-Neelsen (ZN) staining, bacteria (Gram) and Cryptococci (India 
ink). For Mycobacterial culture, the sediment was inoculated onto two slants 
of Ogawa egg medium and on MB/BacT alert system (Biomerieux, Durham, 
North Carolina, USA) according to the manufacturer’s instruction. Ogawa slants 
were incubated at 37°C and observed twice weekly for 3 months. For culture of 
bacterial pathogens some sediment was inoculated on blood agar and Trypton 
Soy Broth (TSB), while Sabouraud plates were inoculated for growth of fungi. 
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Distilled water was processed in parallel with each CSF sample as a negative 
control. Cryptococcal antigen (CALAS; Meridian Diagnostics, Cincinnati, Ohio, 
USA) testing was also done on all CSF samples. At the time of our study, the 
GeneXpert system was not yet operational in Indonesia.
Real time PCR for M. tuberculosis
DNA was extracted from 200 µl of CSF sediment by using QIAmp DNA mini kit 
(Qiagen, USA). CSF samples were spiked with a known concentration of PhHV as 
an inhibition control. Each batch of extraction included CSF negative controls 
to rule out any contamination, with a minimum of two negative controls per-18 
CSF samples. Primers and probes used for real time IS6110-PCR amplify fragment 
of IS6110, a repeated insertion sequence specific for M. tuberculosis complex [16]. 
The total PCR volume was 20 μl (7 μl extracted DNA in 13 μl PCR-mix). The PCR-
mix consisted of Platinum Quantitative PCR Supermix-UDG (Invitrogen), 300 nM 
of each primer of IS6110, 150 nM of the FAM-labeled M. tuberculosis probe, 200 
nM of each primer of PhHV inhibition control, and 150 nM of the Cy5-labeled 
PhHV inhibition control probe. PCR amplification was carried out during 2 min 
at 50°C for UDG activation, 10 min at 95°C and 40×15 s at 90°C, 1 min 60°C. Each 
run of the assay included two negative controls to rule out any contamination 
along the preparation of PCR-mix and sample addition, respectively. The positive 
control included the DNA of H37Rv with the Ct value 29 ± 1. PCR was performed 
in Chromo4TMsystem real time PCR detector (Biorad laboratories, Inc.).
Adequate care was taken to prevent carry over amplicon contamination by 
performing the PCR in three separate rooms (clean room, extraction room, 
and amplification room), by using barrier tips, and also by using PCR-mix that 
contained Uracyl DNA-Glycosylase (UDG). CSF samples from additional 40 non-
infectious neurology patients were used as negative controls. For all samples, 
PCR was done blinded to results of CSF microscopy and culture and clinical data. 
Data analysis and statistics
After exclusion of patients with bacterial and cryptococcal meningitis, the 
positivity rate of microscopy for acid-fast bacilli, M. tuberculosis culture using 
solid and liquid media, and IS6110-PCR was expressed as percentage (%) for the 
remaining group. The sensitivity of IS6110-PCR using culture as gold standard was 
Validation of real-time IS6110 PCR for diagnosis of TB meningitis
49
3
expressed as percentage (95% confidence interval). Comparisons were made of 
CSF and clinical characteristics of patients after stratification by M. tuberculosis 
culture- and PCR-results. Continuous variables are expressed as mean (SD) 
if normally distributed and median (interquartile range, IQR) if not normally 
distributed, and categorical variables as percentage. Differences between groups 
were compared using Chi-square test for proportions and Mann-Whitney U test 
for continuous variables, with p-values <0.05 considered statistically significant. 
Statistical analysis was done by SPSS version 16. 
RESULTS
A total of 230 consecutive patients with suspected meningitis were included. 
Patients were mostly male (60%), with a median age of 30 years (range 24-36 
years), presenting after a median of 14 days (range 7-30 days) of symptoms, mostly 
with headache (67%) and altered consciousness (31.3%) as chief complaints. On 
examination, nuchal rigidity (77.2%), lowered consciousness (52.6%), and focal 
neurological signs were common. HIV infection was present in 22.2%; one patient 
was not tested. 
Based on CSF culture and microscopy, subjects were classified into four groups 
(Figure 1). TB meningitis was diagnosed in 207 patients (90%), cryptococcal 
meningitis in 13 (5.6%), bacterial meningitis in 7 (3%), and meningitis was 
excluded in 3 patients (0.1%). Among 207 patients with suspected TB meningitis, 
a definite diagnosis could be established in 105 patients (50.7%) based on culture 
and microscopy (n=102) and microscopy alone (n=3). We could classify 102 
patients (49.3%) as probable TB meningitis. 17.9% of patients with TB meningitis 
were HIV-infected.
IS6110-PCR assay was positive in 143 patients, 140 patients with TB meningitis, two 
patients with confirmed cryptococcal meningitis, and one patient with suspected 
bacterial meningitis. For the patient with suspected bacterial meningitis, TB was 
also confirmed by direct spoligotyping of the CSF sample for M. tuberculosis, as 
described elsewhere [17]. None of the 40 patients in the control group had a 
positive IS6110-PCR result.
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Figure 1.  Diagnosis among 230 meningitis suspects based on clinical characteristics 
and CSF microscopy and culture.
Figure 2 shows the comparison of diagnostic modalities for TB meningitis. The 
diagnostic yield of IS6110-PCR was much higher (68%, 95% CI 62-74%) compared 
to solid culture (36%, 95% CI 29-42%; p<0.001) and microscopy (11%, 95% CI 
7-15%; p<0.001), and higher than liquid culture (44%, 95% CI 37-51%) although 
this was not statistically significant (p=0.262). As shown in Figure 2, this was 
true for HIV-infected and -non-infected patients although the positivity yield of 
IS6110-PCR was lower among HIV-infected patients (49%, 95% CI 33-65% vs 73%, 
95% CI 66-80%; p=0.004). Larger CSF samples were more often PCR-positive; 50% 
of samples < 4 mL (n=22) were positive, compared with 71% of samples > 4 mL 
(n=181, p=0.05). 
M. tuberculosis culture (either solid or liquid) was positive in 102 patients, and 
IS6110-PCR in 140 patients (Table 1). Using culture as the gold standard, IS6110-
PCR had a sensitivity of 92% (95%CI 87-97%), compared with 21% (95% CI 13-
29%) for microscopy. Among 46 culture-negative PCR-positive patients, 43 were 
clinically diagnosed as probable TB meningitis. For all of those patients there 
was supporting evidence for a diagnosis of TB: 17 patients had confirmed TB 
outside the CNS; 13 were cured after TB treatment; and 13 had been taking TB 
Validation of real-time IS6110 PCR for diagnosis of TB meningitis
51
3
Figure 2.  Positivity rate of different diagnostic tests for TB among 207 meningitis 
patients. 
Patients with cryptococcal (n=13), bacterial (n=7), and no meningitis (n=3) were excluded, HIV-status was 
unknown for one patient. ZN staining was used for microscopy, Ogawa for solid culture, and MB/BacT system 
for liquid culture. Differences between IS6110-PCR and solid culture (p<0.001) and microscopy (p<0.001) were 
statistically significant. 
Table 1.  Comparison of M. tuberculosis culture and IS6110-PCR results among 207 TB 
meningitis patients
Culture
Total
Positive Negative
IS6110-PCR Positive 94 (45%) 46 (22%) 140 (67%)
Negative 8 (4%) 59 (29%) 67 (33%)
Total 102 (49%) 105 (51%) 207
drugs for some days before lumbar puncture, while it is known that CSF cultures 
quickly become negative after start of TB treatment.
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Among patients with a negative M. tuberculosis culture, positive IS6110-PCR was 
associated with a lower CSF glucose, and a higher CSF cell count and protein, 
a longer duration of illness, and more frequent history of previous TB treatment 
(Table 2). Clinical features of this group of patient were in accordance with that 
of TB meningitis. On presentation 44% had decreased level of consciousness, 
28% had fever, 86% had neck stiffness, 32% had motor deficit, and 22% had 
cranial nerve palsies. 14% of these patients were HIV-positive. Among 21 HIV-
infected patients with negative M. tuberculosis culture, similar differences were 
found, although none were significant. 
Table 2.  CSF and clinical characteristics of 166 HIV-negative patients with suspected 
TB-meningitis according to culture and PCR-result
Culture 
positive 
(n=88)
Culture negative (n=78)
PCR positive 
(n=39)
PCR negative 
(n=39)
p-
value
Duration of illness (days) – median (IQR)
History of TB – no. (%)
CSF 
Cells/mL – median (IQR)
PMN % – median (IQR)
MN % – median (IQR)
Protein (mg/dL) – median (IQR)
Glucose (mg/dL) – median (IQR)
CSF:blood glucose ratio – median (IQR)
14 (7-30)
13/86 (15.1)
136 (47-262)
37 (20-62)
63 (38-80)
160 (63-370)
16 (9.8-32.0)
0.13 (0.09-0.24)
14 (7-21)
12/38 (31.6)
66.5 (7-121)
13 (0.5-52)
72 (41-95.5)
125 (40-342.5)
36.5 (18.8-48.8)
0.34 (0.17-0.46)
8 (6-14)
5/36 (13.9)
11 (0.8-334.8)
10 (0-44)
72 (30-95)
55 (40-412.5)
48 (37-60.8)
0.46 (0.34-0.56)
.104
.068
.302
.750
.423
.620
.026
.017
Three culture negative / PCR positive patients were not included because microscopy was positive. 
PMN=polymorphonuclear cell, MN=mononuclear cell, IQR=interquartile range
DISCUSSION
In this study real time IS6110-targeted PCR had a high positivity rate (68%) among 
patients with suspected TB meningitis, higher than M. tuberculosis microscopy 
(11%), and M. tuberculosis culture using solid (36%) and liquid (44%) media, both 
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among HIV-infected and non-infected subjects. CSF characteristics and clinical 
data of culture-negative/PCR-positive patients were in line with a diagnosis of 
TB meningitis, and specificity of the IS6110-PCR was 100% in a control group of 
patients with alternative diagnoses.
Untreated TB meningitis is almost uniformly lethal and delay in treatment is 
associated with increased mortality and morbidity. Unfortunately, CSF microscopy 
has poor sensitivity, while M. tuberculosis culture is slow and therefore has a 
limited role in decisions about treatment of possible TB meningitis. M. tuberculosis 
PCR has the potential to be the ideal tool for rapid diagnosis of TB meningitis. 
Unfortunately, commercial PCR tests from Roche, Abbott, and Genprobe 
before 2003 only have a moderate sensitivity for diagnosis of TB meningitis, 
as summarized in a systematic review [8]. Some studies have reported higher 
sensitivity for in-house PCR assays, but their role in diagnosis of TB meningitis 
remains uncertain. In the present study we evaluated in-house real time IS6110-
PCR in CSF samples from a well characterised cohort of 230 meningitis patients, 
larger than previous series [18,19]. The high prevalence of TB meningitis in our 
cohort was confirmed bacteriologically in the majority of patients, more than in 
most published case series [18,20]. 
In-house IS6110-PCR had a higher positivity rate (68%) in our cohort compared 
to many other case series evaluating in-house PCR, some using IS6110 as a target 
[6,7,21,22,23]. This may have been due to the use of large volume CSF samples 
(5-10 mL), as was nicely shown in an earlier study [5], and IS6110, which has 
multiple copies present in the genome of M. tuberculosis complex, as the PCR 
target [16]. We used PhHV as an inhibition control in each sample to rule out the 
possibility of PCR inhibition with a false negative PCR result. The positivity rate 
of IS6110-PCR in our study was lower among HIV-infected patients, in line with 
a study from India [24], and possibly due to the fact that cerebral toxoplasmosis 
may mimic TB meningitis in the absence of neruradiology, as we have recently 
shown [25], underlining the need for more extensive microbiological testing in 
HIV-infected patients. Compared with culture, IS6110-PCR had a sensitivity of 
92%, in line with some earlier previous studies [3,21,26] but superior compared to 
some other studies which reported sensitivity rates of 32-75% [7,12,22,23,27,28]. 
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Two patients with cryptococcal meningitis, and one with bacterial meningitis had 
a positive IS6110-PCR result. Mixed infections of mycobacterial with cryptococcal 
meningitis [25,29] and bacterial meningitis have been reported previously [24,30]. 
The presence of M. tuberculosis DNA in our patient with bacterial meningitis was 
confirmed by M. tuberculosis spoligotyping. 
The detection of IS6110 PCR in culture-negative patients (n=46) was often (40%) 
supported by TB outside the CNS or a good response to TB treatment. In addition, 
some patients had been taking TB drugs, which is known to sterilize CSF cultures 
within days [31]. The higher positivity of IS6110-PCR compared to culture (although 
not statistically significant compared with liquid culture) in these patients may 
have been due to amplification of DNA from non-viable organisms. Further 
support for the specificity of IS6110-PCR was derived from a closer examination 
of the group of culture-negative patients. Those with positive PCR results usually 
had a lower CSF glucose, raised protein level, and more pronounced pleiocytosis. 
A previous history of TB was more common in patients with a positive IS6110-
PCR result (33% vs 14%), and duration of illness was typically longer (median 14 
days vs 7 days). Obviously, the sensitivity of this assay will be lower in areas with 
a substantial prevalence of M. tuberculosis strains with no or only a few IS6110 
copies. However, this seems to be relatively rare, and multiple copies of IS6110 
were present in all strains from a previous study we conducted in Indonesia [32].
The positive IS6110-PCR results obtained from those patients could not be due 
to amplicon contamination as physical separation rooms were used for sample 
processing, PCR setup, amplification process, carefull handling procedure, the use 
of barrier tips, dUTP-uracil glycosylase system, and unambiguous negative results 
from our negative IS6110-PCR controls. Real time PCR allows direct observation 
of amplicon reaction without the need to open PCR tubes, thereby avoiding the 
possibility of amplicon contamination. Finally, none of the patients in the control 
group with non-infectious CNS disease had a positive IS6110-PCR result.
The strength of our study is the validation of in-house IS6110-PCR in a large 
group of TB meningitis patients, much larger than most previously published 
series. Other strenghts include the use of comparative M. tuberculosis culture 
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(solid and liquid) and microscopy, a work-up for other pathogens, and the fact 
that laboratory results were linked with clinical data. Unfortunately no direct 
comparison could be made with a commercial PCR. Despite this limitation, we 
can conclude that in-house PCR targetting IS6110 is a very sensitive and specific 
method for diagnosis of TB meningitis, which may speed up diagnosis and timely 
treatment of this deadly disease. It should be noted that this assay, evaluated in a 
single highly-qualified laboratory, may not perform equally well in other settings.
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ABSTRACT
Background
HIV-associated subacute meningitis is mostly caused by tuberculosis or crypto-
coccosis, but often no etiology can be established. In the absence of CT or MRI 
of the brain, toxoplasmosis is generally not considered as part of the differential 
diagnosis. 
Methodology / principal findings
We performed cerebrospinal fluid real time PCR and serological testing for 
Toxoplasma gondii in archived samples from a well-characterized cohort of 64 
HIV-infected patients presenting with subacute meningitis in a referral hospital 
in Indonesia. Neuroradiology was only available for 6 patients. 
At time of presentation, patients mostly had newly diagnosed and advanced 
HIV infection (median CD4 cell count 22/µl), with only 17.2% taking ART, and 
9.4% PJP-prophylaxis. CSF PCR for T. gondii was positive in 21 patients (32.8%). 
Circulating toxoplasma IgG was present in 77.2% of patients tested, including 
all in whom the PCR of CSF was positive for T. gondii. Clinically, in the absence 
of neuroradiology, toxoplasmosis was difficult to distinguish from tuberculosis 
or cryptococcal meningitis, although CSF abnormalities were less pronounced. 
Mortality among patients with a positive CSF T. gondii PCR was 81%, 2.16-fold 
higher (95% confidence interval 1.04 – 4.47) compared to those with a negative 
PCR.
Conclusions / significance
Toxoplasmosis should be considered in HIV-infected patients with clinically 
suspected subacute meningitis in settings where neuroradiology is not available. 
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INTRODUCTION
In settings of Africa and Asia, the most common cause of subacute meningitis 
in patients with advanced HIV infection is either tuberculous or cryptococcal 
infection [1,2]. However, in many patients, the etiology of subacute meningitis 
cannot be established [1,3]. In line with a large retrospective cohort of adult 
meningitis patients in South Africa, where 52.8% had no definite diagnosis 
despite extensive microbiological testing [1], we could not identify the causative 
pathogen in 48.9% of HIV-infected meningitis patients in an Indonesian setting 
[4]. 
Toxoplasmosis is a common and serious central nervous system (CNS) infection in 
patients with advanced HIV infection [5-8], although its incidence has decreased 
with introduction of antiretroviral treatment (ART) [6,9]. Cerebral toxoplasmosis 
mostly presents as cerebral mass lesions with headache, confusion, fever, 
lethargy, seizures, cranial nerve palsies, psychomotor changes, hemiparesis and/
or ataxia [10]. Some of these symptoms may also mimic meningitis, but cerebral 
toxoplasmosis is generally not considered as a differential diagnosis of subacute 
meningitis in HIV-infected patients. This is especially the case in low-resource 
settings where no CT or MRI can be performed. We have therefore examined 
if toxoplasmosis can be diagnosed in HIV-infected patients presenting with 
subacute meningitis of unknown origin in Indonesia, using cerebrospinal fluid 
(CSF) PCR for T. gondii. 
METHODS
Ethics statement 
Anonymized CSF and blood samples were used from an already-existing hospital 
collection, from a cohort of patients collected as part of a project ‘Optimization 
of diagnosis of meningitis’, approved by the Ethical Committee of Hasan Sadikin 
Hospital/Medical Faculty of Universitas Padjadjaran, Bandung, Indonesia (No. 85/
FKUP-RSHS/KEPK/Kep/EC/2006). As this study was done using already existing 
sample collection, no separate consent was asked for this study. HIV testing 
is done routinely with oral informed consent for all patients with suspected 
meningitis in Hasan Sadikin hospital, after 24% were found HIV-positive in 
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a previous cohort study of 185 patients in the same hospital [4]. Consent is 
obtained from closest relatives (husband/wife or parents) for those patients who 
are unstable or unconscious at time of presentation. With approval from the 
ethical committee HIV testing was done anonymously afterwards for those who 
had died before consent could be obtained.
Setting and patients
We included adult patients presenting with suspected meningitis at Hasan 
Sadikin Hospital, the top referral hospital for West Java Province, Indonesia, 
between December 2006 and October 2010. Clinical data including outcome was 
recorded in individual case report form. Definite TB meningitis was diagnosed 
if CSF culture or real time PCR were positive for M. tuberculosis, cryptococcal 
meningitis if either CSF India Ink examination or cryptococcal antigen testing 
were positive, and toxoplasmosis if CSF T. gondii PCR was positive. HIV testing is 
done routinely for patients presenting at this hospital, but cerebral CT-scanning 
is rarely done in this setting and is not covered by the government health 
insurance for the poor. 
Laboratory examinations
CSF cell count and differentiation, protein and glucose were measured. CSF 
microscopy was done for cryptococci, acid-fast bacilli and bacterial pathogens. 
CSF was cultured for Mycobacterium tuberculosis (solid Ogawa and liquid MB-
BacT, Biomerieux), bacterial pathogens (blood agar, chocolate agar, and brain-
heart infusion) and fungi (Sabouraud). Cryptococcal antigen (CALAS, Meridian 
Diagnostics) testing was done on CSF samples following the manufacturer’s 
instructions. Five to 7 mL CSF samples were used for molecular testing. After 
centrifugation of CSF samples at 3000 x g for 10 minutes, DNA was extracted 
from 200 µl of CSF sediment by using QIAmp DNA mini kit (Qiagen, USA). CSF M. 
tuberculosis real time PCR was done using IS6110, a repeated insertion sequence 
specific for M. tuberculosis, as a target [11]. Measurement of CD4-cell count for HIV-
patients only became available during the time of the study and was measured 
only for those who survived for more than 4 days. Real time PCR for T. gondii, 
using the multicopy B1 gene of the T. gondii as the target as described elsewhere 
[12], was performed to archived CSF samples at Radboud University Nijmegen 
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Medical Centre. CSF specimens from 22 HIV-negative meningitis patients (16 
with definite TB meningitis, 2 with bacterial meningitis, and 4 with no definite 
diagnosis), and nine patients with non-infectious CNS diseases, all recruited at 
Hasan Sadikin Hospital, were used as controls for T. gondii PCR. These samples 
were collected during the study period over a similar time scale compared to 
the case CSF samples. Toxoplasma immunoglobuline G (toxoplasma IgG) were 
measured by electro chemiluminescent assay (ECLIA, Elecsys, Roche) in archived 
serum samples of patients included in the study.
Data analysis and statistics
Characteristics of patients with definite tuberculosis, cryptococcosis and toxo-
plasmosis were compared using Chi-square test for proportions and Mann-
Whitney U test for continuous variables. Progression to death using 2-month 
mortality data was examined by Kaplan–Meier estimates. 
RESULTS
During the period, 401 patients presented with clinical meningitis, 76 were 
diagnosed with HIV infection, and 64 had archived CSF samples and were 
included in this study. Patients included in the study presented after a median 
7 days, with meningismus (86.0%), headache (80.8%), lowered consciousness 
(33.3%), fever (28.8%), hemi- or tetraparesis (28.6%), cranial nerve palsies (12.5%), 
and seizures (10.9%). HIV was newly diagnosed in 53 patients (82.8%). All 11 
patients previously diagnosed with HIV were taking ART, and 6 were using co-
trimoxazole as Pneumocystis jiroveci (PJP) prophylaxis at time of presentation. The 
median CD4 cell count was 22/µl, and less than 200/µl in 22 out of 23 patients 
tested (96%). 
CSF T. gondii PCR was positive in 21 of 64 HIV-infected patients (32.8%), with a 
median Ct-value of 36.0 (IQR: 34.2-39.3). None of the 22 HIV-negative control and 
9 non-infectious CNS disease patients had a positive T. gondii PCR. Archived serum 
sample was not available in 14 patients. Toxoplasma IgG was positive in 78% of 
patients tested, including all patients with positive CSF T. gondii PCR. Toxoplasma 
IgG titers were higher among patients with a positive CSF T. gondii PCR (p=.017). 
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A definite diagnosis of TB meningitis was established in 21/64 patients (32.8%). 
Out of 21 patients with positive T. gondii PCR, five had combined tuberculosis 
and toxoplasmosis. Cryptococcosis was diagnosed in 15/64 patients (23.4%), 
including two who were also diagnosed with tuberculosis. In 14 patients (21.9%) 
no causative pathogen was isolated. 
Neck stiffness, headache and fever, the classical signs of meningitis, were 
equally common in patients diagnosed with toxoplasmosis, cryptococcosis 
and tuberculosis, as were most other signs and symptoms, except hemiparesis 
(Table 1). None of the patients with toxoplasmosis had received ART or co-
trimoxazole prophylaxis prior to admission with meningitis. CT scans were 
available for 6 patients, including 4 with a positive T. gondii PCR. Three showed 
signs of hydrocephalus, one a hypodense lesion that showed no enhancement 
using contrast, and two were normal. No mass lesions typical for cerebral 
toxoplasmosis were seen. 
CSF cell count and protein were normal or mildly elevated in patients with 
toxoplasmosis, and hypoglycorrhachia was less common compared with tuber-
culosis or cryptococcosis (Table 1). CD4 counts, missing in two-thirds of patients 
due to early death or the unavailability of CD4 cell testing during the initial phase 
of the cohort study, were low in all but one patient. Table 2 lists the CSF findings 
of individual patients, Figure 1 is a graphic representation of the CSF cell count, 
protein and glucose ratio, showing the overlap in CSF findings between patients 
with toxoplasmosis, cryptococcal and tuberculosis CNS infection. 
Patients with confirmed cryptococcosis received amphotericine B, followed 
by fluconazole; all others received empiric tuberculosis treatment combined 
with adjunctive corticosteroids [13]. No toxoplasmosis treatment was given, 
as T. gondii PCR was performed retrospectively and was not available at time 
of presentation. Eight patients were lost to follow up and were not included 
in Kaplan Meier analysis. Mortality among those with positive CSF T. gondii 
PCR was 2.16-fold (95% CI 1.04 – 4.47) higher compared to those who had a 
negative PCR result; median survival was 7 days for toxoplasmosis, 7 days for 
tuberculosis meningitis, 110 days for cryptococcosis, and 32 days for patients 
with an unknown cause of meningitis (Figure 2). 
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Table 1.  Characteristics of patients according to microbiological diagnosis 
Tuberculosis
(n=14)
Cryptococcosis
(n=13)
Toxoplasmosis
(n=16)
General 
Age in year - median (IQR) 30 (27-34) 30 (27-32) 31 (28-33)
Male sex - no. (%) 11 (78.6) 11 (84.6) 11 (68.8)
History of TB treatment 3 (21.4) 3 (23.1) 4 (25.0)
Duration of illness, days – median (IQR) 14 (6-28) 7 (2-14) 7 (4-12)
ART prior to admission – no. (%) 2 (14.3) 4 (30.8) 1 (6.3)
PJP-prophylaxis 0 3 (23.1) 0
Signs and symptoms on presentation – no. (%)
Headache 10/12 (83.3) 10/11 (90.9) 10/12 (83.3)
Seizure 0/13 (0.0) 2/11 (18.2) 2/13 (15.4)
Neck stiffness 12/13 (92.3) 9/11 (81.8) 13/16 (81.3)
Body temperature > 38oC 4/11 (36.4) 1/8 (12.5) 4/13 (30.8)
Altered consciousness (GCS < 14) 6/10 (60.0) 2/10 (20.0) 4/10 (40.0)
GCS – median (range) 13 (6-15) 15 (9-15) 14 (12-15)
Hemi- or tetraparesis 8 (57.1) 0/12 (0.0) 6 (37.5)
Cranial nerve palsy 1 (7.1) 2 (15.4) 3 ( 18.8)
CSF
Leukocytes / mL – median (IQR) * 76 (6-272) 46 (24-188) 14 (2-26)
% lymphocytes – median (IQR) 49 (16-70) 70 (58-96) 70 (50-100)
Protein, g/dL – median (IQR) 140 (87-235) 151 (105-245) 130 (90-300)
CSF:blood glucose ratio – median (IQR) ** 0.13 (0.06-0.43) 0.20 (0.09-0.41) 0.40 (0.33-0.53)
Blood examination
CD4 cell count – range *** 2-98 4-45 9-30
Titer of toxo-IgG > 1:300 5/9 (55%) 3/10 (30%) 11/11 (100%)
Radiological Examination
Abnormal Chest X-ray 8/11 (66.7) 4/9 (44.4%) 5/10 (50.0%)
Patients with combined TB-toxoplasmosis (n=5), combined TB-Cryptococcus (n=2), and no definite diagnosis 
(n=14) were excluded from the table. Data are presented as no. of patients / no. evaluated (%) unless stated 
otherwise. 
GCS = Glasgow Coma Scale. *significantly different: TB vs. toxoplasmosis (.01); cryptococcosis vs. 
toxoplasmosis (.02). **significantly different: TB vs. toxoplasmosis (p=.03), cryptococcosis vs. toxoplasmosis 
(.02). ***CD4 cell counts were only available for 16 patients with definite diagnoses. 
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Table 2.  Line list of all patients
No Age Sex
CSF examination* Causative pathogen
DiagnosisCell 
number
Protein
Glucose 
ratio Toxo
φ TBε Cryptoυ
1 31 M 4 26 0.33 pos neg neg toxoplasmosis
2 30 M 17 100 0.35 pos neg neg toxoplasmosis
3 33 M 18 160 — pos neg neg toxoplasmosis
4 18 F 11 150 — pos neg neg toxoplasmosis
5 29 F 2 90 0.32 pos neg neg toxoplasmosis
6 24 F 1 300 0.54 pos neg neg toxoplasmosis
7 28 M 13 630 0.4 pos neg neg toxoplasmosis
8 19 F 22 310 0.33 pos neg neg toxoplasmosis
9 30 M 49 130 0.83 pos neg neg toxoplasmosis
10 36 M 1 60 0.58 pos neg neg toxoplasmosis
11 33 M 30 434 0.32 pos neg neg toxoplasmosis
12 35 F 14 95 0.52 pos neg neg toxoplasmosis
13 32 M 26 131 0.5 pos neg neg toxoplasmosis
14 30 M 180 100 0.43 pos neg neg toxoplasmosis
15 34 M 0 50 0.38 pos neg neg toxoplasmosis
16 32 M —  —  — pos neg neg toxoplasmosis
17 25 F 143 100 0.13 neg pos neg TB
18 31 M 696 39 0.07 neg pos neg TB
19 30 M 7 260 0.06 neg pos neg TB
20 21 F 105 700 0.05 neg pos neg TB
21 52 M 193 190 0.55 neg pos neg TB
22 29 M 1120 — 0.03 neg pos neg TB
23 32 M 104 160 0.04 neg pos neg TB
24 30 M 48 40 0.24 neg pos neg TB
25 28 M 507 6980 0.1 neg pos neg TB
26 23 F 0 73 0.4 neg pos neg TB
27 31 M 26 140 — neg pos neg TB
28 40 M 4 112 0.47 neg pos neg TB
29 56 M 0 100 0.4 neg pos neg TB
30 29 M 10 210 —  neg pos neg TB
31 31 M 109 120 0.64 pos pos neg TB-toxo
32 39 M 919 630 0.04 pos pos neg TB-toxo
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33 22 M 13 10 0.25 pos pos neg TB-toxo
34 31 M 0 200 0.43 pos pos neg TB-toxo
35 23 F 23 64 0.46 pos pos neg TB-toxo
36 27 M 34 200 0.43 neg neg pos Cryptococcosis
37 30 M 2 22 0.01 neg neg pos Cryptococcosis
38 27 M 419 110 0.06 neg neg pos Cryptococcosis
39 30 M 167 120 0.2 neg neg pos Cryptococcosis
40 38 M 20 230 0.12 neg neg pos Cryptococcosis
41 32 M 209 610 0.01 neg neg pos Cryptococcosis
42 25 F 28 70 0.4 neg neg pos Cryptococcosis
43 32 M 49 100 0.15 neg neg pos Cryptococcosis
44 36 M 46 270 0.51 neg neg pos Cryptococcosis
45 29 M 3 200 0.17 neg neg pos Cryptococcosis
46 22 F 35 151 0.38 neg neg pos Cryptococcosis
47 32 M 248 130 — neg neg pos Cryptococcosis
48 32 M 92 260 0.34 neg neg pos Cryptococcosis
49 27 M 0 — 0.16 neg pos pos TB-crypto
50 34 M 0 120 0.27 neg pos pos TB-crypto
51 30 F 0 44 0.39 neg neg neg unknown
52 27 M 0 180 0.49 neg neg neg Unknown
53 33 M 259 110 0.57 neg neg neg Unknown
54 32 M 2 130 0.48 neg neg neg Unknown
55 30 M —  —  — neg neg neg unknown
56 28 M 143 9850 0.04 neg neg neg unknown
57 30 M 146 40 0.19 neg neg neg unknown
58 36 M 17 16 0.51 neg neg neg unknown
59 24 M 0 30 0.6 neg neg neg unknown
60 29 M 43 44 0.21 neg neg neg unknown
61 39 M 18 na 0.24 neg neg neg unknown
62 32 M 184 480 0.08 neg —  neg unknown
63 28 M 298 317 0.34 neg neg neg unknown
64 34 M 166 133 — neg — neg unknown
M = male; F = female; neg = negative; pos = positive
*cell numbers are in cells/µl; protein in mg/dL; glucose ratio = CSF glucose : blood glucose
φ toxoplasmosis; ε TB meningitis; υcryptococcosis
Table 2.  (continued)
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Figure 1.  CSF characteristics according to causative pathogen
CSF cell count (A), protein concentration (B) and CSF:blood glucose ratio (C) for cases with confirmed 
toxoplasmosis (•), crypotoccococis ( ), and tuberculosis ( )
Toxo = toxoplasmosis; crypto = cryptococcosis; TB = TB meningitis
Figure 2.  Kaplan Meier survival estimates.
Patients with available long term follow up data: Toxoplasmosis (n=14), Cryptococcosis (n=13), TB meningitis 
(n=14), no diagnosis (n=13)
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DISCUSSION
In our cohort of HIV-infected patients presenting with clinical signs and symptoms 
of CNS infection, CSF T. gondii PCR was positive in 32.8% of patients, sometimes 
in conjunction with tuberculosis. In the absence of CT or MRI of the brain, 
toxoplasmosis could not be distinguished from tuberculosis or cryptococcosis. 
Mortality in this cohort of newly diagnosed and advanced HIV infection was 
extremely high and associated with a positive T. gondii PCR.
Cerebral toxoplasmosis typically causes space occupying lesion(s), leading to 
subacute or acutely developing confusion, with or without focal neurological 
deficits [14]. In the absence of CT or MRI of the brain, common findings like 
headache, fever, hemiparesis and decreased level of consciousness [10] may 
mimic those of meningitis [4, 15-17]. In previous series of cerebral toxoplasmosis 
[18,19], meningeal signs have been reported in 3 to 16 % of the patients, 
although in many reports neck stiffness is not mentioned [14]. Although rare, 
cases of spinal cord toxoplasmosis have also been reported [20]. No typical mass 
lesions were found in 6 patients with an available CT scan. This is not surprising, 
as this study depended on the availability of CSF samples, that would not have 
been obtained if typical mass lesions had been found.
We used T. gondii PCR for diagnosis of cerebral toxoplasmosis. In previous studies 
CSF T. gondii PCR had a sensitivity of 50-60% to confirm cerebral toxoplasmosis 
in HIV-infected patients [21, 22]. The sensitivity is possibly higher among patients 
with meningoencephalitis compared to those with space-occupying lesions 
only, but this has not been examined. Specificity of T. gondii PCR is high, between 
97 and 100% [22-24]. The positivity rate of 32.8% in our study might therefore 
be an underestimate, especially in the category of patients in whom no other 
pathogen was isolated despite extensive microbiological testing.
In our cohort, toxoplasmosis could not be distinguished clinically from 
tuberculosis and cryptococcosis. From our previous series [4], CSF samples were 
available for the current study for 36 / 47 HIV-infected patients. Ten out of 17 
patients who were diagnosed with ‘probable TB meningitis’ and ‘unknown’ 
Chapter 4
72
in the previous study were found to have a positive T. gondii PCR (and no 
bacteriological confirmation of tuberculosis) in the current study. Diagnosis of 
cerebral toxoplasmosis is usually based on clinical findings and CT or MRI of 
the brain. However, if cerebral imaging is lacking, toxoplasmosis may not be 
considered. Positive toxoplasma serology, which has a high sensitivity but very 
poor specificity, is helpful to exclude but not to confirm cerebral toxoplasmosis, 
although some reports suggest that high toxoplasma IgG titers are only found 
in patients with symptomatic toxoplasmosis [25]. Indeed, in our study, patients 
with a positive T. gondii PCR had a higher IgG titers compared to those who had 
a negative PCR. An autopsy study from India provides further support for the 
notion that cerebral toxoplasmosis is not always considered; among 233 HIV 
patients, toxoplasmosis accounted for 6.8% of deaths, but in none of these cases 
toxoplasmosis had been suspected clinically [26]. 
The incidence of cerebral toxoplasmosis varies between countries [14] and is 
related to the seroprevalence of toxoplasmosis in the general population [19, 25]. 
In the United States, toxoplasma seroprevalence varies from 3% to 30%, whereas 
in France 73%–90% of the population is infected [10]. Reported seroprevalence 
rates were varied from 13-31% in the general population, and 45-68% in HIV 
patients in studies from several developing countries [8, 27, 28]. In our study, 
78% of patients had detectable toxoplasma IgG, but this does not reflect the 
seroprevalence in the general population or among unselected HIV-infected 
patients, as only meningitis patients were examined. 
Mortality in this cohort of patients was very high, higher compared to reported 
rates in other series [8, 9, 29]. One explanation is that patients mostly presented 
with advanced and untreated HIV infection. In addition, no toxoplasmosis 
treatment was provided, as PCR was done retrospectively on archived samples. 
In our previous study, HIV infection was associated with a 2.5-fold increased 
mortality among patients presenting with meningitis [4]. Data from the current 
study suggests that this may is at least in part attributable to a high prevalence 
of (unrecognized and untreated) toxoplasmosis. Future studies should examine 
the benefit of timely diagnosis and/or empiric treatment of toxoplasmosis for 
patients in settings like ours. Empiric treatment for subacute meningitis in HIV-
Cerebral toxoplasmosis presenting as subacute meningitis in HIV-infected patients
73
4
infected patients should probably also include tuberculosis, which is difficult 
to exclude as culture is slow and microscopy and commercial PCR assays have 
insufficient sensitivity [30]. 
Our study suffers from several limitations. Most importantly, no CT or MRI of the 
brain could be performed. In addition, clinical data, CD4 cell counts and other 
laboratory parameters were missing in a number of patients. Despite these 
limitations the data strongly suggest that toxoplasmosis should be included 
in the differential diagnosis of HIV-infected with clinically suspected subacute 
meningitis, and that molecular testing or empiric treatment for toxoplasmosis 
should be considered in these patients, especially if no CT or MRI can be 
performed. Obviously, timely diagnosis and treatment of HIV will help prevent 
this severe opportunistic infection. 
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SUMMARY
Background 
Intensified antibiotic treatment might improve the outcome of tuberculous 
meningitis. We assessed pharmacokinetics, safety, and survival benefit of several 
treatment regimens containing high-dose rifampicin and moxifloxacin in patients 
with tuberculous meningitis in a hospital setting.
Methods 
In an open-label, phase 2 trial with a factorial design in one hospital in Indonesia, 
patients (aged >14 years) with tuberculous meningitis were randomly assigned 
to receive, according to a computer-generated schedule, first rifampicin standard 
dose (450 mg, about 10 mg/kg) orally or high dose (600 mg, about 13 mg/kg) 
intravenously, and second oral moxifloxacin 400 mg, moxifloxacin 800 mg, or 
ethambutol 750 mg once daily. All patients were given standard dose isoniazid, 
pyrazinamide, and adjunctive corticosteroids. After 14 days of treatment all 
patients continued with standard treatment for tuberculosis. Endpoints included 
pharmacokinetic analyses of the blood and cerebrospinal fluid, adverse events 
attributable to tuberculosis treatment, and survival. Analysis was by intention to 
treat. This trial is registered with ClinicalTrials.gov, number NCT01158755.
Findings 
60 patients were randomly assigned to receive rifampicin standard dose (12 no 
moxifloxacin, ten moxifloxacin 400 mg, and nine moxifloxacin 800 mg) and high 
dose (ten no moxifloxacin, nine moxifloxacin 400 mg, and ten moxifloxacin 800 
mg). A 33% higher dose of rifampicin, intravenously, led to a three times higher 
geometric mean area under the time-concentration curve up to 6 h after dose 
(AUC0–6; 78.7 mg.h/L [95% CI 71.0–87.3] vs. 26.0 mg.h/L [19.0–35.6]), maximum 
plasma concentrations (Cmax; 22.1 mg/L [19.9–24.6] vs. 6.3 mg/L [4.9–8.3]), and 
concentrations in cerebrospinal fluid (0.60 mg/L [0.46–0.78] vs. 0.21 mg/L [0.16–
0.27]). Doubling the dose of moxifloxacin resulted in a proportional increase in 
plasma AUC0–6 (31.5 mg.h/L [24.1–41.1] vs. 15.1 mg.h/L [12.8–17.7]), Cmax (7.4 mg/L 
[5.6–9.6] vs. 3.9 mg/L [3.2–4.8]), and drug concentrations in the cerebrospinal fluid 
(2.43 mg/L [1.81–3.27] vs. 1.52 mg/L [1.28–1.82]). Intensified treatment did not 
result in increased toxicity. Six-month mortality was substantially lower in patients 
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given high-dose rifampicin intravenously (ten [35%] vs. 20 [65%]), which could 
not be explained by HIV status or severity of disease at the time of presentation 
(adjusted HR 0.42; 95% CI 0.20–0.91; p=0.03).
Interpretation 
These data suggest that treatment containing a higher dose of rifampicin and 
standard-dose or high dose moxifloxacin during the first 2 weeks is safe in patients 
with tuberculous meningitis, and that high-dose intravenous rifampicin could be 
associated with a survival benefit in patients with severe disease.
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INTRODUCTION
Meningitis is the most severe form of tuberculosis, resulting in death or 
neuro logical disability in 50% of patients [1,2]. The treatment in patients with 
tuberculous meningitis follows the model for short-course chemotherapy in 
patients with pulmonary tuberculosis, but the optimum drug regimen and 
duration have not been established.
Rifampicin is important in the treatment of tuberculous meningitis as shown by 
the high mortality in patients with rifampicin-resistant tuberculous meningitis 
[3,4].
However, the dose used is at the low end of the dose response curve [5,6], and 
the penetration of rifampicin into cerebrospinal fluid is low [7]. Higher doses 
of rifampicin for pulmonary tuberculosis have been assessed in several clinical 
trials reported before 1985 [8,9]. Until now, no data were available for the use 
of high-dose rifampicin in tuberculous meningitis, although one clinical trial is 
underway in Vietnam [10]. Apart from a higher dose of rifampicin, intravenous 
rather than oral administration might improve the drug penetration into the 
plasma and cerebrospinal fluid.
Penetration of other standard drugs for tuberculosis, isoniazid and pyrazinamide, 
into the cerebrospinal fluid is good and they are important for treatment of 
tuberculous meningitis. By contrast, neither ethambutol nor streptomycin, both 
commonly used drugs, show good penetration into the cerebrospinal fluid in 
the absence of inflammation. Fluoroquinolones might be good alternatives 
to these drugs. Of the fluoroquinolones, moxifloxacin has the highest activity 
against Mycobacterium tuberculosis in vitro and in mice [11,12]. The combination 
of rifampicin and moxifloxacin has been assessed in clinical trials with the aim of 
shortening the treatment in patients with tuberculosis [13–15]. Moxifloxacin has 
a good penetration in cerebrospinal fluid [16] and in patients with tuberculous 
meningitis [17]. Of note, data from in-vitro studies and those in animals suggest 
that the optimum dose of moxifloxacin for tuberculosis could be higher than the 
standard dose of 400 mg once daily [18,19] particularly because rifampicin lowers 
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the plasma concentrations of moxifloxacin by about 30% [20]. Therefore, in view 
of the high morbidity and mortality associated with tuberculous meningitis, we 
have assessed intensified treatment regimens containing high-dose rifampicin 
and moxifloxacin.
METHODS
Study design
This study was an open-label, randomized, phase 2, clinical trial with a factorial 
design. It was done at Hasan Sadikin Hospital, Bandung, Indonesia—the referral 
hospital for West Java province (population 43 million).
High-dose rifampicin and standard-dose or high-dose moxifloxacin were 
assessed as part of a four-drug regimen for tuberculous meningitis. Patients were 
given intensified regimens for the first 2 weeks of treatment and then all patients 
were given standard treatment. Most deaths occur during the first few weeks, 
and longer intravenous treatment would be difficult because most patients who 
survive the initial stage return home after 2 weeks of hospital admission.
The primary objectives were to assess the pharmacokinetics and safety or 
tolerability of the intensified treatment regimens. Secondary objectives were 
to compare neurological response and mortality in patients with tuberculous 
meningitis given intensified or standard treatment.
The study was approved by the ethical review board of Hasan Sadikin Hospital and 
Medical Faculty of Universitas Padjadjaran, Bandung, Indonesia, and the ethical 
committee of Radboud University, Nijmegen, Netherlands. Compliance with the 
study protocol was assessed by internal monitoring and two external audits. 
Written informed consent for participation in the trial, and rapid HIV testing, was 
obtained from patients or close relatives of patients who were unconscious.
Patients
All patients older than 14 years admitted with clinically suspected meningitis 
between October 2010 and December 2011 had an initial screening that 
included standard cerebrospinal fluid and blood tests, and chest radiography. 
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis
85
5
In Indonesia, neuroradiology is rarely done in patients in this setting and is not 
covered by government health insurance for the poor.
Microbiological testing included microscopy for cryptococci, acid-fast bacilli, 
and bacterial pathogens in the cerebrospinal fluid; culture for M tuberculosis, 
bacterial pathogens, and fungi; cryptococcal antigen testing; and M tuberculosis 
drug-resistance testing with proportional methods.
CD4-cell testing and antiretroviral treatment were available for individuals who 
tested positive for HIV. Hepatitis C virus antibodies and hepatitis B virus surface 
antigen were also tested, and a 12-lead electrocardiogram (ECG) was done to 
check for possible ECG abnormalities, including prolonged QTc (>0.42 s for male 
and >0.45 s for female patients).
All patients with definite, probable, or possible tuberculous meningitis [21] were 
eligible for the study.
Exclusion criteria were failure to do a diagnostic lumbar puncture or evidence 
of bacterial or cryptococcal meningitis. Other exclusion criteria were treatment 
for tuberculosis for more than 7 days before admission, a history of tuberculous 
meningitis, pregnancy, lactation, a known contraindication to moxifloxacin, 
alanine aminotransferase activity more than five times the upper limit of normal, 
known hypersensitivity or intolerance to rifampicin or moxifloxacin, rapid clinical 
deterioration (e.g., signs of sepsis, decreasing consciousness or signs of cerebral 
edema, or herniation) during the screening process, and no informed consent. 
The neurological status of patients was classified according to a modification 
of the British Medical Research Council (BMRC) grading system as 1 (Glasgow 
Coma Scale [GCS] 15 with no focal neurological signs), 2 (GCS 11–14 or 15 with 
focal neurological signs), or 3 (GCS <10) [22].
Randomization and masking
An independent person, not involved in patient care, computer generated the 
randomization list. None of the physicians or investigators had access to this 
list. Investigators, notified by treating physicians, enrolled patients meeting the 
inclusion criteria into the study.
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Patients were randomly assigned to one of six groups after stratification for HIV 
infection as the strongest risk factor for death in tuberculous meningitis [1]. In 
accordance with the factorial design, patients were first randomly assigned to 
receive a regimen with rifampicin at a standard dose (450 mg once daily, about 10 
mg/kg, orally) or high dose (600 mg once daily, about 13 mg/kg, intravenously). 
The patients were then randomly assigned to receive oral ethambutol (750 mg), 
standard dose moxifloxacin (400 mg), or high-dose moxifloxacin (800 mg). All 
patients were given oral isoniazid (300 mg/day), pyrazinamide (1500 mg/day), 
and pyridoxine (50 mg/day). The fixed dosing of standard first-line drugs for 
tuberculosis (irrespective of weight) was in accordance with prevailing practice. 
The allocated treatment regimen was not masked from doctors, nurses, and 
patients because intravenous and oral routes of rifampicin were compared.
Treatment
After 14 days, all patients continued taking the standard regimen, consisting 
of oral isoniazid 300 mg/day, rifampicin 450 mg/day, pyrazinamide 1500 mg/
day, and ethambutol 750 mg/day for 2 months, with subsequent rifampicin 
450 mg/day and isoniazid 300 mg/day for 4 months in accordance with the 
Indonesian National Tuberculosis Program. All participants were given adjunctive 
dexamethasone intra venously for the first 6–8 weeks, starting with 0.4 mg/kg 
for grade 2 or 3, and 0.3 mg/kg for grade 1 tuberculous meningitis, with dose 
reduction as described previously [22]. Patients with both tuberculous meningitis 
and newly diagnosed HIV infection were started on antiretroviral treatment 4–8 
weeks after the start of treatment [23].
For the intervention groups, intravenous rifampicin (Rifadin, Sanofi Aventis, 
Gouda, Netherlands) and moxifloxacin 400 mg tablets (Avelox, Bayer, Jakarta, 
Indonesia) were used. Government-approved standard treatment consisted of 
oral rifampicin, isoniazid, pyrazinamide, and ethambutol (Ethambutol, PT Kimia 
Farma, Bandung, Indonesia). These drug formulations had previously been 
assess ed in this setting [8], and the Indonesian rifampicin formulation had shown 
bioavailability equal to the international reference [24]. All oral drugs were given 
once daily on an empty stomach.
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For unconscious patients who could not swallow, drugs were dissolved in 30 mL 
plain water in a closed syringe and delivered through a nasogastric tube, which 
was then flushed. For a more reliable route of administration in the intensified 
regimen, 600 mg of rifampicin was diluted in 250 mL of normal saline infusion 
(0.9% sodium chloride) and given over 90 min. During the first 2 weeks of 
treatment, facility-based directly observed treatment was used by the physicians 
or nurses to administer the drugs. Intake of drug was checked with the hand-
and-mouth procedure. After these 2 weeks, adherence was monitored by pill 
count every 2–4 weeks.
Pharmacokinetic assessment
Pharmacokinetic sampling was done in the first 3 days of drug administration. 
Serial blood sampling was done just before and at 1 h, 2 h, 4 h, 6 h, and 24 h 
after dosing as previously described [8]. Two samples of cerebrospinal fluid were 
taken on the same day as the blood samples and more than 24 h after the first 
sampling of cerebrospinal fluid, between 3 h and 6 h and starting from 6 h until 
9 h after drug administration, respectively.
The total (protein-bound plus unbound) plasma and cerebrospinal concentrations 
of rifampicin and moxifloxacin were assessed at Radboud University Nijmegen 
Medical Centre, Nijmegen, Netherlands, using high performance liquid 
chromatography assays that were validated and that performed well in an 
international quality control program [8,20]. For rifampicin, accuracy for 
standard concentrations was between 99.8% and 100.4% dependent on the 
concentration. The intra-assay and inter-assay coefficients of variation were less 
than 4% for a concentration of 0.26–30 mg/L. The lower limit of quantification 
was 0.26 mg/L. For moxifloxacin, accuracy was greater than 95% at all standard 
concentrations. Intra-assay and inter-assay coefficients were from 1.4% to 5.4% 
and 0.2% to 3.9%, respectively. The lower limit of quantification was 0.03 mg/L.
Pharmacokinetic parameters for rifampicin and moxifloxacin in plasma were 
assessed non-compartmentally with WinnonLin Professional (version 5.0). The 
highest plasma concentrations were defined as Cmax, with the corresponding 
times as Tmax. The area under the time-concentration curve up to 6 h after dose 
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(AUC0–6) and up to 24 h after dose in plasma were calculated with the log-linear 
trapezoidal rule from zero up to 6 h and 24 h, respectively. If the concentration 
at 24 h after dose (C24) was less than the limit of quantification, it was calculated 
with the formula:
C24 = Clast x e
–βx(24 – Tlast)
in which Clast is the last measurable concentration at Tlast and β is the first-order 
elimination rate constant. β was obtained with least squares linear regression 
analysis on log C versus time, with the absolute slope of the regression line 
being β/2.303. If β could not be estimated (in view of the sampling only being 
done up to 6 h after dose), only AUC0–6 was assessed. Cmax in the cerebrospinal 
fluid was estimated as the highest concentration measured in the intervals of 
3–6 h and 6–9 h after dose.
Follow-up
Patients were followed up until 6 months after the start of treatment. In the first 2 
weeks of treatment, possible drug-related adverse events were monitored daily, 
with twice weekly ECG, full blood count, and liver transaminases. More frequent 
or other investigations were done as clinically indicated. After discharge, patients 
were reviewed monthly. Because of the severity of tuberculous meningitis, with 
a six-month mortality of 47% in our previous series [1], adverse events were 
defined as those possibly or probably related to treatment (i.e., hepatotoxicity, 
cardiotoxicity, hypersensitivity, and hematological changes). All other adverse 
events (e.g., new neurological signs and respiratory failure) were not incorporated 
in the assessment of safety and toxicity. Classification of adverse events was 
based on the US National Institutes of Health Common Terminology Criteria for 
Adverse Events version 4.0 (see http://evs.nci.nih.gov/ftp1/CTCAE). The various 
grades of toxicity were managed in accordance with our predetermined toxicity 
management guidelines; treat ment was stopped in patients who had grade 4 
toxicity.
Survival was monitored during hospital admission, and afterwards through social 
workers for patients who did not attend scheduled appointments. The cause of 
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis
89
5
death was ascertained with clinical and laboratory assessments, and classified as 
neurological, non-neurological, or uncertain. No post mortem was done.
Statistical analysis
Because this study was exploratory, no sample size calculation was done, but 
subgroups of 20 (moxifloxacin) and 30 patients (rifampicin) were judged to be 
sufficient to assess safety and pharmacokinetics of intensified versus standard 
treatment for tuberculous meningitis.
Patients’ characteristics, and pharmacokinetic and safety or tolerability data 
were presented descriptively for each group. Differences in pharmacokinetic 
parameters between study groups were not tested. Groups were pooled to 
present pharmacokinetic data for rifampicin dose (three groups combined), 
or moxifloxacin dose (two groups combined) if descriptive analysis suggested 
differences no larger than 25% in geometric mean AUC or Cmax values between 
groups. Differences in pharmacokinetic parameters were tested with the 
independent samples t test on logarithmically transformed values of AUC and 
Cmax. Tmax values were compared with the Wilcoxon rank-sum test. The χ
2 test 
was used to compare proportions of patients with rifampicin peak plasma 
concentrations within the reference range of 8–24 mg/L [25].
Data for safety or tolerability and survival were analyzed in accordance with the 
intention-to-treat principle. χ2 tests were also used for comparison of proportions 
of patients with adverse events. A Cox regression analysis was used to assess 
the effects of rifampicin dose, moxifloxacin use and dose, HIV status, rifampicin 
resistance, and GCS at the time of treatment initiation on survival in all patients, 
and in those with culture-confirmed tuberculous meningitis. All analyses were 
planned and no post-hoc analysis was done. All statistical analyses were done 
with SPSS (version 18.0.2) for Windows. p values of less than 0.05 were judged 
significant in all analyses.
This trial is registered with ClinicalTrials.gov, number NCT01158755.
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Role of the funding source
The funders of the study had no role in the study design, data gathering, analysis, 
or interpretation of the results, and writing of the report. All authors had full 
access to the data. The corresponding author had the final responsibility for the 
decision to submit the report for publication.
RESULTS
60 of 160 suspected cases of meningitis screened between October 2010 and 
December 2011, were randomly assigned to receive standard-dose or high-dose 
rifampicin (Figure 1). Informed consent was obtained from close relatives of 46 
patients who were unconscious at presentation. Table 1 shows the baseline 
characteristics of patients randomly assigned to receive the two doses of 
rifampicin. 55% of patients were men (table 1); median duration of symptoms 
before presentation was 14 days (IQR 7–21). 12% of patients had an HIV infection 
(Table 1). The six groups were not equally balanced in terms of age and sex 
(Table 1). Symptoms at presentation included reduced consciousness (47 [78%]), 
headache (58 [97%]), seizures (four [7%]), weight loss (42 [70%]), and cough 
(34 [57%]). Six patients (10%) reported previous treatment for tuberculosis. On 
physical examination, lowered consciousness was noted in 47 patients (78%; 
median GCS 13, range 8–15). Neck stiffness (57 [95%]), cranial nerve palsies 
(23 [38%]), and motor deficit, most commonly hemiparesis (30 [50%]), were 
also noted. Most patients presented with BMRC grade 2 (49 [82%]) or grade 3 
(seven [12%]) tuberculous meningitis. Chest radiography suggested pulmonary 
tuberculosis in 28 patients (47%), based on infiltrative (n=21), miliary (n=6), and 
cavitary (n=1) lesions.
Consistent with a diagnosis of tuberculous meningitis, cerebrospinal fluid 
showed pleocytosis with a predominance of lymphocytes (median 96 cells per 
μL [IQR 29–260]; 80% mononuclear cells [43–90]), a low ratio of cerebrospinal 
fluid to blood glucose (0.28 [0.11–0.41]), and raised protein concentration (1660 
mg/L [1000–3130]).
Tuberculous meningitis was bacteriologically confirmed in 31 patients (52%), 
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based on a combination of culture (n=29) and microscopy (n=9). With the clinical 
scoring system [21], 20 remaining patients (33%) had probable tuberculous 
meningitis, whereas the other nine (15%) had possible tuberculous meningitis. 
Bacterial and cryptococcal meningitis were excluded in all patients.
Figure 1.  Patient flow
Clinical follow-up was continued until 6 months of treatment. PK = pharmacokinetic assessment of blood and 
CSF; MXF = moxifloxacin.*This subject was excluded from rifampicin PK only, and not for moxifloxacin; leaving 
52 patients available for rifampicin PK assessments, and 35 for moxifloxacin assessments.
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Seven patients died before the pharmacokinetic sampling was done (Figure 
1). For 22 patients, sampling was done 1 day after the start of treatment. For 
logistical reasons (e.g., weekends and heavy patient loads), sampling was done 
on day 2 in 20 patients and on day 3 in 11.
In view of the short duration of sampling, up to 6 h after rifampicin dosing, 
assessment of plasma AUC0–24 was difficult in most patients. Geometric mean 
AUC0–6 and Cmax for rifampicin in plasma were at least three times higher in patients 
given a high dose intravenously (Table 2). Five (19%) of 26 patients taking oral 
rifampicin at the standard dose (450 mg) had low Cmax (<4 mg/L) compared with 
none of the 26 given a high dose intravenously. Standard dose oral rifampicin 
resulted in low concentrations in the cerebrospinal fluid (Table 2).
At least one sample of cerebrospinal fluid was available for 25 patients on 
standard dose rifampicin; in 16 of these patients (64%), rifampicin concentrations 
in cerebrospinal fluid were below the assay limit of quantification (0.26 mg/L). 
By contrast, rifampicin concentrations in the cerebrospinal fluid were below 
the limit of quantification in one (4%) of 25 patients on high dose intravenous 
rifampicin. Administration of the high dose increased rifampicin concentrations 
by almost three times in the cerebrospinal fluid (Table 2).
For moxifloxacin, plasma AUC0–24 could be reliably assessed in 24 of 35 patients; 
in the other 11 patients, plasma concentrations were still increasing at 6 h. 
Doubling the dose of moxifloxacin led to a roughly two times increase in plasma 
AUC0–24, AUC0–6, and Cmax.
Moxifloxacin concentrations in the cerebrospinal fluid were high and above the 
limit of quantification in all patients from whom samples of cerebrospinal fluid 
were obtained. 800 mg moxifloxacin resulted in 1.6 times higher concentrations 
in the cerebrospinal fluid (Table 3).
Within the first 2 weeks of the study, 57% of patients had adverse events that 
were possibly or probably related to study drug (Table 4). Hepatotoxicity of all 
grades seemed to be equally distributed between rifampicin standard-dose 
and high-dose groups, and between the moxifloxacin standard-dose and high-
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dose groups. Grade 3 transaminase increases (n=7) were transient in all patients, 
despite continued antituberculous treatment. In accordance with our protocol, 
treatment was interrupted in patients with grade 4 hepatotoxicity. Hematological 
toxicity (thrombocytopenia, anemia, or leukopenia) did not occur. Mild QTc 
prolongation occurred in 20 patients (33%), including 15 (39%) of 38 patients 
given moxifloxacin (Table 4). Three patients, all in the rifampicin high-dose group, 
Table 2.  Pharmacokinetic data of rifampicin (n= 52) 
Rifampicin dose Ratio of 
intravenous to 
oral
p-value600 mg, i.v.
(n=26)
450 mg, p.o.
(n=26)
Plasma
AUC0-6 (mg.h/L) 78.7
(71.0 – 87.3)
26.0
(19.0 – 35.6)
3.0
(2.2 – 4.2)
<0.0001*
Cmax (mg/L) 22.1
(19.9 – 24.6)
6.3
(4.9 – 8.3)
3.5
(2.6 – 4.8)
<0.0001*
Cmax (> 8 mg/L) (n,%) 26 (100%) 13 (50%) — <0.0001†
Tmax (h; median, range) 2 (1 – 2) 2 (1 – 6) — 0.048 ‡
CSF 
Cmax (mg/L) § 0.60
(0.46-0.78)
0.21
(0.16-0.27)
2.92
(2.03-4.20)
<0.0001*
Data are number (%) or geometric mean (95% CI), unless otherwise indicated. Rifampicin concentrations 
were measured for plasma AUC0–6 and CSF Cmax in samples obtained during the first 3 days of treatment. 
Assessment of plasma AUC0–24 values was difficult in 41 patients because rifampicin concentrations at C24 
were below the limit of quantification. Estimation of the C24 based on the last measurable concentration 
and the elimination rate constant was not possible because the elimination rate for rifampicin could not be 
assessed reliably with sampling at 2 h, 4 h, and 6 h after dose. For this reason, only AUC0-6 is shown. 
AUC0–6=area under the time-concentration curve up to 6 h after dose. AUC0–24=area under the time-
concentration curve up to 24 h after dose. Cmax=maximum plasma concentration. Tmax=time to Cmax. 
CSF=cerebrospinal fluid. C24=rifampicin concentration at 24 h after dose.
* Independent-samples t test after log transformation. † χ2 test. ‡ Wilcoxon rank-sum test. § CSF samples 
were obtained from 25 patients on 600 mg intravenous and 25 patients on 450 mg oral rifampicin; in one 
and 16 patients, respectively, rifampicin, concentrations in CSF were below the limit of quantification of 
the assay (0.26 mg/L) and were set at half the limit of quantification (0.13 mg/L) to enable comparison of 
exposures in CSF.
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had a hypersensitive reaction. Two reactions were mild and resolved within 3 
days without stopping the drugs. One patient developed an anaphylactic shock 
on the first day of drug administration while receiving high-dose rifampicin and 
high-dose moxifloxacin, and died within 2 h after drug administration.
None of the patients were lost to follow-up. 30 patients (50%) died within 6 
months, mostly in the first few weeks of treatment. For those who died within 
the 1-month follow-up (n=22), the main cause of death was respiratory failure 
(n=9), and then neurological deterioration (n=7), sepsis (n=2), and anaphylaxis 
(n=1). Cause of death was uncertain in the remaining three patients. Mortality 
was much lower in patients in the rifampicin high-dose group (Figure 2a), 
and when only patients with culture-confirmed tuberculous meningitis were 
Table 3.  Pharmacokinetics data of moxifloxacin (n=35) 
800 mg
(n=16)
400 mg
(n=19)
Ratio of 800 mg 
to 400 mg
p-value
Plasma
AUC0-24 (mg.h/L)* 60.4 (45.4 – 80.3) 28.6 (24.2 – 33.8) 2.1 (1.6 – 2.9) <0.0001†
AUC0-6 (mg.h/L) 31.5 (24.1 – 41.1) 15.1 (12.8 – 17.7) 2.1 (1.5 – 2.8) <0.0001†
Cmax (mg/L) 7.4 (5.6 – 9.6) 3.9 (3.2 – 4.8) 1.9 (1.4 – 2.6) <0.0001†
Tmax (h; median, range) 2 (1 – 6) 2 (1 – 6) — 0.301‡
CSF
Cmax (mg/L) § 2.43 (1.81 – 3.27) 1.52 (1.28 – 1.82) 1.60 (0.34 – 2.20) 0.006
 †
Data are number (%) or geometric mean (95% CI), unless otherwise indicated. Moxifloxacin concentrations 
were measured for plasma AUC0–24 and AUC0–6 and CSF Cmax in samples obtained during the first 3 days of 
treatment.
AUC0–24=area under the time-concentration curve up to 24 h after dose. AUC0–6=area under the time-
concentration curve up to 6 h after dose. Cmax=maximum plasma concentration. Tmax=time to Cmax. 
CSF=cerebrospinal fluid. 
* Could be assessed in 24 patients. † Independent samples t test after log transformation. ‡ Wilcoxon rank-
sum test. § CSF samples were obtained in 15 patients on moxifloxacin 800 mg and 17 patients on 400 mg. All 
concentrations were above the limit of quantification of the assay.
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analyzed (Figure 2b). Table 5 shows the mortality for the various drug regimens. 
The effect of rifampicin was similar in both moxifloxacin groups and there was 
no interaction between the two drugs, confirmed with Cox regression analysis 
(p=0.54). However, the statistical power in this study was too small to exclude 
possible interaction between the two interventions. The cumulative 6-month 
mortality was 65% in patients in the rifampicin standard-dose group versus 34% 
in the high-dose group. In the multivariable analysis, corrected for moxifloxacin 
Table 5.  6-month mortality by rifampicin regimen 
Oral rifampicin 
450 mg
Intravenous rifampicin
600 mg
Total
Ethambutol 750 mg 7/12 (58%) 3/10 (30%) 10/22 (45%)
Moxifloxacin 400 mg 6/10 (60%) 2/9 (22%) 8/19 (42%)
Moxifloxacin 800 mg 7/9 (78%) 5/10 (50%) 12/19 (63%)
Total 20/31 (65%) 10/29 (34%) 30/60 (50%
Data are n/N (%). All patients received standard dose isoniazid, pyrazinamide, and adjunctive corticosteroids.
Figure 2a.  Patient survival according to rifampicin treatment, all patients
Survival among all patients (n=60) treated with high dose i.v. (solid line) and standard dose p.o. (dashed line) 
rifampicin-containing treatment regimen during the first two weeks. Adjusted HR 0.42 (95% Cl 0.20–0.87)
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use, HIV status, and GCS at baseline, high-dose rifampicin remained a significant 
and strong predictor of survival (Table 6). In patients with culture-confirmed 
tuberculous meningitis, drug resistance did not affect outcome; resistance to 
streptomycin was present in two patients, but no resistance to rifampicin or 
isoniazid was noted (data not shown). Patients in the high-dose rifampicin group 
had more rapid resolution of coma (median 4 days [IQR 2–8] vs. 5 days [3–7]). Also, 
more patients in this group had a complete neurological recovery after 6 months 
of treatment (nine [31%] of 29 vs. four [13%] of 31).
DISCUSSION
Intensified treatment given for 2 weeks strongly increased drug exposure, did not 
increase drug-related adverse events, and improved the survival of patients. To 
our knowledge, this is the first report of a higher dose of intravenous rifampicin in 
patients with tuberculous meningitis (panel). 
Figure 2b.  Survival according to rifampicin treatment, bacteriologically proven TBM 
only
Survival among those with bacteriologically proven TBM (n=31) treated with high dose i.v. (solid line) and 
standard dose oral (dashed line) rifampicin-containing treatment regimens during the first two weeks. 
Adjusted HR 0.32 (0.11 – 0.92).
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Table 6.  6-month mortality and Cox regression analysis
Deaths Univariable Multivariable p-value
Oral rifampicin 450 mg (n=31) 20 (65%) 1.00 1.00 0.03*
Intravenous rifampicin 600 mg (n=29) 10 (35%) 0.42 (0.20 – 0.91) † 0.42 (0.20 – 0.91) †
No moxifloxacin (n=22) 10 (45%) 1.00 1.00 0.55 ‡
Moxifloxacin 400 mg (n=19) 8 (42%) 0.74 (0.29 – 1. 89) § 0.76 (0.30 – 1.94) § 
Moxifloxacin 800 mg (n=19) 12 (63%) 1.40 (0.60 – 3. 25) § 1.27 (0.53 – 3.02) §
HIV positive (n=7) 4 (57%) - 1.80 (0.59 – 5.53) 0.31
Glasgow Coma Scale at baseline - - 0.82 (0.68 – 0.99) 0.04
Data are number (%) or hazard ratio (95% CI), unless otherwise indicated. 
*For differences between both rifampicin doses. 
†Patients given 400 mg, 800 mg, or no moxifloxacin were pooled for comparison of rifampicin doses. 
‡For differences between all moxifloxacin doses. 
§ Patients given 450 mg or 600 mg rifampicin were pooled for comparison of different doses of moxifloxacin.
Previous research has shown that rifampicin, a key drug for treatment of tuber-
culous meningitis, does not penetrate well into the cerebrospinal fluid [7]. 
Rifampicin concentrations in cerebrospinal fluid have been reported in 18 
studies and only in seven of these studies were mean or individual rifampicin 
concentrations of more than 1.0 mg/L in cerebrospinal fluid recorded at any 
time point [7]. Indeed, patients given standard-dose oral rifampicin in our trial 
had moderately low concentrations in plasma and very low concentrations 
in the cerebrospinal fluid. Of note, rifampicin concentrations in plasma and 
cerebrospinal fluid cannot be compared directly because plasma concentrations 
refer to total (i.e., protein-bound plus unbound) rifampicin, whereas only the 
unbound (active) fraction penetrates the cerebrospinal fluid because this fluid 
has a very low protein content compared with plasma. A 1.3 times higher dose 
of rifampicin given intravenously led to roughly three times higher plasma 
AUC0–6 and Cmax values and also three times higher drug concentrations in 
the cerebrospinal fluid. In a previous study, we noted a nonlinear (1.65 times) 
average increase in systemic exposure to rifampicin when the daily oral dose 
was increased 1.3 times from 450 mg to 600 mg [8]. In another study, we 
assessed that rifampicin 450 mg intravenously resulted in a 40% higher drug 
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Panel: Research in context
Systematic review
We searched PubMed for articles published up to Sept 12, 2012, with 
the search terms “tuberculous meningitis”, “TB meningitis”, OR “high-dose 
rifampicin”, in combination with (“randomized controlled trial”[Publication 
Type] OR (“randomized”[Title/Abstract] AND “controlled”[Title/Abstract] 
AND “trial”[Title/Abstract])), and “tuberculous meningitis” OR “TB 
meningitis” with “moxifloxacin”.
69 studies were identified. No published data for patients with 
tuberculous meningitis given high-dose rifampicin were found, 
although the trial protocol of an ongoing assessment of high-
dose oral rifampicin with levofloxacin was described in one study 
[10]. The pharmacokinetics of regimens containing four different 
fluoroquinolones were compared in 61 patients with tuberculous 
meningitis in a randomised study [26]. We identified a systematic 
review of high-dose rifampicin in patients with pulmonary tuberculosis 
[9]. Of 14 trials (4256 participants) included in this systematic review, 
12 were done before 1980, and the only recent study judged to be 
of high quality was done by our group [8]. The pharmacokinetics of 
moxifloxacin in plasma and cerebrospinal fluid were described in four 
patients [17].
Interpretation
Our study is the first in which intensified antibiotic treatment including 
high-dose rifampicin was assessed in patients with tuberculous meningitis. 
The findings show that an increased dose of rifampicin, administered 
intravenously for the first 2 weeks, might improve the outcome of patients 
with tuberculous meningitis.
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exposure than the same dose given orally [27]. Therefore, the higher exposure 
to rifampicin in our study suggests a combination of a higher dose, intravenous 
administration, and non-linear pharmacokinetics of this antibiotic. This increase 
in rifampicin exposure might be relevant because the antibiotic has exposure-
dependent effects [5,6]. Average rifampicin concentrations were lower than in 
patients with pulmonary tuberculosis taking a similar oral dose of rifampicin in 
the same setting [8] possibly because of lower absorption when rifampicin is 
given through a nasogastric tube or when patients are severely ill.
Another possible approach for improving outcome of tuberculous meningitis 
might be the use of more effective antituberculous drugs like fluoroquinolones. 
After a pharmacokinetic study in 61 patients [26], a phase 3 trial is now underway 
to assess whether a combination of levofloxacin with oral rifampicin 15 mg/kg 
improves survival of patients with tuberculous meningitis [10]. We assessed 
another fluoroquinolone, moxifloxacin, which might have better pharmacokinetic 
properties [17], and stronger activity against M tuberculosis than did three other 
fluoroquinolones (ofloxacin, sparfloxacin, and ciprofloxacin) in animals [12]. 
Our study is the first in which the pharmacokinetics of moxifloxacin in the 
plasma and cerebrospinal fluid were assessed in a large series of patients with 
tuberculous meningitis. A higher dose of moxifloxacin (800 mg), which might be 
more potent, led to an almost proportional increase in drug concentrations in 
the plasma and cerebrospinal fluid.
Increasing the dose of rifampicin and moxifloxacin did not seem to greatly 
increase toxicity, which is in agreement with data for the use of a higher dose 
of rifampicin for tuberculosis [9] and other indications and with the few data 
available for high-dose moxifloxacin [17,28].
Although our study was not powered to detect a difference in mortality, high-
dose intravenous rifampicin, when given for the first 2 weeks, led to a roughly 
50% reduction in 6-month mortality. Moxifloxacin did not seem to be associated 
with a survival benefit. It should be noted that mortality in patients given 
standard-dose rifampicin was higher than in some other studies—e.g., 36.5% in 
the landmark corticosteroid trial from Vietnam [22].
Chapter 5
102
One contributing factor to the fairly high mortality in our study might be that our 
study population consisted of mostly patients with very advanced disease. Only 
7% of our patients presented with BMRC grade 1 tuberculous meningitis (table 
1), compared with 32.2% in the Vietnam study. In patients given corticosteroids 
in the Vietnam study [22], the mortality was 16.7% in patients with grade 1 
tuberculous meningitis, 31.1% with grade 2, and 54.8% with grade 3. In our study, 
the respective values for mortality were 25% (one of four), 50% (24 of 49), and 
71% (five of seven).
Our study has several limitations. Because of the high early mortality, pharma-
cokinetic data were not available for all patients. Also no serial lumbar punctures 
were done, so no pharmacokinetic curves could be generated for cerebrospinal 
fluid. The apparent mortality benefit of high-dose intravenous rifampicin, 
although significant, should be interpreted with caution because of the size of 
the study. Since this study was open label we cannot exclude potential bias in 
people providing treatment and care for the patients. Despite these limitations, 
we feel that our results challenge the current treatment model for tuberculous 
meningitis. Definition of the optimum regimen, which might be given for more 
than 2 weeks and include an even higher dose of oral (rather than intravenous) 
rifampicin, would help implementation of intensified treatment for tuberculous 
meningitis in settings where it is most needed.
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ABSTRACT 
Background
Previous studies have shown that serum cryptococcal antigenemia may 
precede development of cryptococcal meningitis and accounts for early death 
among patients with advanced HIV infection. We examined the prevalence and 
significance of cryptococcal antigenemia in Indonesia, which is experiencing a 
rapidly growing HIV epidemic with a very high mortality.
Methods
We included ART-naïve HIV patients with CD4 cell count below 100 cells/μL 
and no signs of meningitis in a hospital setting. Baseline clinical data and follow 
up were retrieved from a prospective database, and cryptococcal antigen was 
measured in stored serum samples using a semiquantitative lateral flow assay. 
Cox regression analysis was used to identify factors related to mortality.
Results
Among 810 patients (median CD4 cell count 22), 58 (7.1%) had a positive 
cryptococcal antigen test with a median titer of 1:80 (range: 1:1 – 1:2560). 
Cryptococcal antigenemia at baseline was strongly associated with development 
of cryptococcal meningitis and early death and loss to follow up. After one year, 
both death (22.4% vs. 11.6%; p=0.016; adjusted HR 2.19; 95% CI 1.78 – 4.06) and 
the combined endpoint of death or loss to follow up (67.2% vs. 40.4%; p<0.001; 
adjusted HR 1.57; 95% CI 1.12 – 2.20) were significantly higher among patients 
with a positive cryptococcal antigen test, and this was not due to confounding.
Conclusions
Cryptococcal antigenemia is common and clinically relevant among patients 
with advanced HIV in this setting. Routine screening for cryptococcal antigen 
and preemptive antifungal treatment for those who are positive may help 
reducing early mortality.
Key words: cryptococcal meningitis; HIV infection; antigen testing; lateral flow 
assay; Indonesia
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INTRODUCTION
Cryptococcal meningitis is a major cause of subacute meningitis and death in 
patients with advanced HIV infection, affecting an estimated one million people 
each year, especially in sub-Saharan Africa [1,2]. Cryptococcal meningitis is 
usually diagnosed by microscopic detection or culture of cryptococci from 
cerebrospinal fluid (CSF), or detection of cryptococcal antigen in CSF or serum 
[3–5]. Serum cryptococcal antigen has also been found in HIV patients without 
clinical meningitis. In a cohort in South Africa, cryptococcal antigen screening 
adequately identified patients at risk for cryptococcal meningitis and death [6]. 
Therefore, preemptive antifungal treatment for patients with asymptomatic 
serum cryptococcal antigenemia has been advocated [7,8]. Besides the South 
African study, several studies, most of them smaller, have been published from 
Uganda, Thailand and Cambodia [3,9–12]. We report the largest cohort study so 
far, from Indonesia, which has one of the most rapidly growing HIV epidemics in 
Asia [13]. Most patients in Indonesia present with advanced disease, and early 
mortality is very high [14]. We determined the prevalence and clinical significance 
of serum cryptococcal antigenemia among ART-naïve patients with CD4 count 
below 100 cells/μL. We used a recently developed and reliable point-of-care test 
for detection of cryptococcal antigen [8], which would allow implementation of 
targeted preemptive treatment of cryptococcosis even in the most remote areas.
METHODS
Setting and design
The study was conducted in Hasan Sadikin Hospital, the top referral hospital for 
West Java Province, Indonesia (population: 42 million). Since December 2004, 
integrated in- and outpatient services are provided for HIV-infected individuals. 
Services include HIV counseling and testing, HIV treatment, and management 
of opportunistic infections. Since September 2007, patients are included into a 
cohort study and characterized prospectively using a standard questionnaire, 
physical examination, and laboratory examination. Baseline blood samples are 
archived for all patients. Patients on ART generally visit the clinic monthly, with 
scheduled clinical and laboratory follow up, including measurement of CD4 cell 
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count and plasma HIV-RNA [15]. Patients with symptoms suggesting central 
nervous system infection are referred to a neurologist for further investigations. 
Cerebrospinal fluid, if taken, is examined for M. tuberculosis, bacteria and 
cryptococci [16]. Cryptococcal meningitis is diagnosed if cryptococci are found 
in CSF, either with direct India ink staining or culture, or if cryptococcal antigen 
testing is positive. Cryptococcal meningitis is treated with oral fluconazole 
(800mg/day) or intravenous amphotericin B (0.7 – 1 mg/kg bodyweight) if 
available [16]. Cerebral imaging is rarely done in this setting and not supported 
by the government insurance for the poor, but lumbar puncture is performed 
routinely as indicated. In-hospital death is recorded in medical records, but the 
cause of death is often not recorded, and autopsy is not performed. Outpatients 
are classified as dead if reported by family or community organizations or 
confirmed by telephone calls from the clinic. Patients not returning to the clinic 
are traced by telephone calls. No home visits are done as confidentiality might 
be breached since many patients do not disclose their HIV status to others. 
Baseline data and follow up are recorded in an electronic database. 
For this study, newly enrolled HIV-infected adult patients between November 
2007 and October 2011 who were ART-naïve and had a CD4 count below 100 
cells/μL were included. Subjects with a diagnosis of cryptococcal meningitis on 
admission were excluded. Patient data needed for this study including sex, age, 
CD4 cell count, plasma HIV-RNA concentration (‘viral load’), body mass index 
(BMI), baseline history of illness, and follow up were retrieved from database of 
the HIV clinic. Tuberculosis (TB) at time of enrollment was defined as TB treatment 
started at some point between one month before and one month after baseline. 
The definition of cerebral toxoplasmosis was based on a physician’s decision to 
start treatment with pyrimethamine and clindamycin for presumed cerebral 
toxoplasmosis. Oral candidiasis was diagnosed clinically. During follow up the 
time until initiation of ART was recorded, and clinical response was defined as 
alive, dead, lost to follow up, or transferred out. Length of follow up was counted 
from the day of inclusion until the date of death or the most recent date the 
patient was known to be alive. Patients were considered lost to follow up if they 
had not returned to the HIV clinic within 6 months if ART-naive, or 3 months if 
already taking ART, and the last date they visited the clinic plus one day was 
considered the date of loss to follow up. 
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Ethics statement
Anonymous blood samples were used from an already-existing hospital 
collection, collected as part of baseline laboratory assessment for patients 
included in the HIV cohort, and approved by the Ethical Committee of Hasan 
Sadikin Hospital/Medical Faculty of Universitas Padjadjaran, Bandung, Indonesia 
(No. 114/FKUP-RSHS/KEPK/Kep./EC/2007). Informed consent had been asked 
prior to participation into the cohort, including consent to use archived samples, 
therefore no separate consent was asked for this particular study. 
Laboratory examinations
For cryptococcal antigen testing, our hospital used latex-based antigen 
testing (CALAS, Meridian Bioscience, USA) until April 2011, and lateral flow 
assay (LFA, Immuno-Mycologics, USA), recently approved by the US Food and 
Drug Administration [8], since April 2011. For this study, serum cryptococcal 
antigen was measured retrospectively using serum samples archived at time 
of enrollment in HIV-care (‘baseline’). Quantification of the concentration of 
cryptococcal antigen in all positive samples was done using LFA according to 
the manufacturers instruction. LFA titers were determined semiquantitatively by 
diluting samples in LFA diluent solution and assessing reactivity as described 
above. The highest sample dilution that produced a positive result as read by 3 
observers was recorded as the LFA titer. 
Data analysis and statistics
Baseline characteristics of patients with and without cryptococcal antigenemia 
were compared. Continuous variables are presented as mean (standard 
deviation) if normally distributed and median (interquartile range, IQR) if not 
normally distributed, and categorical variables as percentage. Differences 
between groups were compared using Chi-square test for proportions and 
Mann-Whitney U test for continuous variables, with p-values <0.05 considered 
statistically significant. Progression to the primary endpoints death and a 
composite endpoint of death or loss to follow up was examined by Kaplan–
Meier estimates. Associations between cryptococcal antigenemia and these 
endpoints were examined using Cox regression. In multivariable Cox regression, 
we adjusted for possible confounding factors including CD4 cell count, 
hemoglobin, ART (as a time-dependent variable), oral candidiasis, toxoplasmosis 
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and TB treatment, age and gender. Multiple imputation (five times imputation) 
was performed for time of death (as outcome), WHO clinical stage, and body 
height and weight, with assumption that all predictors were missing at random. 
All variables including time of death were used as predictors. Variables with 
p-value < 0.100 in univariable analysis were included in the multivariable cox 
regression model, and the final model was determined by backward selection. 
Statistical analysis was done by SPSS version 18.0.2. The analysis presented used 
pooled data from the imputation, unless stated otherwise. Survival curves were 
drawn using GraphPad Prism version 5.0. 
RESULTS
From 1948 patients registered in the HIV clinic during study period, 857 patients 
were eligible and 810 could be included in the study (Figure 1). Patients were 
mostly young males presenting with advanced disease and a very low CD4 cell 
count. Fifty-eight patients (7.1%) had a positive cryptococcal antigen test. There 
were no significant statistical differences in sociodemographic characteristics, 
Figure 1.  Patient flow
*All HIV-infected patients included in the HIV clinic cohort during study period (2007-2011)
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clinical status, laboratory parameters, and symptoms at presentation between 
patients with and without serum cryptococcal antigen, except for WHO 
clinical staging as recorded in the medical records (Table 1). Titration of serum 
cryptococcal antigen using LFA showed a median titer of 1:80 (range: 1:1 – 
1:2560). We found a moderate correlation between CD4 cell count and the titer 
of cryptococcal antigen (r=-.309, p=.056). 
Table 1.  Baseline characteristics of patients according to cryptococcal antigenemia 
status§
All patients
(n=810)
CrAg-positive
(n=58)
CrAg-negative
(n=752)
p-value
Sociodemographics
   Age – year (IQR) 30 (27-34) 30 (25-32) 30 (27-34) .345
   Male sex –  % 76.3 72.4 76.6 .471
   History of injecting drug use –  % 59.7 62.2 59.5 .721
Clinical status
   WHO clinical stage 4 – % 66.0 81.1 64.8 .016
   BMI < 18.5 kg/m2 –  % 59.2 70.4 58.6 .225
Laboratory parameters
   CD4 cells/μL– median (IQR) 20 (7 – 45) 18 (4-37) 21 (7-45) .327
   HIV-RNA /mL – log (IQR) 5.2 (4.4-5.6) 5.0 (4.8-5.7) 5.2 (4.3-5.6) .923
   Hemoglobin in g/dL – median (IQR) 11.3 (9.6-12.9) 11.1 (9.5-12.5) 11.4 (9.6 – 12.9) .322
   Anemia* –  % 68.9 75.9 68.4 .248
   Positive HBsAg –  % 7.7 2.2 8.1 .144
   Positive anti-HCV –  % 60.7 59.6 60.7 .875
Symptoms at presentation
   Fever –  %
   Cough > 1 week –  %
   Weight loss > 10% –  %
43.9
34.6
58.9
44.8
36.2
58.6
43.8
34.5
58.9
.884
.789
.969
Co- infections at presentation
    TB treatment –  %
    Cerebral toxoplasmosis treatment – % 
    Oral candidiasis –  %
19.2
9.3
56.7
17.2
12.1
66.7
19.3
9.0
56.0
.700
.444
.138
§Data were missing for TB treatment  (n=1), Hemoglobin (n=19), weight loss (n=20), cough (n=21), fever 
(n=22), oral candidiasis (n=82), history of IDU (n=88), WHO clinical stage (n=115), HBsAg (n=187), anti HCV 
(n=195), BMI (n=271), HIV-RNA (n=720)
CrAg = cryptococcal antigen test
*Anemia was defined as  < 11.0 g/dL for females, and < 13.0 g/dL for males
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Patients were followed for a median 343 (IQR 21 – 1000) days (total observation: 
1190 patient years). 561 patients (69.3%) started ART, after a median of 24 (IQR 
14 – 42) days. After one year, 100 patients had died and 243 patients were lost 
to follow up; corresponding with 12.3% one-year mortality and 30.0% one-year 
loss to follow up. Loss to follow up was significantly higher among patients 
with a positive cryptococcal antigen test as compared to those with negative 
result (44.8% vs. 30.5%, p=0.011). Death and loss to follow up especially occurred 
during the first few months; 39 patients (39.0% of all deaths in one year) died 
within one month, and another 158 patients (65.0% of all patients loss to follow 
up in one year) did not return after their initial visit. 
During follow up, 6 out of 58 patients (10.3%) with a positive cryptococcal 
antigen test were diagnosed with cryptococcal meningitis, while none of the 
752 patients with a negative test did so. The cases of cryptococcal meningitis 
were diagnosed after a median of 91 days (range 17 – 219 days); three patients 
were diagnosed within 3 weeks after starting ART. Two out of six patients with 
confirmed cryptococcal meningitis died despite treatment with amphotericin 
B. The risk of developing cryptococcal meningitis did not correlate with the 
cryptococcal antigen titer (median titer 1:80 for those who developed meningitis 
vs. 1:40 for those who did not; p=0.813).
The date of death was missing for seven patients, for whom multiple imputations 
were performed. All variables had a similar distribution among those with missing 
data. A positive cryptococcal antigen test was clearly associated with increased 
mortality. Survival analysis revealed that cryptococcal antigenemia was strongly 
associated with one-year mortality (HR 2.57, 95%CI 1.43 – 4.60; p=0.002; Figure 
2a). It is likely that some patients who were lost to follow up may actually have 
died, especially those who dropped out during the first few months. Indeed, 
more patients with a positive cryptococcal antigen test did not return after their 
initial visit to the clinic (44.8% vs. 30.5%; p=0.011), and more had reached the 
combined endpoint of death or loss to follow up after one year (HR 2.05, 95% CI 
1.47 – 2.86; p<0.001; Figure 2b). Mortality remained significantly higher among 
patients with a positive cryptococcal antigen test after two (22.4% vs. 11.7%) and 
three years (24.1% vs. 12.9%).
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Figure 2b. Combined death or loss to follow-up in one year of subjects with and 
without cryptococcal antigenemia 
(Hazard ratio 2.05 (1.47 – 2.86), p < 0.001)
CrAg+ = positive cryptococcal antigen test; CrAg- = negative cryptococcal antigen test
Figure 2a.  Death in one year of subjects with and without cryptococcal antigenemia
(Hazard ratio 2.57 (95% CI 1.43 – 4.60), p = 0.002)
CrAg+ = positive cryptococcal antigen test; CrAg- = negative cryptococcal antigen test
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Besides cryptococcal antigenemia, other factors associated with one-
year mortality included ART administration, low CD4 cell count, anemia at 
baseline, WHO clinical stage 4, BMI < 18.5 kg/m2, a high plasma HIV-RNA, and 
oral candidiasis. After correction for other factors, cryptococcal antigenemia 
remained significantly associated with one-year survival (Table 2a) and the 
combined endpoint of death or loss to follow up (Table 2b). 
ART was associated with a survival benefit. It reduced the risk of dying by 61% 
with every month of ART administration (p<0.001). CD4 cells count reduced 
the risk by 8.5% with every 10 cells increment (p<0.001). This benefit of having 
Table 2a.  Factors associated with one-year mortality §
Dead
n=100
Alive
n=467
Univariable# Final model£
HR  (95% CI) p value HR (95% CI) p value
ART (time dependent) – – 0.39 (0.25 – 0.60) < 0.001 0.44 (0.27 – 0.71) 0.001
Positive Cryptococcal Ag – % 13.0 4.1 2.57 (1.43 – 4.60) 0.002 2.19 (1.78 – 4.06) 0.013
Male sex – % 72.0 78.4 0.74 (0.48 – 1.15) 0.181 – –
Age in years, median 31 30 1.02 (0.99 – 1.05) 0.261 – –
CD4 cells / μL, median 11 23 0.98 (0.98 – 1.00) 0.004 – –
WHO stadium 4 – % 82.0 58.4 2.81 (1.37 – 5.79) 0.007 2.28 (1.17 – 4.43) 0.017
HIV-RNA in log/mL, median 5.45 5.16 2.34 (1.21 – 4.53) 0.011 – –
Anemia* – % 83.0 63.5 2.59 (1.53 – 4.37) < 0.001 – –
Oral candidiasis – % 66.0 52.0 2.50 (1.54 – 4.05) < 0.001 2.26 (1.38 – 3.65) 0.001
Cerebral toxoplasmosis – % 13.0 8.7 1.25 (0.93 – 1.69) 0.445 – –
TB at admission – % 17.0 19.4 0.76 (0.85 – 0.99) .300 – –
Cox regression was performed using pooled data from multiple imputations. Data were missing for anemia 
(n=8), candidiasis (n=56), WHO clinical stadium (n=115), 
BMI (n=115), HIV-RNA (n=473)
# Variables with p-value >0.100 were not included in multivariable analysis
£ HIV-RNA and BMI were not included in the final model because of the many missing values. Candidiasis was 
not included in the final model because of the 
possible interaction with WHO stadium
*Anemia was defined as < 11.0 g/dL for female, and < 13.0 g/dL for male
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ART was significant for both cryptococcal antigen-positive and -negative 
cases, although the benefit was more prominent in the group of patients with 
cryptococcal antigenemia (risk reduction of 73.3% vs. 58.7%). Higher CD4 cells 
were only beneficial in those without cryptococcal antigen (risk reduction 9.1% 
with every 10 cells increment, p<0.001). 
DISCUSSION
In this cohort of 810 patients with advanced HIV-infection but with no clinical 
suspicion of meningitis, 7.1% had a positive serum cryptococcal antigen 
test. Those with a positive result had a much higher chance of developing 
cryptococcal meningitis, and of early loss to follow up and death, also when 
corrected for possible confounding factors. To our knowledge, this is one of the 
largest cohorts of HIV patients examined so far, the first study from Indonesia, 
and one of the first to use the newly developed laminar flow assay that can easily 
be implemented in low-resource settings. 
The prevalence of serum cryptococcal antigenemia in our cohort was comparable 
to previously published studies that have screened HIV patients for circulating 
cryptococcal antigen in the absence of signs suggesting meningitis. In Uganda, 
cryptococcal antigenemia was found in 5.8% of 377 patients with CD4 count 
below 100 cells/μL [9], and 8.8% of 295 similar patients in another study [11]. 
In South Africa, 7% of 707 patients screened were positive, including 12.5% 
of those with CD4 count below 100 cells/μL [6]. A smaller study among 131 
ART-naïve patients in Thailand found cryptococcal antigen in 9.2%, especially 
among those with CD4 count below 100 cells/μL (n=85, 12.9%) [12]. Finally, in 
Cambodia, among a subgroup of 295 patients most of whom had CD4 count 
below 100 cells/μL but none of whom had signs of meningoencephalitis, 10.8% 
were positive [10].
In our study, one in every ten patients with a positive serum cryptococcal 
antigen test was diagnosed with cryptococcal meningitis during follow up. In 
fact, this number may have been much higher as early loss to follow up was very 
high and significantly associated with cryptococcal antigenemia. The majority of 
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meningitis cases occurred after initiation of ART, probably due to the ‘unmasking’ 
effect of ART [17]. Compared to a previous series from South Africa [6], meningitis 
in our cohort was diagnosed somewhat later (median 91 vs. 35 days). First, this 
may be due to the lower cryptococcal antigen titers in our cohort, even though 
we used a method that roughly produces five-times higher titers compared to 
the latex agglutination method [8]. The difference in titers might reflect the lower 
burden of cryptococcal infection in our setting compared to Africa [1]. Second, 
fluconazole use for oral candidiasis, possibly more common in Indonesia, may 
have delayed the development of meningitis. 
The presence of serum cryptococcal antigen was associated with at least a 
two-fold higher risk of death during follow up, also after correction for possible 
confounding factors. Similar to the development of meningitis, our risk estimate 
for increased mortality may be an underestimate, as many cryptococcal antigen-
positive patients who were classified as early loss to follow up may in fact have 
developed severe cryptococcal meningitis leading to death. Mortality associated 
with cryptococcal antigenemia appeared lower, and seemed to occur somewhat 
later in our series (median time to death 80 days) compared to a study in South 
Africa (median time to death 53 days) and Uganda (median survival 26 days) 
[3,9], but again this may have been biased by the high loss to follow up in the 
first months.
All patients in this cohort had an indication for ART, but 30% never started 
treatment, mostly because of early death or loss to follow up. We were not able 
to retrace those patients who were loss to follow up mainly because of fear of 
breaching confidentiality and stigmatization. However, in line with a systematic 
review and meta-analysis addressing loss to follow up among HIV patients [18], 
it seems likely that many have died. 
This prevalence of cryptococcosis among asymptomatic patients found in our 
setting emphasizes the importance of screening of patients with low CD4 cell 
count for cryptococcal antigen, as has been advocated by experts in this field, 
and as was recently recommended by WHO [7,8,19,20]. This should preferably be 
done with simple and accurate point-of-care tests like the LFA method used in 
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this study [5,19]. After completing this study we have implemented screening for 
cryptococcal antigen for all ART-naïve patients with CD4 count below 100 cells/
μL, followed by lumbar puncture for those with a positive result, and preemptive 
fluconazole treatment for those with a positive result but no meningitis. A recently 
published study from Uganda showed that primary prophylaxis of cryptococcal 
disease with fluconazole effectively prevented development of cryptococcal 
meningitis and cryptococcal-related death in HIV-infected individuals with no 
cryptococcal antigenemia, although all-cause mortality was not affected [21]. 
The WHO has recently recommended screening of circulating cryptococcal 
antigen in all ART-naïve adults with CD4 count below 100 cells/μL prior to ART 
initiation in settings where the prevalence of cryptococcal antigenemia is more 
than 3%, followed by preemptive anti-fungal therapy if the result is positive 
[11,20]. Such a targeted approach starting with cryptococcal antigen testing 
may be more cost-effective than universal prophylaxis for all patients with low 
CD4 cell count like in the Ugandan trial [21]. 
Our study suffers from several limitations. The outcome of patients who were 
lost to follow up could not be verified. In addition, we may have missed cases 
of subclinical or mild cryptococcal meningitis at baseline. Since cryptococcal 
antigen testing was done retrospectively, no neurologist was consulted and no 
lumbar puncture was performed if there were no obvious signs of meningitis. 
On the other hand, as part of an ongoing cohort study on meningitis in our 
hospital [16,22], physicians in our HIV clinic have a high vigilance for diagnosing 
meningitis. The study also suffers from missing data including baseline HIV-RNA 
concentration, and the unavailability of neuroradiology, and from the fact that 
fluconazole use (for possible other purposes) was not well recorded. However, 
despite these limitations, we feel that this large cohort with long follow up 
provides further evidence for the need to screen HIV-patients with low CD4 
cell count for serum cryptococcal antigenemia, in an effort to reduce the high 
mortality of such patients. Future studies should be conducted to optimize 
screening and preemptive treatment of cryptococcosis. 
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ABSTRACT
Background
Tuberculosis (TB) meningitis, the primary manifestation of TB involving the brain, 
usually develops gradually over 1-2 weeks. The main factor associated with the 
high mortality of TB meningitis in late presentation. The majority of patients with 
TB meningitis in Indonesia present with very advanced disease characterized 
by loss of conscioussness and focal neurological signs. We examined how 
perception of illness and health-seeking behavior may contribute to this late 
presentation. 
Methods
Twenty consecutive TB meningitis patients and their relatives were subjected 
to in-depth interviewing in a referral hospital in Bandung, Indonesia about their 
perception of illness and health-seeking behavior prior to hospital admission. 
Results
From the in-depth interviews, it appeared that meningitis patients and their 
relatives were not alarmed by the initial symptoms such as severe headache. 
In addition, when they finally went to health care facilities, medical personnel 
did not seem to appreciate the significance of patients’ signs and symptoms, 
often sending them home. Communication between health care workers and 
patients seemed unsatisfactory as patients had virtually no understanding 
about their illness or the treatment. Delays in accessing appropriate treatment 
occurred both at the household health facility level. As a result, most patients 
were finally brought to hospital when they lost consciousness or developed 
other neurological complications. 
Conclusion
A lack of awareness about meningitis among patients/laypeople and health 
professionals is likely to contribute to the late presentation and severe outcome 
of patients with TB meningitis in Indonesia. 
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INTRODUCTION
Tuberculosis (TB) is the most common cause of subacute meningitis, an infection 
involving the brain coverings, in Indonesia like in many other countries [1-3]. It 
has a very high mortality [1, 4-7], and the main risk factor for death is severity of 
disease at time of presentation. A study in Egypt revealed that patients presenting 
after 4 weeks of symptoms had a mortality of 80%, while mortality in patients 
presenting after 2 weeks was 40% [8]. In the largest study sofar in Vietnam, the 
average mortality was 16.7% among patients in stage I (with headache only), but 
31.1% if patients present with stage II (focal neurological signs with or without 
altered consciousness), and 54.8% in stage III (more severe focal neurological 
signs or altered consciousness [4]. In the largest Indonesian cohort, more than 
three quarters of the TB meningitis patients presented with grade II or III of TB 
meningitis, and more than 50% of the patients died during six-months follow 
up [1, 9, 10]. It therefore seems likely that earlier presentation and treatment will 
improve the prognosis of patients with TB meningitis. 
Many factors drive people to seek medical advice. Perceptions of illness as well as 
religious, philosophical or ideological beliefs of an individual determine how he 
or she perceives health, illness, severity of illness, etc., and this in turn affects their 
attitude and health-seeking behavior [11]. In this study, perception and health-
seeking behavior of TB meningitis patients and their relatives were analyzed in 
order to understand reasons of late presentation and to find ways to increase 
awareness and decrease late presentation and treatment. 
Subjects and methods
Setting and design 
This was a cross-sectional study. The study was conducted in Hasan Sadikin 
Hospital, the top referral hospital for West Java Province, Indonesia (population: 
42 million), between 6 July and 31 August 2012. Twenty patients aged 15 years 
or more who were consecutively admitted to the neurology ward with a clinical 
suspicion of TB meningitis were approached and included after giving informed 
consent. Family members who were involved in the decision for hospital 
admission were also approached to participate. This study was approved by 
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the Ethical Committee of Hasan Sadikin Hospital/Medical Faculty of Universitas 
Padjadjaran, Bandung, Indonesia. Informed consent was asked to patient or 
closest relatives if the patient was unconscious. Consent was also asked to 
relatives to participate in this study. 
Examinations
Patients underwent physical and laboratory examinations according to standard 
diagnostic procedures in the hospital [1]. Diagnosis of meningitis was made 
using clinical signs, cerebrospin fluid (CSF) findings, and a TB meningitis scoring 
system as recently developed by a panel of experts, with values ranging from 
0 – 14 [5]. Definite TB meningitis was diagnosed if CSF microscopy, culture or 
PCR were positive for M. tuberculosis. Probable TB meningitis is diagnosed with 
a score > 10, and possible TB meningitis with a score of 6 – 9. The neurological 
status of patients was classified according to a modification of the British Medical 
Research Council (BMRC) as grade I (Glasgow Coma Scale, GCS, of 15 with no 
focal neurologic signs); grade II (GCS 11-14, or GCS 15 with focal neurologic 
signs); or grade III (GCS < 10) [4]. HIV testing was performed with consent from 
patients or their relatives in case of unconscioussness of the patient.
Interviews were conducted in a quiet room or at the bedside after the patients 
were admitted to the neurology ward, within the first 3 days of hospitalization. If 
the patients were not capable of giving answers due to their medical condition, 
relatives were interviewed in the presence of the patient. The interview template 
was developed prior to recruitment and pretested in three patients. This led to 
minor changes. The final template was used for the in-depth interviews. Results 
of the interview were then transcribed verbatim. 
Data analysis and statistics
Baseline characteristics of patients were collected and tabulated. Continuous 
variables are presented as means (SD) if normally distributed and median 
(interquartile range, IQR) if not normally distributed, and categorical variables 
as percentage. Qualitative data was analyzed using thematic analysis based on 
interview transcripts.
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RESULT 
Twenty patients were interviewed. Most patients were male (n=14, 70%), and the 
median age was 33 years. Patients mostly presented with neck stiffness (90%), 
headache (85%), fever (25%) and lowered consciousness (70%). Two patients had 
experienced seizures, and on examination weakness or paralysis of arms or legs 
was found in 70% of patients. The median time from the first complaint to the 
time of presentation at hospital was 24 days. One patient (5%) was diagnosed 
as having TB meningitis grade I, 18 (90%) as grade II and one (5%) as grade III. 
At time of admission, 16 patients (80%) were classified as having probable, and 
4 (20%) as having possible TB meningitis. Microbiological examination later 
confirmed TB meningitis in nine (45%) patients. Nineteen patients underwent 
HIV serology examination, and one was positive.
Perception of patients and relatives about the disease
None of the patients or their relatives was able to mention the name the 
disease meningitis, and none had heard of it, or had associated this illness 
with tuberculosis. Some symptoms such as headache, seizure, muscle cramp, 
hypertension, cough, fever, stomachache, cholesterol and typhoid fever were 
mentioned; but no one associated this condition with TB. As for etiology of 
disease, no one associated it with bacterial infection. Half of the patients and 
relatives associated this condition with emotional stress and having too many 
problems in life, while the rest associated this with common cold or mild illness. 
One patient said to his father before getting sick: 
“Let it only be me who knows what (my illness is), and what is happening 
to me. I don’t want to make everyone busy. Let it be me who suffers from 
this” (H., male)
The statement was then interpreted by the father that his son was ill because 
he had too many things on his mind which made him anxious and which led to 
accessing primary health care. 
Many patients complained about having recurrent headaches, but they 
correlated the headaches with emotional stress. The state of decreased level 
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of consciousness that was suffered by most patients was also correlated to 
headache. One relative perceived that this condition had something to do with 
head trauma
“... He had stumbled from second floor when he was 4 years old, and when 
he was at the secondary school he also had accident with another head 
injury. He always has problem with his head ... “ (mother of P, male)
The majority of patients and relatives believed that there was a natural cause for 
this illness, and they did not think that the condition was caused by supernatural 
phenomena such as curses, black magic, or the like. However, they still doubted 
it, that they also went to religious authorities to ask for some remedies to 
overcome it.
Social effect of the disease
Patients and relatives perceived that this illness made their lives harder, especially 
from a lower socioeconomic level. Most patients (60%) were the breadwinners, 
and their illness made them unable to earn money for the family. The fact that 
most of them had no permanent jobs made the condition worse. However, the 
patients did not mention financial constraints as a cause for delay in seeking 
treatment since they were covered by government insurance for the poor. 
Socially, their illness did not affect their relation with relatives, neighbors, and 
friends. The disease was not perceived as contagious or shameful. 
Perceived expected outcome
Despite the bad clinical condition at time of hospital admission, almost all 
relatives believed that the patients would get well, when they saw the patients 
improving after hospitalization. There was a fear though, that if the disease 
became protracted, it would make their lives difficult since no one would earn 
money for the family. 
Health-seeking behavior
More than 80% patients firstly took over-the-counter medicine (mostly analgesics) 
when they had early symptoms of the disease. When they felt that these over-
the-counter pills had no effect, they went to a primary health service or a private 
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practice (in Indonesia, it is a common practice that medical doctors run a private 
practice after office hour, or even run a small clinic by their own. Midwives and 
nurses also provide such services). Almost 50% patients even went to a district 
hospital, but all were sent home. Most of the time these health providers either 
in primary health service or referral hospital did not explain anything about the 
condition of the patients, and even when the patients or relatives asked about 
it only vague definitions were mentioned like “stomach ache”, “sign of typhoid 
fever”, “head problem”, and “lung problem”. On the other hand, patients were 
also reluctant to ask when the doctor did not open the communication about 
the illness showing that there may have been an issue in power relationship 
between doctor and patients. One subject said that the medical doctor in his 
primary health care did not tell anything about the disease but only ordered 
a chest radiography without further explanation. The communication issue is 
depicted in the following quotes:
“I received many kinds of medicine. But they did not say what the disease 
was. (I didn’t ask further) because I was so panic that I was trembling. 
Imagine, she was on the rice field and suddenly she just collapsed” 
(husband of Patient A, female)
“From a clinic, I was given a prescription to be given to this private hospital. 
The doctor referred my son to the internist when he should’ve been referred 
to the neurologist. I was scolded by the doctor at the hospital because of it 
when actually that was the fault of the clinic’s doctor, not mine” (mother 
of patient P, male)
“I didn’t receive the conclusion (of the disease), even I have not received 
the result of the X-ray test yet. So the communication with the doctor was 
not really good, I even had not met the doctor so I decided to change (the 
hospital)” (husband of Patient O, female)
All patients received medication from the health service providers, but they 
either did not get any information about the drugs they were taking, or did not 
understand the information they were given. In the interview, none of the patients 
could mention the name and the use of the drugs they received at the primary 
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health care; they only remembered that they got three of four drugs, and some 
still remembered the color of the drugs. In two-thirds of patients (n=13), relatives 
self-referred the patients to hospital, mostly because they noticed a decreasing 
level of consciousness of the patients, and one because the patient got a seizure. 
At some points all patients had come to primary health care providers, none 
of whom seemed to recognize the condition as serious illness, as as none had 
referred the patients to hospital. Ten patients (50%) went to different doctors 
before they finally came to Hasan Sadikin hospital. A statement from one relative 
may explain the process more clearly:
“After having stomachache for several weeks, we noticed that our son got 
fever. I already asked him to let me take him to a doctor, but he refused. 
He said it was only a stomachache. Then I asked a medical doctor to visit 
my son at home. He told us that my son got typhoid fever and gave him 
medicine. I have done what the doctor told me; our son should get a full 
bed rest, but we did not see any improvement. Then I took him to a hospital, 
and he was hospitalized. He got infused, but the following day I saw that 
he could not move his right leg. Then a neurologist paid a visit, and he 
told us that our son needed to be taken to other hospital to get his head 
scanned. We took him for scanning and we then took him back to our 
previous hospital. On Thursday, after seeing the result, the neurologist said 
that this case needed a consultation to neurosurgery. Then I was told that 
our son needed to be treated in ICU, but since the hospital does not have 
ICU available, on Sunday the patient was moved to here (Hasan Sadikin 
hospital). We reached the hospital at 3 pm, and at 7 pm all the laboratory 
examination were completed. Then someone came, asking permission to 
take some fluid from the low back of the patient, and we need to wait until 
4 at dawn because he needed to stay immobile until around 6 hours (after 
lumbar puncture procedure).” (mother of patient F, male). 
In addition, one of the patient’s relative made a statement that she was the one 
who took the patient to the hospital:
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“I was the one who had the initiative (to take the patient to the hospital) 
because I was anxious, I had taken him to that doctor for many visits but 
no improvement at all” (wife of Patient H, male)
Besides medical treatment, some patients and their relatives reported asking 
for spiritual help with holy water, “bekam” (a traditional method of healing that 
involves sucking out ‘dirty’ blood from the patient’s body by bleeding), or other 
religious rituals.
DISCUSSION
In this study, we found that most of patients presented late to the hospital not 
merely due to lack of knowledge of the patients and relatives, but also because 
health professionals did not seem to recognise the importance of symptoms. All 
patients visited health providers before admission, almost half of them even at 
some points went to referral hospital but were sent home. Two third of hospital 
admission was self-referred.
The early symptoms of meningitis were usually not perceived as serious, and this 
probably led to delay in seeking medical advice. Previous studies estimate that 
around 70-90% of all self-recognized episodes of illness are dealt with exclusively 
outside the formal health care system, in which the “popular” and “folk” sectors 
(self-treatment, family care, self-help groups, religious practitioners, heterodox 
heales, and so forth) provide most of the care [12]. 
In addition, patients and their relatives did not consider infection as a cause 
of headache. The study shows that headache is mostly referred as an effect of 
emotional stress, hence no physical treatment was sought. When the symptom 
persisted patients mostly used over-the-counter drugs, because headache is not 
culturally perceived as a sign of serious illness. This is in line with what Kleinman 
said that cultural belief affects how we present symptoms, when and to whom 
we go for care [12]. Since the process of illness and health seeking behavior 
begins with symptom perception and appraisal [11], one can understand that 
patients in this setting do not seek medical intervention when they have a 
headache.
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When symptoms got worse, patients went to primary health care providers. 
However, primary health care providers did not seem to recognize the patient’s 
complaints as a sign of serious illness, and therefore only prescribed symptomatic 
treatment. This might be caused by the medical provider’s inability to diagnose 
the disease in an early stage, and the patients’ inability to explain their symptoms 
clearly. Interestingly, in a study in the UK, when general practitioners were 
faced with patient’s complaints without a clear ascertainable medical disorder, 
they often considered symptoms to be trivial, not an appropriate reason for a 
doctor’s visit, and a waste of the doctor’s time [11]. This finding is also similar 
to what was found in a health seeking behavior study related to acute bacterial 
meningitis in Malawi. This study showed that patients were sometimes viewed 
as too demanding when they come repeatedly with the same complaint [13]. 
This explains why patients went to different doctors, and finally to hospital as 
self-referrals. 
The communication between patient and doctor seemed unsatisfactory, as 
most of the patients could not state the diagnosis the primary health care 
provider had made, nor the the name and the use of the medicine prescribed 
to them. This needs further study as communication is a major determinant of 
appropriate use of health facilities [14]. Culture definitely influences how health 
providers communicate with patients. From the interviews it seemed that in 
Indonesia, the doctor-patient relationship is still more of an ‘adult-child’ rather 
than ‘adult-adult’ relationship. This is important because ‘adult-adult’ relationship 
increase respect, autonomy, accountability, trust and humanity [15].
This present study also highlights how doctor’s delay contributes to late diagnosis 
and treatment of TB meningitis. This is similar to a study involving pulmonary TB 
patients in Jogjakarta, Indonesia, and a study in bacterial meningitis in Malawi 
[13], which also identified patient and as well as provider’s delay as a cause of 
treatment failure [16]. It is worrying that very few of the patients in our study were 
referred to hospital by health providers, while most were eventually brought to 
hopsital when they lost consciousness.
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Our study had some limitations. Firstly, it was based on anamnesis of reported 
historical events, which is prone to recall bias. To minimize bias, we did not probe 
patients or relatives with leading questions. The fact that some interviewees 
were not the ones who made decision to take the patients to hospital added 
further bias. Selection bias might also influence the result. No subject mentioned 
economic constraints as a cause of delay in hospital presentation. This might be 
due to selection bias, since patients with no government insurance for the poor 
might never reach the hospital. 
Despite these limitations, this qualitative study revealed that delay in seeking 
medical advice was not merely caused by patients’ ignorance, but also by 
unawareness among health providers. This study shows that both patient’s and 
doctors’ delay contribute to late presentation and poor outcome of tuberculous 
meningitis in Indonesia. Further study is needed to discover health care provider’s 
knowledge, attitude, and practice related to meningitis diagnosis and treatment, 
and to develop effective strategies to reduce delay and improve early diagnosis 
and treatment. 
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SUMMARY OF RESEARCH FINDINGS
This thesis addresses the etiology, diagnosis, outcome and treatment of adult 
meningitis in Indonesia. The studies were conducted in Hasan Sadikin Hospital, 
Bandung, the third referral hospital for West Java province, Indonesia between 
December 2006 and August 2012. 
In Chapter 2 we carefully characterized and followed a cohort of adult patients 
presenting with meningitis. We found that the vast majority of patients present 
with subacute meningitis. HIV had high prevalence (24%), was newly diagnosed 
in more than 70% of the patients, and associated with very low CD4 cell counts. 
An extensive microbiological work-up showed that bacterial meningitis was 
rare. The most common diagnosis was TB meningitis (80%), while cryptococcal 
meningitis was found in one-third of HIV patients. Approximately half of patients 
died, 41% within the first month of follow up, with HIV infection as the strongest 
risk factor for death. 
In our initial cohort, TB meningitis was confirmed in 50% of cases, in line with 
experience elsewhere which shows that bacteriological confirmation of TB 
meningitis is difficult. Culture is slow and often negative, and microscopy has 
an even much lower sensitivity. In Chapter 3 we evaluated in-house real-time 
PCR (rt-PCR) targeting insertion sequence IS6110 among 230 consecutive adult 
meningitis patients. IS6110-PCR of cerebrospinal fluid (CSF) samples had a much 
higher sensitivity than microscopy of ZN-stained slides, and this in-house rt-PCR 
identified more cases of TB meningitis than CSF culture, many of them with a 
somewhat milder presentation. IS6110-PCR was negative in all CSF samples from 
non-meningitis control patients. 
In our initial cohort, approximately 50% of HIV-infected patients either had TB or 
cryptococcal meningitis, leaving the other half without a definite diagnosis. In 
Chapter 4 we examined if toxoplasmosis accounted for some of these cases. In 
the absence of CT or MRI of the brain, toxoplasmosis is generally not considered 
as part of the differential diagnosis of meningitis. Among 64 HIV-infected 
patients with clinically suspected meningitis, CSF PCR for Toxoplasma gondii was 
Chapter 8
144
positive in one third. Clinically, in the absence of neuroimaging, toxoplasmosis 
was difficult to distinguish from TB or cryptococcal meningitis, although CSF 
abnormalities were less pronounced. Without specific toxoplasmosis treatment 
(as this study was done retrospectively on archived samples) patients with 
a positive T. gondii PCR had a roughly two-fold higher mortality compared to 
those with a negative PCR.
Even when diagnosed and treated promptly, TB meningitis generally has a poor 
outcome. Intensified antibiotic treatment might possibly improve outcome, 
especially since rifampicin and some other TB drugs do not penetrate well into 
the brain. In Chapter 5 we examined intensified antibiotic treatment containing 
a higher dose rifampicin intravenously and/or moxifloxacin, a fluoroquinolone 
with high potency against M. tuberculosis, besides standard dose INH, pyrazi-
namide and adjuvant corticosteroids. Sixty patients were randomized in a phase 
II open label randomized clinical trial. Standard oral rifampicin showed poor 
penetration into the CSF, but a 33% higher dose administered intravenously 
led to three times higher rifampicin concentrations in blood and CSF. 
Moxifloxacin penetrated well into CSF. Intensified treatment regimens did not 
result in increased toxicity. Finally, high dose rifampicin was associated with an 
approximately 50% reduction in 6-month mortality (35% vs. 65%). 
A key factor in the poor outcome of meningitis in Indonesia is the severity of 
disease at time of presentation. Among HIV-infected patients with low CD4 
count, screening of cryptococcal antigen prior to ART administration has been 
proposed by experts and recently advised by the World Health Organization 
(WHO) to prevent the development of cryptococcal meningitis and subsequent 
death. This is especially true in countries with high burden of cryptococcal 
meningitis (sub-Saharan Africa). In Chapter 6 we investigated the prevalence 
and clinical significance of cryptococcal antigenemia in Indonesian patients. 
Among 810 ART-naïve HIV patients with CD4 count less than 100 cells/μL, 7.1% 
had a positive cryptococcal antigen, and cryptococcal antigenemia at baseline 
was strongly associated with the development of cryptococcal meningitis, early 
loss to follow-up, and early death. 
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 Also for TB meningitis, the late presentation clearly contributes to high mortality 
in our setting. In Chapter 7 we assessed health-seeking behavior of patients with 
TB meningitis. From in-depth interviews it appeared that meningitis patients 
and their relatives were not alarmed by the initial symptoms such as severe 
persistent headache. In addition, when they finally went to primary health care 
facilities, health providers usually did not appreciate the significance of typical 
signs and symptoms, and often sent them home. As a result, most patients were 
self-referred when presenting at the hospital, mostly with loss of consciousness 
and focal neurological signs. These data indicate a lack of awareness about 
meningitis among patients/laypeople as well as health providers. 
GENERAL DISCUSSION
Clinical presentation, diagnosis, and outcome (Chapters 2, 3, and 4)
Table 8.1 shows the research questions related to clinical presentation, etiology, 
diagnosis and outcome of meningitis. The table also contains the main findings 
with the implications for practice or further research.
Clinical presentation and HIV
Clinically, our patients were mostly young males, possibly reflecting the higher 
susceptibility of men for TB, or the rise of HIV, which in Java is mostly driven by 
young males injecting drugs [1,2]. Patients mostly had a subacute presentation, 
usually with headache and fever, and often with altered consciousness (45%) 
and focal neurological signs (30%), reflecting a more advanced course of disease. 
HIV prevalence was unexpectedly high (25% in the initial study; 18.9% among 
410 patients recruited since year 2006), with two-thirds of patients not aware 
of their HIV status until hospital admission. Available CD4 cell counts were very 
low (median of 22 cells/mL), in line with the late detection of HIV in Indonesia 
(median of 37 cells/mL in outpatient clinic in the same setting) [3]. 
Our research findings have had immediate implications for patient care. Provider 
initiated testing and counseling (PITC) for HIV is performed to all patients 
immediately after admission, usually at the emergency room. The result of HIV 
testing also determines the flow of CSF samples for microbiological testing 
(Figure 8.1)
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Microbiological diagnosis
In our initial study, a definite cause of meningitis was found in 55% of patients. 
Confirmation of cryptococcal meningitis (introduced as part of these studies) is 
straight forward, but bacteriological confirmation of TB meningitis was much 
lower (56%). Different from studies in Vietnam and Argentina that revealed 
positive results up to 60% among HIV positives [4,5], the positivity rate in 
HIV positive patients in our cohort was much lower (32.3%), possibly due to 
methods used for bacteriological confirmation at the time of the study (direct 
Table 8.1.  Clinical presentation, etiology, diagnosis and outcome of meningitis
Clinical presentation, etiology, diagnosis and outcome
Questions Findings Implications
•	 What are the main 
pathogens causing adult 
meningitis in Indonesia? 
(Chapter 2)
•	 What is the prevalence of 
HIV infection and what is 
its effect on outcome of 
meningitis? (Chapter 2)
•	 What is the performance of 
IS6110 rt-PCR for diagnosis of 
TB meningitis? (Chapter 3) 
•	 Are there any other possible 
infectious agents in HIV-
infected patients presenting 
with subacute meningitis? 
(Chapter 4)
•	 TB and cryptococcal 
meningitis are the main 
causes, bacterial meningitis is 
extremely rare 
•	 One fourth of adult meningitis 
patients are HIV-infected. HIV 
increases mortality by more 
than two-folds 
•	 IS1610 rt-PCR is highly specific 
and more sensitive than CSF 
culture and microscopy 
•	 Toxoplasma PCR was positive 
in CSF in one third of archived 
samples from HIV-infected 
meningitis cases
•	 Mortality among patients with 
undiagnosed toxoplasmosis 
was very high
•	 Clinical and laboratory 
flowchart for meningitis 
patients was established and 
introduced. Empiric treatment 
now includes TB
•	 Provider-initiated testing 
and counseling for HIV is 
performed immediately to 
patients presenting with 
subacute meningitis 
•	 IS6110 rt-PCR is technically 
demanding and cannot be 
implemented easily in routine 
care. Automated Xpert TB and 
MODS should be tested
•	 Toxoplasmosis should be 
included in the differential 
diagnosis of subacute 
meningitis, especially if 
neuroradiology is not available
•	 Empiric anti-toxoplasmosis 
treatment should be evaluated 
in HIV-infected meningitis 
patients 
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staining and solid/liquid culture only). Molecular testing (rt-PCR) was specific 
and had a positivity rate which was 6 times higher than microscopy and 1.5 
times higher than culture [6]. Interestingly, very few patients (less than 3%) in 
our setting present with acute bacterial meningitis, different from series from 
other Asian countries where acute bacterial meningitis is diagnosed in around 
30% of patients [7–9]. It could be that patients with acute bacterial meningitis 
never reach our hospital, either because they die earlier or because they receive 
antibiotic treatment elsewhere. 
These findings have led to the development of a diagnostic algorithm for 
patients with subacute meningitis in our hospital (Figure 8.1), and for a change 
in empiric treatment, which now always contains TB drugs.
In patients with advanced HIV infection, cerebral toxoplasmosis is usually consi-
dered when patients present with subacute or acutely developing confusion, 
with or without focal neurological deficits [10]. Confirmation of diagnosis is 
usually achieved by finding space occupying lesion(s) in cerebral imaging. If 
neuroimaging is not performed, cerebral toxoplasmosis is usually not considered 
in this group of patients. Our hypothesis that toxoplasmosis might mimic 
subacute meningitis in our setting was confirmed by the finding of positive T. 
gondii PCR in one third of HIV-infected patients with meningitis, all of whom 
had toxoplasma IgG in their blood. Toxoplasmosis was similarly frequent with 
TB and cryptococcal meningitis, and could not be distinguished easily. Because 
of these results, in the absence of CT or MRI of the brain, we recommend that 
toxoplasmosis should be part of the differential diagnosis in patients presenting 
with clinical signs and symptoms of subacute meningitis [4,11,12], especially if 
cryptococcal or TB infection cannot be confirmed by CSF microscopy. Further, 
empiric treatment for toxoplasmosis should be considered in such patients. 
The high proportion of non-definite meningitis cases, especially in HIV-infected 
patients underlines the need to search for other possible causative agents. We 
ruled out neurosyphilis [11], which is common among HIV patients in the western 
world. Aiming for more bacteriological confirmation, we evaluated in-house 
IS6110 TB-PCR. Real-time PCR had a 100% specificity and a high positivity rate 
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Figure 8.1.  Meningitis flowchart
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(68%), higher than other TB diagnostic modalities, higher than often reported 
in literature [13–15], probably due to the use of large CSF samples used [11], 
and the use of IS6110, which has multiple copies present in the genome of M. 
tuberculosis complex, as the PCR target [16]. Although this PCR was reliable in a 
research setting, it proved too difficult and technically demanding to implement 
in daily practice. The recently developed geneXpert (XpertTB), a very robust 
and closed PCR [17], should be evaluated as an alternative. To the best of our 
knowledge, the use of GeneXpert in TB meningitis has only been studied in 
small numbers of meningitis patients in Germany and India [18,19]. At present 
we are also busy evaluating microscopic observed drug susceptibility testing 
(MODS) as a rapid culture system for TB meningitis.
Improving outcome: HIV, late presentation and other operational issues
In our initial cohort, approximately 50% patients died within 6 months, most of 
them in the first month. HIV infection and late presentation increased mortality, 
as well as a positive CSF T. gondii PCR among those with HIV. In the absence of 
toxoplasmosis treatment, not less than 83% of patients died within 2 months, 
compared to 64% of patients treated for TB meningitis, and 46% for cryptococcal 
meningitis [20]. 
This extreme mortality in HIV-infected patients emphasizes the need for earlier 
detection and treatment of HIV. Unfortunately, HIV is mostly diagnosed very 
late in Indonesia, and even when diagnosed, many patients remain without 
treatment [21]. Earlier detection and treatment of HIV using the ‘universal test 
and treat’ approach, where every adult gets tested annually and gets immediate 
treatment irrespective of CD4 count, would decrease mortality and morbidity 
resulting from late diagnosis as well as significant cost savings in the longer 
term [22]. Of course this approach poses conceptual, ethical, programmatic, 
and financial issues [23], and operational research is needed to implement such 
measures [24]. At a more simple level, recognition of simple signs of HIV, like 
chronic diarrhea and oral candidiasis, and targeted counseling and testing of 
risk groups such as prisoners has shown great benefit in our setting in Bandung 
[25–27].
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Another approach should target late presentation of meningitis, as it strongly 
correlates with higher mortality, as shown in a study in Vietnam where mortality 
was 16.7% in grade I, 31.1% in grade II and 58.8% in grade III TB meningitis [28]. 
Less than 10 % of our TB meningitis patients present with grade I TB meningitis, 
all the others with more advanced stages. In-depth interviews showed 
considerable delay both at the level of patients and health providers. Both 
patients and health care providers should be made aware of the initial signs of 
meningitis to increase early detection and treatment of meningitis. Operational 
research should be conducted to limit delay once patients admit to hospital, and 
increase timely start of antibiotic treatment, as has been shown for other diseases 
[29]. Further studies are needed to examine the benefit of timely diagnosis and/
or empiric treatment meningitis patients in settings like ours, which possibly 
include treatment for tuberculosis and toxoplasmosis. 
Treatment (Chapter 5)
Table 8.2. summarizes the research questions, findings and implications of 
studies in this thesis on treatment of TB meningitis. 
Intensified antibiotic treatment
Our findings from the phase II clinical trial suggest a clear benefit of high 
dose rifampicin. Standard dose rifampicin results in a very low concentration 
of rifampicin in CSF. Administration of oral rifampicin in this study results in a 
lower plasma concentration when compared to administration of similar dose to 
pulmonary TB patients in the same setting [30], possibly due to lower absorption 
when rifampicin is given through a nasogastric tube or when patients are severely 
ill. Higher dose of rifampicin, given intravenously, significantly increased drug 
exposure both in serum and CSF. AUC0–6 78.7 mg.h/L, Cmax plasma 22.1 mg/L, 
and concentrations in CSF 0.60 mg/L that were resulted from administration of 
this higher dose of rifampicin exceed minimal inhibitory concentration (MIC) in 
liquid medium (0.2 – 0.4 mg/mL) [31], and considered adequate for treatment 
of TB meningitis.
As to moxifloxacin, this drug penetrates well into CSF. With standard dose (400 
mg), its AUC0–6 15.1 mg.h/L, Cmax 3.9 g/L, and drug concentration in CSF 1.52 
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g/L were considered favorable for treatment of TB meningitis [32]. Doubling the 
dose of moxifloxacin gives rise to proportional increase in those parameters. 
Of note, the fact that rifampicin reduces concentration of moxifloxacin by 30% 
when administered together [33] might support the use of higher dose of 
moxifloxacin.
Increasing the dose of rifampicin and moxifloxacin did not seem to increase 
toxicity, in agreement with data for the use of a higher dose of rifampicin for 
tuberculosis [30] and other indications and with the few data available for high-
dose moxifloxacin [34,35].
Most importantly, mortality was much lower in patients treated with rifampicin 
high-dose i.v. (cumulative 6-month mortality 34% vs. 65%), and this was not due 
Table 8.2.  Treatment of TB meningitis in this thesis 
Treatment
Questions Findings Implications 
•	 Is intensified treatment of TB 
meningitis safe? 
•	 Is intensified treatment 
associated with better drug 
exposure in blood and CSF?
•	 Does intensified treatment 
lead to better treatment 
results? 
•	 Treatment regimens including 
high dose rifampicin iv and 
standard and high dose 
moxifloxacin did not lead to 
more drug toxicity
•	 Standard rifampicin is associated 
with very low drug exposure in 
the CSF
•	 Moxifloxacin has good 
penetration
•	 Intensified treatment 
leads to much higher drug 
concentrations 
•	 High dose rifampicin improves 
neurological outcome and 
significantly increased patient 
survival 
•	 Intensified treatment should 
be evaluated in larger phase 
3 trials
•	 Pharmacokinetics of 
rifampicin i.v. and an even 
higher dose of oral rifampicin 
should be compared 
•	 Rifampicin high dose and 
moxifloxacin standard dose 
throughout the intensive 
phase
•	 Intensified treatment should 
be evaluated in larger phase 
3 trials
•	 Adjuvant treatment should 
be further explored as 
mortality remains high
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to confounding. Longer administration of high dose rifampicin might further 
reduce the mortality. Moxifloxacin did not seem to affect mortality, but this 
phase II trial was actually not powered to detect differences in survival. 
One immediate question for implementation of the findings of this study is 
the use of intravenous preparation of rifampicin. Oral administration (rather 
than intravenous) of rifampicin would simplify intensified treatment, as it is 
more readily available worldwide. A bioavailability study comparing 600 mg i.v. 
rifampicin with an even higher dose oral rifampicin is need to define the optimal 
oral dose. A phase III multicenter randomized clinical trial comparing intensified 
and standard treatment will be the next step before proposing change of 
international treatment guidelines. 
Adjuvant treatment
Corticosteroid as adjuvant in TB meningitis treatment reduces mortality, espe-
cially in HIV-negative patients but do not prevent development of neurological 
complications [28,36], and longer follow up revealed that the benefit was 
only seen until 2 years [37]. Recent evidence suggests that the effect of 
corticosteroids is dependent on genetic variation, opening the way for tailored 
steroid treatment in the future [38]. Aspirin might be another adjuvant option, 
as it may reduce stroke, a common complication of TB meningitis [39]. Other 
treatment modalities, such as neurosurgical interventions for treating increased 
intracranial pressure, as well as more aggressive treatment for accompanying 
metabolic conditions might help to reduce morbidity and mortality from this 
deadly and devastating disease. 
Prevention (Chapter 6 and 7)
Two studies were performed in the field of prevention, one for cryptococcal 
meningitis among ART-naïve patients, and one addressing health-seeking 
behavior of TB meningitis patients. The questions, findings and implications of 
research findings are listed in Table 8.3.
The significant prevalence of cryptococcal antigenemia among ART-naïve HIV 
patients in our setting warrants routine screening. Screening of patients with 
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low CD4 cell counts for cryptococcal antigenemia has been advocated by 
experts in this field [40–42], and has also been recommended by WHO since 
late 2011 [43]. The use of simple and accurate point-of-care tests like the LFA 
method [41,44] is preferred. Patients who are positive should probably get a 
proper neurological examination and lumbar puncture. The high early mortality 
and loss to follow-up suggest that we may have missed some (sub)clinical cases 
of cryptococcal meningitis. If meningitis is excluded, those with asymptomatic 
cryptococcal antigenemia should receive pre-emptive treatment [41,43], as this 
proved a significant risk factor for subsequent meningitis and death. Further 
operational research is needed to optimize this strategy in our setting.
As mentioned above, late presentation is a strong risk factor for poor outcome. 
Patient as well as provider’s delay has been identified as a cause of failures in 
pulmonary TB control in a study in Indonesia [45], and a qualitative study in our 
cohort revealed that delay in seeking medical advice was not merely caused by 
patient’s ignorance, but also by unawareness among health providers. Further 
steps should be taken to examine this in more depth and to develop strategies 
to counteract this problem. 
Table 8.3.  Prevention of meningitis in this thesis
Prevention
Questions Findings Implications 
•	 What is the prevalence and 
clinical significance of serum 
cryptococcal antigenemia 
among HIV patients with 
CD4 cell counts below 100/
mL? (Chapter 6)
•	 What factors caused delay in 
presentation of meningitis 
patients in Indonesia? 
(Chapter 7)
•	 High prevalence of 
cryptococcal antigenemia 
among ART-naïve patients, 
higher early mortality and 
drop out among patients with 
positive result 
•	 Unawareness among patients 
and providers in diagnosis of 
TB meningitis
•	 Cryptococcal antigen 
screening has been 
implemented in HIV clinic 
following the study
•	 Pre-emptive treatment for 
antigen-positive patients 
should be examined
•	 Further study to examine 
knowledge, attitude and 
performance of health 
providers towards meningitis, 
and ways to education lay 
people 
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FURTHER RESEARCH PRIORITIES
In the past 6 years we have learned a lot about the clinical management 
of meningitis in Indonesia. One of the most striking conclusions is the high 
proportion of TB meningitis. However, although the research has had a big 
impact on diagnosis, we can still only get bacteriological confirmation of TB 
meningitis in around 50%, and mostly through culture, which is too slow to 
guide initiation of treatment. Similarly, intensified treatment containing high-
dose rifampicin seems very promising, and is likely to be implemented in some 
forms in the coming years. But despite these advancements, the mortality of 
meningitis remains very high. The problems addressed in this thesis are not 
specific for Indonesia; around the world, diagnosis and treatment of TB meningitis 
remain a huge challenge. And in HIV-infected patients, cryptococcal meningitis 
and cerebral toxoplasmosis pose a big burden. Surely, much more need to be 
done to improve care of meningitis patients in Indonesia and elsewhere. In 
addition, many questions regarding the pathophysiology of meningitis remain 
unanswered. 
Therefore, we hope to address two important questions in future studies. 
•	 Why do some patients develop TB meningitis and not lung or asymptomatic 
TB infection? 
•	 How can the poor prognosis of meningitis be improved? 
Based on these questions and in light of our previous studies we can define 
three priorities: basic sciences, operational research, and a new clinical trial for 
TB meningitis, as would now briefly explain below.
Basic sciences
It is not known why some patients develop TB meningitis and not lung TB or 
asymptomatic TB infection. Both human and bacterial genetic factors may be 
involved, but the exact mechanisms are unknown. Variation in certain host 
genes is associated with TB. This has also been the focus of earlier studies in 
Bandung, using a cohort of more than 1,100 Indonesian pulmonary TB patients 
and 1,100 healthy controls. This allowed to confirm or disprove associations in 
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TIRAP [46], a locus on chromosome 11p13 [47], TLR 8 [48], and autophagy genes 
[49] among others.
The particular clinical phenotype of TB (pulmonary TB, TB meningitis, etc.) 
may also be genetically determined, but this has not been properly examined 
as only three genetic studies have included TB meningitis, the most severe 
manifestation of TB [50–52]. Since TB meningitis is associated with more severe 
forms of acquired immunodeficiency (e.g. caused by advanced HIV infection or 
strong immunosuppressive drugs), one might hypothesize that the same holds 
true for genetic risk factors: compared to pulmonary TB, mutations leading to 
more pronounced loss of host immunity might be ‘needed’ for development of 
TB meningitis. However, this has not been studied. The degree of evolutionary 
adaptation of certain M. tuberculosis lineages might also affect the clinical 
phenotype of active TB [53], with certain M. tuberculosis lineages overrepresented 
among TB meningitis patients, but this has only been studied in a single study 
from Vietnam [50].
The interaction between human and mycobacterial genotypes, and the relation 
with the disease ‘phenotype’ requires further study. We have now established 
a large cohort of TB meningitis patients in Bandung, which will allow us to 
conduct such studies to increase our understanding of the pathogenesis of TB 
meningitis.
Operational research
In dealing with the problems in meningitis, operational studies should be 
conducted as outlined in the previous sections. In the field of diagnostics, 
GeneXpert MTB/RIF assay, a novel diagnostic tool that integrates rapid diagnosis 
of TB and detection of rifampicin resistance [17], and other (much cheaper) 
methods such as MODS should be evaluated [54,55]. TB meningitis caused by 
drug-resistant mycobacteria has a far worse outcome than disease caused by 
susceptible organisms, but timely confirmation of drug-resistance in TB meningitis 
is problematic [56–58]. Fortunately, our preliminary data show low prevalence 
rates of drug resistance among TB meningitis (Lidya Chaidir, unpublished data). 
Still, methods for rapid evaluation and risk stratification should also be evaluated.
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The use of uniform case definition for TB meningitis has been proposed by 
a committee of experts, in order to make the result of studies from different 
setting comparable [59]. However, implementation of the scoring system in 
daily routine is somewhat difficult, and cut-off points for including patients into 
clinical diagnosis of possible/probable TB meningitis requires further validation 
among settings [60]. Other operational studies should focus on late presentation. 
The knowledge, attitude and practice of health providers towards this topic 
should be examined and appropriate interventions should be designed. In the 
field of treatment for meningitis other than TB, operational research should be 
done to optimize diagnosis and treatment of HIV-associated meningitis, i.e. 
implementation of anti toxoplasmosis treatment and screening and treatment 
of cryptococcosis. Often, diagnostic delay seems not only caused by patients’ 
ignorance, but also by lack of awareness among health care providers. Increasing 
awareness of the disease is the first step to improve patient management, which 
can be done both to lay people and health care providers. 
In general, we hope that dissemination and implementation of our operational 
findings in diagnosis and treatment, and our clinical algorithms to other hospitals 
in Indonesia, will help improve care for meningitis patients. 
Defining an optimal treatment regimen – need for further trials
There seems to be two possible approaches to improve treatment of TB 
meningitis. First, as shown in our phase II clinical trial, intensified antibiotic 
treatment with high dose rifampicin should be further explored. The use of 
equivalent oral dose of the intravenous rifampicin in the trial will make the regimen 
more practical and easy to deliver, and give less financial burden to health system. 
Second, more effective adjuvant treatment should be developed. In a landmark 
trial in 2004, Thwaites et al proved the benefit of adjuvant corticosteroids for TB 
meningitis, with a clear reduction in mortality (RR 0.69, 95% CI 0.52 – 0.92, p=0.01) 
[28]. However, no significant effects were noted on neurological disability, and 
the benefit of dexamethasone was only seen up to two years of follow-up [37]. 
Interestingly, stratification according to a functional SNP in the promoter region 
of the lta4h, a gene involved in eicosanoid metabolism, reveals differences in 
the effect of corticosteroids. Adjunctive dexamethasone only showed survival 
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benefit in patients with the pro-inflammatory lta4h genotype [38]. Replication 
of this finding in other cohorts would explain some of the variability in trials 
evaluating the beneficial effect of dexamethasone and would open the way for 
individualized corticosteroid treatment of TB meningitis.
Another possible adjuvant is aspirin. Stroke is a common complication of TB 
meningitis, typically located in the basal ganglia, mostly in the middle cerebral 
arterial territory and associated with poor outcome [61,62]. Aspirin appeared to 
reduce mortality and neurological outcome in a trial from India [39], although this 
trial was flawed by its lack of blinding, relative small size, incomplete corticosteroid 
treatment, and high dropout from the aspirin group. Besides its inhibition of 
platelet aggregation, aspirin may harbour direct antimycobacterial effects [63], 
may modulate antituberculous drugs [64,65] and has immunomodulatory effects 
[66,67], and effects on the eicosanoid metabolism implicated in susceptibility 
and outcome of TB infection. 
It seems rational to combine these two approaches, intensified antibiotics and 
low-dose aspirin, in a large randomized clinical trial. Intensified treatment was 
proven to be very effective by itself, and aspirin is unlikely to antagonize this 
effect. In addition, combining two or more drugs in developing TB treatment 
is encouraged by Stop TB Partnership, and in keeping with new regimen deve-
lopment paradigm to shorten the development of TB drug that traditionally 
requires many years [68,69]. If we would be able to conduct (and fund) such a 
trial, it should preferably be multi-site and blinded. The outcome of such a trial 
would have an important impact on treatment of TB meningitis.
Concluding remarks
This thesis is a result of a longstanding multidisciplinary and international colla-
boration. In Indonesia, the infrastructure to conduct clinical trials and phar-
macological researches is not fully established yet, and experience of conducting 
such studies is limited. More collaboration among Indonesian researches is 
needed, along with improvement of infrastructure and scientific conducts. 
Partnership with other researchers from different disciplines and other countries 
may help to empower Indonesian researchers to engage in this type of work. 
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This thesis is the continuation of the work in the field of TB and HIV conducted 
by my Indonesian colleagues Bachti Alisjahbana, Ida Parwati, Rovina Ruslami, 
Rudi Wisaksana and others who have conducted research in the field of TB and 
HIV, including operational, bacteriological, and pharmacological research. Their 
efforts and the longstanding academic collaboration between Indonesia and 
the Netherlands in this particular field have helped establish the studies in this 
thesis, which I hope again will be a ‘stepping stone’ for future researches. 
The findings in this thesis provide some important data regarding the etiology, 
diagnosis and outcome of meningitis in Indonesia. In addition, they shed 
light on the likely benefit of intensified antibiotic treatment for outcome of TB 
meningitis, and on the prevention of meningitis. Clearly, more effort is needed 
to help improve patient management and increase our basic understanding of 
meningitis. 
I am grateful that I was able to engage in this research in the last 6 years, and 
I hope I can contribute to future studies in collaboration with professionals in 
Indonesia and abroad. 
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RINGKASAN
Ringkasan hasil penelitian
Tesis ini membahas etiologi, diagnosis, luaran dan pengobatan meningitis pada 
pasien dewasa di Indonesia. Penelitian yang disebutkan dalam tesis ini dilakukan 
di Rumah Sakit Umum Pusat dr. Hasan Sadikin, Bandung, yang merupakan rumah 
sakit rujukan provinsi Jawa Barat pada kurun waktu Desember 2006 hingga 
Agustus 2012. 
Bab 2 membahas karakteristik pasien kohort yang terdiri dari orang dewasa 
yang datang untuk dirawat dengan gejala meningitis. Pada kohort ini kami 
mendapati bahwa sebagian besar pasien yang datang menderita meningitis 
subakut. Prevalensi HIV pada kelompok pasien ini tinggi (24%), dan lebih dari 
70% pasien dengan HIV-positif baru mengetahui status HIV mereka saat dalam 
perawatan ini. Jumlah sel CD4 pada pasien-pasien ini sangat rendah. Pada 
kohort ini, diagnosis klinis yang paling sering ditegakkan adalah meningitis TB 
(80%); dan pada kelompok pasien HIV-positif, meningitis kriptokokus dijumpai 
pada satu dari tiga pasien. Meningitis bakterialis jarang ditemukan, meskipun 
telah dilakukan pemeriksaan mikrobiologi yang cukup menyeluruh terhadap 
sediaan cairan serebro spinal (CSS) pasien-pasien ini. Separuh dari pasien dalam 
kohort ini meninggal dalam waktu 6 bulan, dan kematian paling banyak terjadi 
pada satu bulan pertama (41%). Infeksi HIV merupakan faktor risiko kematian 
yang paling kuat. 
Diagnosis pasti pada kelompok pasien dengan diagnosis klinis meningitis TB 
pada umumnya baru didapatkan setelah beberapa pekan, yaitu setelah kultur 
bakteri tumbuh. Tidak seperti TB paru, diagnosis segera melalui pemeriksaan 
mikroskopis (pewarnaan Ziehl Nielsen) jarang mendapatkan hasil positif 
karena sedikitnya jumlah kuman di dalam CSS. Secara umum diketahui bahwa 
konfirmasi bakteriologis meningitis TB sulit didapatkan. Hal ini disebabkan oleh 
karena kultur TB memerlukan waktu yang lama dan sering menunjukkan hasil 
negatif, sementara pemeriksaan mikroskopis langsung mempunyai sensitivitas 
yang lebih rendah. Hal ini menjadi masalah, karena diagnosis pasti yang 
terlambat dapat membuat penanganan penyakitnya menjadi terlambat juga. 
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Karena itu pada Bab 3 kami mengevaluasi kegunaan in-house real-time PCR (rt-
PCR) yang menggunakan insertion sequence IS6110 sebagai primer. Penelitian 
dilakukan terhadap bahan pemeriksaan CSS dari 230 pasien meningitis yang 
dikumpulkan selama 3 tahun. Pemeriksaan IS6110-PCR dengan menggunakan 
bahan pemeriksaan CSS menunjukkan sensitivitas yang jauh lebih tinggi 
dibanding pemeriksaan mikroskopis langsung, dan dapat mengidentifikasi lebih 
banyak kasus meningitis TB dibandingkan dengan kultur, bahkan pada kasus 
dengan gejala klinis yang lebih ringan. IS6110-PCR menunjukkan hasil negatif 
pada semua bahan sediaan CSS yang berasal dari pasien non-meningitis. 
Pada kohort penelitian kami, sekitar separuh pasien HIV menderita meningitis 
TB atau kriptokokus, sementara separuh yang lain tidak memiliki diagnosis 
pasti. Pada Bab 4 kami menyelidiki kemungkinan toksoplasmosis sebagai 
penyebab keadaan klinis pada pasien-pasien ini. Pada praktek sehari-hari, tanpa 
adanya hasil pemeriksaan CT-scan atau MRI, toksoplasmosis umumnya tidak 
menjadi diagnosis banding meningitis. Dari 64 pasien HIV yang diperiksa, kami 
mendapatkan hasil PCR toksoplasma positif pada sepertiga kasus. Secara klinis, 
pasien dengan PCR toksoplasma positif sulit dibedakan dari pasien meningitis 
TB dan kriptokokus, walaupun kelainan CSS-nya lebih ringan. Tanpa pengobatan 
spesifik untuk toksoplasmosis (penelitian ini dilakukan retrospektif terhadap 
bahan pemeriksaan yang tersimpan), pasien dengan PCR toksoplasma positif 
meninggal dua kali lebih banyak daripada pasien dengan hasil PCR negatif. 
Meningitis TB biasanya memiliki luaran yang buruk, bahkan jika diagnosis dan 
pengobatan bisa dilakukan dengan segera. Pengobatan antibiotika yang lebih 
intensif menggunakan obat baru atau dengan menaikkan dosis obat yang 
penting mungkin akan memperbaiki luaran ini. Pada Bab 5 kami mendiskusikan 
hasil penelitian farmakologi obat TB untuk meningitis TB dengan menggunakan 
rifampisis dosis tinggi intra vena dikombinasikan dengan moksifloksasin oral. 
Moksifloksasin merupakan obat golongan florokuinolon yang mempunyai 
potensi tinggi terhadap Mycobacterium tuberculosis. Sejalan dengan kebijakan 
pemberian empat jenis obat untuk penanganan TB, obat TB lain yaitu INH, 
pirazinamid tetap diberikan dalam dosis standar. Kortikosteroid telah menjadi 
bagian dari protokol pengobatan meningitis TB, dan tetap diberikan pada pasien 
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yang masuk pada penelitian ini. Enam puluh pasien meningitis TB menjalani 
randomisasi untuk mendapatkan satu dari beberapa kemungkinan kombinasi 
rifampisin dan moksifloksasin. Hasil pemeriksaan kadar obat dalam darah dan 
CSS menunjukkan bahwa penetrasi rifampisin ke dalam CSS sangat buruk pada 
dosis standar yang diberikan secara oral, namun penaikan dosis 33% melalui vena 
meningkatkan konsentrasi rifampisin sampai 3 kali lipat baik di darah maupun 
di CSS. Moksifloksasin dapat menembus CSS dengan sangat baik. Pemberian 
rejimen intensif ini tidak meningkatkan toksisitas obat. Rifampisin dosis tinggi 
juga berhubungan dengan perbaikan angak kematian dalam follow up 6 bulan 
hingga 50% (35% vs. 65%). 
Salah satu penyebab utama keluaran buruk meningitis di Indonesia adalah 
beratnya derajat penyakit saat datang berobat ke rumah sakit. Hal ini bisa 
dicegah dengan mengenali penyakit secara lebih dini atau mencegah sebelum 
penyakit muncul. Berdasarkan temuan-temuan penelitian terdahulu, WHO pada 
akhir tahun 2011 merekomendasikan pemeriksaan penapisan kriptokokus pada 
pasien HIV dengan jumlah sel CD4 yang sangat rendah sebelum pemberian obat 
anti retroviral. Penapisan ini dapat mencegah timbulnya meningitis kriptokokus, 
dan diketahui dapat mencegah kematian. Hal ini terutama berlaku pada negara-
negara yang mempunyai banyak kasus meningitis kriptokokus (negara-negara 
sub-Sahara di Afrika dan Asia Tenggara). Pada Bab 6 kami menyelidiki prevalensi 
dan aspek klinik dari adanya antigen kriptokokus di dalam darah pengidap 
HIV dengan jumlah CD4 < 100 dan belum mendapat terapi ARV di Indonesia. 
Dari 810 pasien yang memenuhi kriteria inklusi, 7.1% mempunyai antigen 
kriptokokus di dalam darahnya, dan adanya antigen ini pada pemeriksaan awal 
sangat berhubungan dengan kejadian meningitis kriptokokus dan tingginya 
angka loss to follow up dan kematian. 
Hal serupa juga didapatkan pada kasus meningitis TB. Keterlambatan datang 
berobat telah terbukti menjadi salah satu penyebab tingginya angka kematian. 
Pada Bab 7 kami menilai persepsi dan perilaku mencari pengobatan pada 
pasien yang dirawat dengan diagnosis meningitis TB. Dari wawancara mendalam 
terhadap 20 pasien dan keluarganya, didapatkan bahwa pasien dan keluarga tidak 
menyadari bahwa nyeri kepala hebat yang menetap itu merupakan gejala awal 
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meningitis. Namun demikian, saat mereka datang berobat ke fasilitas pelayanan 
kesehatan primer, penyedia pelayanan yang ada umumnya juga tidak menyadari 
bahwa gejala yang ada merupakan tanda kelainan yang berat dan karenanya 
tidak melakukan rujukan. Tidak jarang keluarga pasien yang langsung membawa 
pasien ke rumah sakit saat mendapati pasien mengalami penurunan kesadaran 
atau kejang-kejang. Hal ini menunjukkan adanya kekurangan kewaspadaan akan 
meningitis baik pada level pasien atau penyedia pelayanan kesehatan.
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SAMENVATTING
Samenvatting van de onderzoeksbevindingen
Dit proefschrift behandelt de etiologie, diagnostiek, de uitkomsten en de 
behandeling van meningitis bij volwassenen in Indonesië. De studies die aan het 
proefschrift ten grondslag liggen, zijn tussen december 2006 en augustus 2012 
uitgevoerd in het Hasan Sadikin Hospital, Bandung, het tertiaire verwijscentrum 
voor de provincie West-Java van Indonesië.
In hoofdstuk 2 beschrijven we een cohort van volwassen patiënten die 
zich klinisch presenteerden met meningitis. Dit cohort werd zorgvuldig 
gekarakteriseerd en gevolgd. We stelden vast dat de overweldigende 
meerderheid van patiënten zich met subacute meningitis presenteerde. In deze 
studie toonde HIV een hoge prevalentie van 24%. HIV werd als nieuwe diagnose 
vastgesteld in 70% van de patiënten en was geassocieerd met erg lage aantallen 
CD4-positieve cellen. Een uitgebreide microbiologisch vervolgonderzoek 
toonde dat acute bacteriële meningitis zeldzaam was. De meest voorkomende 
diagnose was tuberculeuze meningitis (80%). Bij HIV-patiënten, werd in een 
derde van de gevallen cryptokokkenmeningitis gevonden. Ongeveer de helft 
van alle patiënten overleed, 41% binnen de eerste maand van follow-up, waarbij 
HIV-infectie de belangrijkste voorspeller voor overlijden was.
In ons oorspronkelijke cohort werd de klinische diagnose tuberculeuze 
meningitis bacteriologisch bevestigd in 50% van de gevallen. Dit is in lijn met 
ervaring elders die laat zien dat bacteriologische bevestiging van tuberculeuze 
meningitis moeilijk is. Het kweekproces gaat langzaam en is vaak fout-negatief. 
Microscopie heeft zelfs een nog lagere sensitiviteit. Als aanvulling op deze 
gebrekkige diagnostische mogelijkheden, evalueerden we In hoofdstuk 3 een 
in-house real-time PCR (rt-PCR) gericht op de M. tuberculosis insertie IS6110 in 
230 opeenvolgende volwassen meningitispatiënten. De IS6110 –PCR op liquor 
cerebrospinalis monsters had een veel hogere sensitiviteit dan microscopie 
van Ziehl-Neelsen gekleurde coupes. Deze in-house rt-PCR stelde meer 
gevallen van tuberculeuze meningitis vast dan conventionele kweek van liquor 
cerebrospinalis, met name in die gevallen die zich milder presenteerden. De 
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IS6110-PCR was negatief op alle liquormonsters van controlepatiënten die geen 
meningitis hadden.
In ons oorspronkelijke cohort had van de HIV-geïnfecteerde patiënten de 
helft ofwel tuberculeuze ofwel cryptokokkenmeningitis, en bleef de andere 
helft aanvankelijk zonder definitieve diagnose. In hoofdstuk 4 hebben we 
onderzocht of toxoplasmose verantwoordelijk zou kunnen zijn voor enkele 
van deze gevallen. De praktijk leert dat als een CT of MRI van de hersenen 
niet beschikbaar is, toxoplasmose op basis van louter de kliniek slechts zelden 
overwogen wordt in de differentiaaldiagnose van meningitis. Retrospectief werd 
onder 64 HIV-geïnfecteerde patiënten bij wie meningitis vermoed werd op basis 
van de klinische presentatie, een PCR op liquor cerebrospinalis voor Toxoplasma 
gondii uitgevoerd die positief was in een derde van de gevallen. Het was 
ingewikkeld om op klinische gronden, in de afwezigheid van neuroradiologie, 
toxoplasmose te onderscheiden van tuberculeuze of cryptokokkenmeningitis, 
al waren bij toxoplasmose de afwijkingen in de liquor minder uitgesproken. 
Zonder dat specifieke behandeling voor toxoplasmose werd ingesteld – deze 
studie werd immers retrospectief uitgevoerd op opgeslagen samples –, toonden 
patiënten met een positieve PCR voor T. gondii grofweg een tweemaal hogere 
mortaliteit dan patiënten met een negatieve PCR.
Zelfs als tuberculeuze meningitis direct vastgesteld en behandeld wordt, 
heeft het in het algemeen een slechte uitkomst. We veronderstelden dat 
een geïntensiveerde antibiotische behandeling het resultaat mogelijk zou 
kunnen verbeteren omdat rifampicine en enkele andere tuberculostatica 
een slechte penetratie naar de hersenen kennen. In hoofdstuk 5 hebben 
we dit onderzocht in een gerandomiseerde, open label fase II klinische trial 
met zestig patiënten. Patiënten ontvingen de standaarddosering isonazide, 
pyrazinamide en adjuvante corticosteroïden en werden gerandomiseerd voor 
wel of niet een hogere dosering rifampicine intraveneus en/of moxifloxacine, 
een fluoroquinolon met een hoge effectiviteit tegen M. tuberculosis. Standaard 
orale rifampicine liet een slechte penetratie in de liquor cerebrospinalis zien, 
maar een 33% hogere dosering die intraveneus werd toegediend leidde tot 
driemaal hogere rifampicine concentraties in het bloed en liquor. Moxifloxacine 
penetreerde goed in de liquor. Een geïntensiveerd behandelschema leidde 
Summary and general discussion | Ringkasan | Samenvatting
179 8
niet tot toegenomen toxiciteit. Ten slotte: een hoge dosering rifampicine was 
geassocieerd met een ongeveer een halvering van de 6-maanden mortaliteit 
(van 65% naar 35%).
Van cruciaal belang voor de slechte uitkomst van meningitis in Indonesië was de 
ernst van de ziekte op het moment van presentatie. Voor HIV-patiënten met een 
laag CD4-getal, is door experts en recent door de Wereldgezondheidsorganisatie 
voorgesteld te screenen op cryptokokkenantigeen voordat met antiretrovirale 
therapie (ART) gestart wordt. Dit om te voorkomen dat zich een cryptokokken-
meningitis ontwikkeld waaraan patiënten kunnen overlijden. Dit is in het 
bijzonder relevant voor landen waarin cryptokokkenmeningitis een hoge 
ziektelast kent (sub-Sahara Afrika). In hoofdstuk 6 hebben we de prevalentie 
en klinische relevantie van het voorkomen van cryptokokkenantigeen in bloed 
onderzocht in Indonesische patiënten. Van de 810 ART-naïeve HIV-patiënten 
met een CD4-getal van minder dan 100 cellen/μL, werd 7,1% positief getest 
voor cryptokokkenantigeen. De aanwezigheid van cryptokokkenantigeen in 
bloed was sterk geassocieerd met het ontwikkelen van cryptokokkenmeningitis, 
vroege loss to follow-up en vroeg overlijden.
Voor meningitis die wèl tuberculose als oorzaak had, speelde een late presentatie 
een duidelijk bijdragende rol aan de hoge mortaliteit in onze klinische setting. 
In hoofdstuk 7 hebben we in kaart gebracht in welke mate waarin patiënten 
met tuberculeuze meningitis op zoek gaan naar zorg. In diepte-interviews 
bleek dat meningitispatiënten en hun naasten niet gealarmeerd waren door 
de oorspronkelijke symptomen zoals een weerbarstige hoofdpijn. Bovendien, 
als patiënten zich uiteindelijk tot de faciliteiten in de primaire gezondheidszorg 
wendden, werden ze vaak naar huis gestuurd door de zorgverleners die de 
typische tekenen en symptomen vaak niet op waarde schatten. Dit had tot 
gevolg dat de meeste patiënten uiteindelijk zonder verwijzing in het ziekenhuis 
binnenkwamen, meestal met gevorderde symptomen zoals bewustzijnsverlies 
en focale neurologische verschijnselen. Deze gegevens laten zien dat er een 
gebrek aan bewustzijn over tuberculeuze meningitis bestaat onder zowel 
patiënten/leken als zorgverleners.
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